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 ABSTRACT 
 
 Cancer is a major public health problem in all countries. Among the several 
forms of cancer, breast and prostate cancers are the ones most frequently diagnosed 
among Women and Men, and a large number of them are hormone-dependent.  
 
 Breast cancer is the most common malignancy in women being the leading 
cause of cancer death worldwide. The natural history of this illness suggests that many 
of these tumors are dependent on estrogens for their development and growth. Among 
the several therapeutic options available, endocrine therapy controlling estrogen 
production has been the guiding principle for more than a century. In the biosynthesis of 
estrogens it is involved the enzyme aromatase, and its inhibition assumes a rational way 
to treat this disease. Nowadays, it has been observed a meaningful evolution in the 
development of aromatase inhibitors (AIs). The recent successful elucidation of the 
crystallized 3D structure of the enzyme, which provided the structural basis for the 
specificity to the interaction with its substrate, was an important milestone. This has 
clarified the establishment of hydrogen bonds between the oxygen atoms of C-3 and C-
17 keto groups and specific amino acid residues of the active site of the enzyme. 
Besides this, it was also observed that C-6 linear side chains of some inhibitors protrude 
into an access channel cavity immobilizing catalytic residues. This new data is very 
useful to understand the action of the inhibitors and for the development of promising 
molecules able to overcome some of the major drawbacks of AIs, such as the side 
effects, which are bone loss, joint pain and heart problems and the acquired resistance 
that they can led to after some years of usage. 
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 In this work, we were interested in the design, synthesis, biochemical and 
biological evaluation of the anti-aromatase activity of steroidal compounds obtained by 
structural modifications within the A-, B- and D-rings of androstenedione, the natural 
substrate of the enzyme. Supported on the results obtained, the features of the steroidal 
compounds determinant for achieving inhibitory activity were elucidated.  
 It is known that aromatase establishes two main hydrogen bonds with the 
carbonyl functions at C-3 and C-17 of androstenedione. Also, former studies have 
revealed that, in spite of this, the presence of the carbonyl group at C-3 is not 
completely mandatory to bind steroid molecules to the enzyme. On the other side, the 
C-17 carbonyl group seems to have a major role on the activity of steroidal AIs. Based 
on this rationale, we have transformed the C-3 carbonyl group into a hydroxyl group. 
From the studied molecules, we observed that C-3 hydroxyl derivatives of 
androstenedione are very active inhibitors specially when the hydroxyl group assumes a 
3β-stereochemistry. Changing both carbonyl groups, at C-3 and C-17, led to a 
significant decrease in activity. These results allowed establishing that the existence of a 
carbonyl group at C-3 is not mandatory for a steroid to be a potent inhibitor, as long as 
there is one at C-17.  
 According to previous results reported on the literature, it was inferred that some 
planarity in the A-ring and in the A,B-ring junction would be required for steroids to 
inhibit the enzyme. Based on this, we have synthesized new AIs and compared the 
influence of double bonds and epoxide functions in several positions along the A-ring. 
It was observed that when introducing the double bond in 4,5-position, the compound 
obtained revealed the highest activity, pointing out the importance of the planarity in the 
position closer to the A,B-ring junction. However, among the epoxide series, the 3,4-
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epoxysteroid revealed to be the most active inhibitor, evidencing the possibility of the 
oxiran oxygen atom to establish hydrogen bonds within the active site of the enzyme.  
 According to former information, it is known that the enzyme may have a 
hydrophobic binding pocket with a limited accessible volume, but that can 
accommodate non-bulky substituents located in the C-6 and C-7 position of the 
steroidal framework. Also, most recently, it was observed that the enzyme has an access 
channel, which allows the accommodation of C-6 side chains present in some inhibitors. 
Further, previous works have revealed the evidence that the aromatase inhibitory 
activity is similar when the same kind of substituent is in the referred C-6 or C-7 
position. With this knowledge in mind, we have synthesized new 6α-methyl and 7α-
allyl androstenedione derivatives that revealed to be strong AIs.  
 Previous work pointed out the importance of the C-17 carbonyl group in the 
steroidal D-ring as a structural feature required to reach maximum aromatase inhibitory 
activity. Based on this, and in order to achieve new structure-activity relationships 
(SAR), we have substituted the C-17 carbonyl group by a hydroxyl, acetyl and also by a 
thionyl isoster group, to compare inhibitory activities. In almost all synthesized 
compounds the C-17 carbonyl derivatives revealed to be stronger AIs.  
 We were also interested in preparing and studying some derivatives of the two 
steroidal AIs that were/are in clinical use for the treatment of breast cancer, formestane 
and exemestane. The C-4 acetoxy and acetylsalicyloxy derivatives from formestane 
were synthesized and evaluated showing that bulky substituents in C-4 position 
diminish the inhibitory activity. With respect to epoxy derivatives of exemestane, which 
are potential metabolites, they revealed to be potent AIs.  
 The activity of the most potent AIs evaluated in placental microsomes was also 
tested in MCF-7aro cells being some of them able to inhibit cell viability and cell 
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proliferation even more efficiently than exemestane. Some of the compounds were also 
studied in SK-BR-3 and LTEDaro cells. 
 
 Concerning prostate cancer, this type of tumor depends on androgens for its 
development and progression. Another illness with this association, and which is also a 
recurrent disease in men, is benign prostate hyperplasia (BPH). In both these situations, 
it is always observed an increase in the activity of the enzyme 5α-reductase, the one 
responsible for converting testosterone into dihydrotestosterone, the main androgen 
implicated in the differentiation and growth of prostate. Hence, the inhibition of 5α-
reductase is a rational way for treating these hyperandrogenic disorders. Despite the 
potency and success of the molecules used nowadays, they still present some 
disadvantages, such as increase in both bone and muscle loss, and impotency. Further, 
when these molecules are used in a profilatic way, they can cause high-grade prostate 
cancers.   
 In this thesis we designed and synthesized steroids with the 3-keto-Δ4 moiety in 
the steroidal A-ring combined with carboxamide, carboxyester or carboxylic acid 
functions at the C-17β position of the D-ring. This rationale was mainly focused on 
analogs of finasteride and dutasteride, two potent irreversible 5α-reductase inhibitors 
(RIs) used in the clinic, sharing in the same molecule the 3-keto-Δ4 moiety present in 
testosterone, the natural substrate of the enzyme, with the C-17β carboxamide group 
present in the referred RIs. The results obtained suggest that lipophilic amides favour 
the enzyme inhibition, being the synthesized steroid with a C-17β N-tert-
butylcarboxamide group the best inhibitor. 
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 Coumarins constitute another group of compounds that can structurally resemble 
steroids in inhibiting aromatase. Theregore, in this thesis we have also synthesized new 
3-thiophenyl coumarin derivatives in order to open a new pathway for the synthesis and 
evaluation of this class of compounds as AIs. Some preliminary results concerning their 
synthesis will be presented.  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Keywords: steroids, breast cancer, aromatase, aromatase inhibitors, prostate 
cancer, benign prostate hyperplasia, 5α-reductase, 5α-reductase inhibitors, design and 
synthesis, structure-activity relationships, coumarins. 
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 RESUMO 
 
 O cancro é dos problemas de saúde pública com maior incidência a nível 
mundial. Dos diferentes tipos de cancro, o cancro de mama e da próstata são dos mais 
frequentemente diagnosticadas na Mulher e no Homem, sendo que um número 
significativo deles são hormono-dependentes.  
  
 O cancro de mama é das doenças mais comuns nas mulheres e constitui a 
principal causa de morte por cancro na população feminina, em todo o mundo. Desde há 
muito que se sabe que a maioria deste tipo de cancro depende de estrogénios, para o seu 
desenvolvimento e crescimento. Entre as diversas opções terapêuticas disponíveis, a 
terapia endócrina de controlo da produção de estrogénios tem sido o princípio 
orientador seguido durante mais de um século. Na biossíntese de estrogénios existe a 
enzima aromatase e a sua inibição constitui uma forma muito eficiente de tratar esta 
doença. Atualmente, tem-se observado uma evolução significativa no desenvolvimento 
dos inibidores da aromatase. A recente elucidação  da estrutura cristalina 3D da enzima 
constitui um importante ponto de viragem, já que esclareceu as bases estruturais para a 
especificidade da interação da enzima com o seu substrato. Este esclarecimento mostrou 
que se estabelecem ligações de hidrogénio entre os átomos de oxigénio dos grupos 
carbonilo em C-3 e C-17 e resíduos específicos de aminoácidos, no local ativo da 
enzima. Para além disso, também foi observado que cadeias lineares posicionadas em 
C-6 de alguns inibidores esteróides se projetam para o interior de um canal de acesso à 
enzima, imobilizando os resíduos catalíticos. Esta nova informação revelou-se muito 
útil na tentativa de se compreender o mecanismo de inibição da aromatase e também no 
desenvolvimento de moléculas promissoras capazes de ultrapassarem algumas das 
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principais desvantagens dos inibidores da aromatase em uso, como sejam, os efeitos 
secundários relacionados com a perda de massa óssea, dores articulares e problemas 
cardíacos, bem como a resistência adquirida, que estes tendem a desenvolver após 
alguns anos de utilização.  
 Neste trabalho estivemos interessados no design, na síntese e na avaliação 
biológica da atividade inibidora da aromatase de compostos esteróides obtidos por 
modificações estruturais nos anéis A, B e D da androstenodiona, o substrato natural da 
enzima. As características determinantes para que estes compostos sejam potentes 
inibidores foram elucidadas com base nos resultados obtidos.  
 Sabe-se que a aromatase estabelece duas ligações de hidrogénio principais com 
os átomos de oxigénio das funções carbonilo em C-3 e C-17 da androstenodiona. 
Estudos anteriores revelaram que, apesar disso, a presença do grupo carbonilo em C-3 
não é absolutamente essencial para que a molécula se ligue à enzima. Por outro lado, o 
grupo em C-17 parece ter um papel predominante na atividade inibitória da aromatase. 
Desta forma, decidimos transformar o grupo carbonilo de C-3 num grupo hidroxilo. Das 
moléculas estudadas, observámos que os derivados C-3 hidroxilados são inibidores 
bastante potentes, especialmente se o grupo hidroxilo assumir a estereoquímica 3β. A 
alteração de ambos os grupos carbonilo em C-3 e C-17 levou, por seu turno, a uma 
diminuição muito significativa da atividade. Estes resultados permitiram estabelecer 
que, de facto, não é essencial a existência de um grupo carbonilo em C-3 num esteróide 
para que este seja um potente inibidor, desde que exista um outro destes grupos em C-
17. 
 De acordo com resultados apresentados na literatura, revelou-se necessário a 
existência de alguma planaridade no anel A e na junção dos anéis A,B, para que os 
compostos esteróides inibam a enzima. Assim, sintetizámos novos inibidores da 
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aromatase e comparámos a influência que as funções, dupla ligação e epóxido, tinham 
quando ocupavam diferentes posições do anel A. Perante os resultados obtidos, 
verificou-se que, quando a dupla ligação estava na posição 4,5, o composto apresentava 
maior atividade, reforçando a importância da planaridade na posição mais próxima da 
junção dos anéis A,B. Todavia, para a série dos epóxidos, o derivado 3,4 mostrou ser o 
inibidor mais ativo, o que levantou a hipótese do oxigénio do anel oxirano conseguir 
estabelecer ligações de hidrogénio com algum aminoácido do local ativo da enzima. 
  De acordo com dados anteriores, sabe-se que a enzima poderá ter uma bolsa 
hidrofóbica, com um volume limitado, mas que poderá acomodar substituintes pouco 
volumosos localizados nas posições C-6 e C-7 dos esteróides. Recentemente, também se 
observou que a enzima tem um canal de acesso que permite a entrada dos esteróides e 
que poderá acomodar cadeias laterais na posição C-6 destes compostos. Para além 
disso, outros trabalhos revelaram que a atividade inibitória é semelhante quando o 
mesmo tipo de substituinte está na posição C-6 ou na C-7. Desta forma, sintetizámos 
novos derivados 6α-metilo e 7α-alilo da androstenodiona que revelaram ser potentes 
inibidores da aromatase.  
 Estudos anteriores mostraram a importância do grupo carbonilo em C-17 no anel 
D esteróide como característica estrutural requerida para atingir atividade inibitória 
máxima. Deste modo, e de forma a estabelecer novas relações estrutura-atividade, 
substituímos o grupo carbonilo em C-17 pelo grupo hidroxilo, acetilo e também pelo 
isóstero tionilo. Em quase todos os compostos preparados, os que contêm o grupo 
carbonilo revelaram ser inibidores mais potentes.  
 Estivemos também interessados em preparar e estudar alguns derivados dos dois 
fármacos usados/em uso na clínica para o tratamento do cancro de mama, o formestano 
e o exemestano. Os derivados C-4 acetoxilo e acetisaliciloxilo do formestano foram 
  xlii 
sintetizados e avaliados. Ficou evidente que substituintes nesta posição diminuem a 
atividade inibitória. Relativamente aos epoxi-derivados do exemestano, que são 
potenciais metabolitos, estes mostraram ser potentes inibidores.  
 A actividade dos inibidores da aromatase mais potentes avaliados nos 
microssomas da placenta foi também testada em células MCF-7aro sendo que alguns 
deles revelaram inibir a viabilidade e proliferação celulares de uma forma ainda mais 
eficiente que o exemestano. Alguns destes compostos foram ainda estudados nas linhas 
celulares SK-BR-3 e LTEDaro.  
 
 Relativamente ao cancro de próstata, este depende de androgénios para o seu 
desenvolvimento e progressão. Outra doença que também partilha destas características 
é a hiperplasia benigna da próstata. Em ambas as situações é sempre observada uma 
atividade anormalmente elevada da enzima 5α-reductase, enzima responsável pela 
conversão da testosterona na di-hidrotestosterona, o principal androgénio implicado na 
diferenciação e crescimento da próstata. Assim, a inibição da 5α-reductase surge como 
uma forma lógica de promover o tratamento destas situações. Apesar das moléculas que 
existem atualmente em uso clínico serem potentes, elas apresentam algumas 
desvantagens, como a perda de massa óssea e de massa muscular e impotência. Além 
disso, quando eles são usados de uma forma profilática podem causar cancro de próstata 
de elevado grau.  
 Nesta tese fizemos o design e sintetizámos esteróides com a função 3-ceto-Δ4 do 
anel A do esteróide combinada com funções carboxamida, carboxiéster e ácido 
carboxílico na posição C-17β do anel D. Na base deste design estão os compostos 
finasteride e dutasteride, dois inibidores potentes e irreversíveis da 5α-reductase usados 
na terapêutica. Assim, procurou-se reunir na mesma molécula, o anel A que existe na 
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testosterona, o substrato natural da enzima, com os substituintes presentes em C-17β 
dos referidos fármacos. Os resultados obtidos sugerem que as amidas lipofílicas 
favorecem a inibição da enzima, sendo que o composto com o grupo N-terc-
butilcarboxamida em C-17β constitui o melhor inibidor.  
 
  As cumarinas constituem outro grupo de compostos que podem assemelhar-se 
quimicamente aos esteróides, na inibição da aromatase. Assim, também sintetizámos 
novos derivados 3-tiofenil da cumarina, de forma a abrir um novo caminho para a 
síntese e a avaliação desta classe de compostos como inibidores da aromatase. Alguns 
resultados preliminares relacionados com a sua síntese são apresentados nesta tese.  
 
 
 
 
 
 
 
 
 
 
 
 Palavras-chave: esteróides, cancro de mama, aromatase, inibidores da 
aromatase, cancro de próstata, hiperplasia benigna da próstata, 5α-reductase, inibidores 
da 5α-reductase, design e síntese, relações estrutura-atividade, cumarinas. 
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 LIST OF ABBREVIATIONS 
 
AIs Aromatase inhibitors 
ATR Attenuated total reflectance 
BOP (Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium 
hexafluorophosphate 
BPH Benign prostate hyperplasia 
BRCA1 Breast cancer gene type 1 
BRCA2 Breast cancer gene type 2 
CDCl3 Deuterated chloroform 
13C NMR Carbon nuclear magnetic resonance 
COSY Correlation spectroscopy 
DCC Dicyclohexylcarbodiimide 
DDQ 5,6-Dicyanobenzoquinone 
DHT Dihydrotestosterone 
DMF Dimethylformamide 
DMSO Dimethyl sulfoxide 
DMSO-d6 Deuterated dimethyl sulfoxide 
E1 Estrone 
E1 mechanism Unimolecular elimination mechanism 
E2 17β-Estradiol 
ER Estrogen receptor 
ESI-MS Electrospray ionization-Mass spectrometry 
FDA Food and drug administration  
HER 2 Human epidermal growth factor receptor 2 
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1H NMR Proton nuclear magnetic resonance 
HPLC High-pressure liquid chromatography 
HRMS High-resolution mass spectrometry 
IC50 Inhibitory concentration for half of maximum activity 
IR Infra-red spectroscopy 
J Coupling constant 
Ki Inhibition constant 
LC-MS Liquid chromatography-Mass spectrometry 
LNCaP cells Human androgen-responsive prostate cancer cell line 
LTEDaro cells Long-term estrogen deprivation human breast cancer cell line 
MCF-7aro cells ER+ aromatase-overexpressing human breast cancers cell line 
Mp Melting point 
NADPH Nicotinamide adenine dinucleotide phosphate 
NOESY Nuclear Overhauser effect spectroscopy 
NSAIDs Nonsteroidal anti-inflammatory drugs 
p-TSA p-Toluenesulfonic acid 
Rf Retention factor 
RIs 5α-Reductase inhibitors 
rt Room temperature 
SAR Structure-activity relationships 
SEM Standard error of the mean 
SERM Selective estrogen receptor modulator 
SK-BR-3 ER- human breast cancer cell line 
SN2 Bimolecular nucleophilic substitution 
T Testosterone 
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TLC Thin layer chromatography 
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UV Ultra-violet spectroscopy 
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 OUTLINE OF THE THESIS 
 
 The present thesis focuses on: 
 i)   achieving new compounds for breast and prostate cancer treatment; 
ii)  establishing structure-activity relationships (SAR) of steroidal compounds as 
aromatase and 5α-reductase inhibitors.  
For that, several compounds where designed, synthesized and screened for their 
aromatase and 5α-reductase inhibitory activity, in order to evaluate their anti-tumor 
potency towards breast and prostate cancer and for BPH treatment, respectively. 
 
 
 
 
 
 
 
 This work is divided in three main sections:  
 
 CHAPTER I – STEROIDAL AROMATASE INHIBITORS AS ANTI-TUMORS 
 In this part, it is made an introduction where the scope of the disease, the 
molecular target, and the compounds used in breast cancer treatment are revised.  
 This chapter is subdivided into five subjects where there are presented: the 
rationale behind the prepared compounds; the synthetic strategies to obtain them and the 
discussion of the encountered SAR. The conclusion about the studies performed on cell 
lines are also made. Molecular modelling studies were performed for some compounds 
Ring-lettering and atom-numbering of the steroidal framework 
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and its conclusions are presented. The experimental part of the prepared compounds in 
chapter I is also disclosed.   
 
 
 CHAPTER II - STEROIDAL 5α-REDUCTASE INHIBITORS AS ANTI-TUMORS AND 
AS DRUGS FOR THE TREATMENT OF BENINGN PROSTATE HYPERPLASIA (BPH)  
 In this part, it is made an introduction presenting the disease and the molecular 
target involved as well as the molecules used in the treatment. 
 This chapter presents the rationale behind the synthesis of the desired 
compounds as well as the synthetic strategies behind it. It is also made a study of the 
SAR and the conclusion about the studies performed in cell lines. The experimental part 
of this section is enclosed in the end of the chapter. 
 
 
 CHAPTER III - FUTURE WORK: DEVELOPMENT OF COUMARINS AS 
AROMATASE INHIBITORS  
 This part of the thesis arose from our interest in extending the study of 
aromatase inhibition to other type of compounds, namely coumarins. A complementary 
study of this kind of compounds was made at the Department of Organic Chemistry of 
the Faculty of Pharmacy of the University of Santiago de Compostela, Spain. The 
presentation of the compounds prepared is made in this chapter.  
 
 
 The biochemical assays and biological studies of the compounds prepared in this 
thesis were performed in the Laboratory of Biochemistry, Department of Biological 
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Sciences, Faculty of Pharmacy, University of Porto, and the Institute for Molecular and 
Cell Biology, University of Porto. 
 The molecular modeling studies were performed in collaboration with the 
CCLab, Department of Health Science, University “Magna Græcia” of Catanzaro, Italy.  
 The X-ray analysis was made in collaboration with the Group of Electronic and 
Magnetic Structure of Materials from the Center of Materials Study through X-ray 
Diffraction at the Physics Department of the Faculty of Sciences and Technology, 
University of Coimbra. 
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 INTRODUCTION 
 
 A.1. Breast Cancer: Some Facts  
 Breast cancer is the most commonly diagnosed cancer and the leading cause of 
cancer death in women worldwide, with an estimated 1.4 million of new cases and 
458,000 deaths in 2008.1 In Figure 1.1 are indicated the most common cancers in 
women in 1984, 2007 and predicted to occur in 2030, for the United Kingdom.2  
 
 
  
 
 
 
 
 
 The three most commonly types of cancer among women expected to be 
diagnosed in 2030 are breast, lung and colorectal, accounting for more than half of the 
estimated cases of cancer in women. Breast cancer alone is expected to account for 29% 
of all the estimated cases. These same predictions were also made for 2012, for the 
United States.3  
 In spite of the rising in breast cancer incidence, the mortality rate is falling in 
developed countries (approximately 6-19 per 100,000 cases) because of the more 
favorable life style, the earlier diagnosis of the disease and the discovery of new specific 
important cancer in 1984 (29% of all cancers) is now in third
position (12% of male cancers), while prostate cancer now
comprises 29% of the total, having comprised only 11% of the
total in 1984. Stomach cancer, the fifth most common type of
cancer in 1984 no longer figures in the top 10 (it ranks 12th, with
o2% of th total), and melanoma (14th with just under 1% of male
cancer in 1984) is predicted to become the fourth most common
male cancer accounting for 4.6% of cases in 2030.
Comparison with Nordpred predictions
We also used the Nordpred package (with a power-5 link and
5-year step functions for age, period and cohort) to project
rates until 2023–2027. Comparison of 2052 age–sex–site–period-
specific projections (for all sites other than breast and prostate,
for ages 40þ years for all sites except for testis, and for ages
15–79 years for testis) were made (Table 2). The median of the
observed absolute differences increased from 9% for 2008–2012 to
14% for 2023–2027. The 95th percentile (i.e., the 488th largest of
the 513 comparisons in each 5-year calendar period) of the
distribution of disagreement was about four times greater than
the median (Table 2).
These results can be compared with those obtained by using the
data until 2002 in Nordpred to predict results for 2003–2008 and
comparing these with the observed data. Here the median absolute
disagreement was 7% and the 95th percentile 28%.
DISCUSSION
The observed data were annual incidence rates, for GB, by cancer
site, sex and 5-year age group from 1975 to 2007. The rates were
converted to numbers of cases for the United Kingdom by
multiplying by the ratio of the respective populations. Compared
with the actual incidence (number of recorded cases) in the United
Kingdom in 2007, the difference between observed and modelled
numbers of cases (using GB rates applied to the UK population)
waso1.5% for all sex/site combinations. In Table 1, we present the
projected changes in ASRs and in the numbers of cases of cancer
between 2007 and 2030. These can be used to split the change in
numbers between changes due to changing rates and changes due
to changing population. Thus, for instance, the 11% increase in
male stomach cancer cases is accompanied by a 33% fall in rates,
so that the effect of the population change is to increase numbers
by 66% (¼ [100þ 11]/[100#33]#1).
We have deliberately shown results on a linear rather than a
logarithmic scale because of the greater uncertainties in predicting
cancers in the young. For ovarian cancer, for instance, cancers in
young women are likely to be germ cell with very different risk
factors from epithelial cancer in older women; therefore, there is
no reason to suspect that cohort effects seen in those aged 15–29
years will carry forward to ages 35–49 years. Rates of melanoma,
ovarian cancer, endometrial cancer (corpus uterus) and testicular
cancer (not shown in Figure 2) are all non-negligible in those aged
25–49 years, and our model is seen to fit these observed data well.
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Figure 4 Pie charts of the most common cancers in women and men in 1984, 2007 and predicted in 2030. The areas of the pies are proportional to the
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Table 2 Agreement between our (spline) model projections and those
of the Nordpred (step function) model
Period
Median percentage
absolute disagreement
95th percentile
absolute disagreement
2008–2012 9 35
2013–2017 10 40
2018–2022 10 37
2023–2027 14 66
UK cancer projections
M Mistry et al
1801
British Journal of Cancer (2011) 105(11), 1795 – 1803& 2011 Cancer Research UK
E
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y
Figure 1.1 - Pie charts of the most common cancers in women in 1984, 2007 and predicted for 2030, for the 
United Kingdom. The areas of the pies are proportional to the numbers of cases2 
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drugs.4 Due to the combination between the high incidence and the favourable 
prognostic, breast cancer is the one with higher survival rate. It is estimated that 
approximately 4,4 millions of women, worldwide, that were formerly diagnosed with 
breast cancer within the last five years, are still alive.5 
 In Portugal, in the beginning of the 90’s, it was observed an inversion in the 
increased tendency of mortality due to breast cancer. The decrease rate was of 2% per 
year (Figure 1.2). This can be explained by the early detection and the easy access to 
effective treatments.5 The incidence rates in the United Sates, as well as in other western 
countries including United Kingdom, have decreased since the early 2000s largely due 
to reduction in the use of hormone replacement-therapy, in post-menopausal women.6,7  
 
  
 
 
 
 
  
 
 
 
 
 There are a number of factors that are known to increase the risk of developing 
breast cancer, being some of them modifiable, accounting to control the development of 
the disease. Besides the gender, age is the most important risk factor for breast cancer. 
Hence, for example, a 20-year old woman has a probability of 0.06% to develop breast 
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Figure 1.2 - Breast cancer-related mortality in Portuguese women (35-74 years), between 1955-20025 
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cancer in the next 10 years, while a 60-year old woman has a risk of 3.45%.8 However, 
in the last years, it has been observed a more frequent diagnosis of breast cancer among 
young women. Women with family history of breast cancer, especially in a first-degree 
relative (mother, sister, daughter, father, or brother), are at increased risk of developing 
the disease. Compared to women without a family history, the risk of breast cancer is 
1.8 times higher for women with one first-degree female relative. This risk also 
increases when the first diagnosis occurs at a younger age.8 Genetic factors are also 
decisive. It is estimated that 5-10% of breast cancer cases arise from inherited 
mutations, including in the breast cancer susceptibility genes BRCA1 and BRCA2. 
Mutations in these two genes account for about 15-20% of familiar breast cancers.8,9 
Reproductive hormones are thought to influence breast cancer risk. Early menarche 
(<12 years) and older age at menopause (>55 years) may increase the risk for breast 
cancer.8,10 Postmenopausal women with high levels of endogenous hormones (estrogen 
or testosterone) have about twice the risk for developing breast cancer.8,11 Younger age 
of child bearing and a greater number of pregnancies decrease the risk of breast 
cancer.1,8 Recently, it has been attributed to the use of oral contraceptives the slightly 
increase in the risk of breast cancer. Also, the use of hormone replacement therapy, with 
combined estrogen and progestin, appears to increase the risk of developing and dying 
from breast cancer.8 There are many other risk factors for breast cancer, such as, high 
breast tissue, high bone density, a fat-rich diet and environmental agents, frequently 
referred to as “endocrine disruptors”, like cigarette smoke, alcohol and exposure to 
harmful radiations.8,10  
 In conclusion, it is accepted that sex-steroid hormones are involved in the 
development of breast tumors. However, some aspects are still to be fully understood.  
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 A.2. Estrogens 
 Estrogens are essential for life. They are a group of steroid hormones that are 
involved in numerous physiological processes including the development and 
maintenance of the female sexual organs, reproductive cycle, reproduction and several 
neuroendocrine functions. However, these hormones also play crucial roles in certain 
disease states, especially in mammary and endometrial carcinomas.12,13 
 
 
  A.2.1. Estrogen Receptors 
 Estrogens induce cellular transformations by different mechanisms being the 
estrogen receptor (ER) (Figure 1.3) the central piece of them.14,15  Estrogens diffuse 
through the cell membrane into the cell and, after the involvement of other non-ER 
plasma membrane-associated estrogen binding proteins,16 they bind to the ER that is 
located in the nucleus belonging to the nuclear hormone receptor superfamily.17,18 It 
was in 1986 that Green, P. et al.19 and Greene, G. L. et al.20 have cloned  the first ER, 
and later in 1996 Kuipier, G. G. et al.14 have reported a second ER. These are nowadays 
known as ERα and ERβ, respectively.  
 
 
 
 
 
 
 
 
Figure 1.3 - Crystal structure of ERα ligand binding domain complexed with estradiol15 
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 The two ER forms present a very high degree of similarity when compared at 
the aminoacid level and they have a similar tertiary structure.21 They share common 
regions, which participate in the formation of independent but interacting functional 
domains: the N-terminal transactivation domain, the DNA-binding domain and the 
ligand-binding domain. They are encoded by separate genes, ESR1 and ESR2, which are 
found in different chromosomal locations.17,18,22  
 ERα and ERβ can be detected in different tissues, being possible to exist both 
receptors in some cells, whereas in others there is only one subtype predominant. ERα is 
mainly expressed in the uterus, prostate stroma, theca cells of the ovary, Leydig cells of 
testes, epididymis, bone, breast, some regions of the brain and white adipose tissue. ERβ 
is in turn expressed in the colon, bone marrow, salivary gland, vascular endothelium 
and in some parts of the brain.18  
 ERs play therefore functional roles both in the physiology and disease. 
Concerning breast, it is known that normal and cancer tissues present different ERα and 
ERβ distribution, which might influence breast cancer risk, hormone responsiveness and 
survival.18 Although, it has been shown that also ERβ is expressed in breast tumors, 
ERα is indeed the predominant estrogen receptor in the female reproductive tract and 
mammary glands, being also the receptor most required for the known estrogenic 
responses.13,23 ERα is the only form clinically measured for medical decision-making 
and treatment.18 Approximately three quarter of breast tumors express hormone 
receptors like ER (ER-positive tumors).  
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 A.2.2. Estrogen Biosynthesis 
 The biosynthesis of steroidal hormones occurs from the precursor cholesterol 
and it is a multi-step process, which involves a series of transformations with different 
enzymes (Figure 1.4). These enzymes promote the synthesis of different families of 
steroidal hormones, not only in specific secretory organs but also in peripheral tissues.24 
 The most predominant estrogen in circulation is 17β-estradiol (E2), which is the 
most biologically active in breast tissue.24 In premenopausal women the synthesis of 
estrogens occurs in the ovaries, and also in the placenta, in pregnant ones. However, in 
postmenopausal women the ovary function and the production of estrogens cease. 
Hence, in this case, peripheral tissues such as liver, skin, muscle as well as adipose 
tissue provide the major source of estrogen synthesis.13,25  
 The last step of biosynthesis of the most potent endogenous estrogen E2 is made 
from testosterone by aromatase, which is generally considered rate-limiting in estrogen 
production. The crucial role played by aromatase in estrogen production has led to 
enormous interest both in the enzyme and its inhibitors.13,26 
  
  
 A.3. Aromatase  
 The human aromatase enzyme is a member of the cytochrome P450 group and is 
the product of CYP19A1 gene. Aromatase is bound in the endoplasmic reticulum27,28 of 
the cell and works in a heterodimer system composed by two major proteins: 
cytochrome P450arom, which contains a heme group and a steroid binding site, and an 
ubiquitous flavoprotein NADPH-cytochrome P450 reductase, which transfers reducing 
NADPH equivalents to cytochrome P450arom.  
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Figure 1.4 - The biosynthesis of steroidal hormones. The enzymes are: cholesterol side-chain cleavage (P450scc), 
3β-hydroxysteroid dehydrogenase (3β-HSD), 17α-hydroxylase/17,20-lyase (P450c17), steroid sulfatase (STS), 
steroid sulfotransferase (SUL), 17β−hydroxysteroid dehydrogenases (17β-HSDs), aromatase (P450arom), 5α-
reductases (5α-Rs). The steroids are: cholesterol (CHOL), pregnenolone (PREG), 17α−hydroxypregnenolone 
(17-OH-PREG), progesterone (PROG), 17α−hydroxyprogesterone (17-OH-PROG), aldosterone (ALDO), 
cortisol (CORT), dehydroepiandrosterone sulphate (DHEAS), dehydroepiandrosterone (DHEA), 5-androstene-
3β,17β-diol (5-DIOL), 4-androstene-3,17-dione (4-DIONE), testosterone (T), dihydrotestosterone (DHT), estrone 
sulphate (E1S), estrone (E1), and estradiol (E2) (adapted from Poirier, D. 200824)  
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 Aromatase promotes the aromatization of androgens being the only enzyme in 
vertebrates known to aromatize a six membered ring.12,28,29 Its substrates are 
androstenedione (Figure 1.5) and testosterone. 
 
 
 
 
 
 
 
 
 
 
 
 
 Aromatization of androstenedione, the preferred substrate, proceeds through 
three successive oxidation steps, each using one mole of NADPH as an electron donor 
and one mole of oxygen, in order to convert one mole of substrate into one mole of 
estrone (Figure 1.5). The first oxidative step is the hydroxylation at the C-19 methyl 
group to generate a 19-hydroxymethyl function. This is then subjected to a 
stereospecific second hydroxylation at the C-19 pro-R position to provide the C-19 
geminal diol, which is the hydrated form of the C-19 aldehyde. In the last step, the C-19 
aldehyde derivative undergoes the third final hydroxylation, probably at the 2β position, 
and aromatizes spontaneously.30 This last step of the aromatization mechanism is not 
thoroughly understood.12,13,26 
Figure 1.5 - Proposed mechanism for the aromatization of androgens29 
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 Aromatase is present in high levels in a variety of places including ovary, 
placenta, adipose tissue, testis and skin. Breast cancer tissues have been shown to 
express aromatase and to produce higher levels of estrogens than non-cancerous cells. 
This is one of the main reasons why aromatase has generated such a huge interest as a 
target in the treatment of breast cancer.12,13 
 During the last years, much of the research that was being performed worldwide 
in order to elucidate the mechanism of aromatase action has relied on site directed 
mutagenesis experiments with specific aromatase inhibitors. Very recently, in 2009, 
there was a significant breakthrough in this field since Gosh et al.28 successfully solved 
the 3D structure of human aromatase, after crystallizing it along with its substrate, 
androstenedione, hence providing a structural basis for its binding to the natural 
substrate (Figure 1.6).  
 
 
 
 
 
 
 
 
 
 
 
 From the 3D crystal structure of the enzyme aromatase, it was found that the 
active site is a distal cavity of the heme-binding pocket and the heme iron atom is the 
Figure 1.6 - The overall structure of aromatase28 
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reaction center of the enzyme. The catalytic site of aromatase is located at the juncture 
of the I and F helices (Figure 1.7).31  
 
    
 
 
 
 
 
 
 
 
 
 
 
 The amino acid residues within the catalytic cleft are Ile305, Ala306, Asp309 
and Thr310 from the I-helix, Phe221 and Trp224 from the F-helix, Ile133 and Phe134 
from the B-C loop, Val370, Leu372 and Val373 from the K-helix-β3 loop, Met374 from 
β3, and Leu477 and Ser478 from β8-β9 loop. Concerning the substrate, the 17-keto 
oxygen of androstenedione makes a hydrogen bond (2.8Å) with the backbone amide of 
Met374 and a weak contact (3.4Å) with NH1 of Arg115. The 3-keto is 2.6Å from the 
carboxylate moiety of Asp309 and may be protonated. Androstenedione binds with its 
β-face oriented towards the heme group and the C-19 of the methyl group positioned at 
a distance of 4.0Å from the heme Fe atom with which is coordinated.28,31,32 
Figure 1.7 - Close-up view of aromatase active site showing the bound androstenedione and 
some of the amino acids involved31 
200 D. Ghosh et al. / Journal of Steroid Biochemistry & Molecular Biology 118 (2010) 197–202
Fig. 3. A close up view of the human placental aromatase active site showing the bound androstenedione molecule within its unbiased electron density surface. Important
side chains, heme andwatermolecules are depicted in the following element colors: gray (carbon), blue (nitrogen), red (oxygen), yellow (sulfur) and firebrick (Fe). The carbon
atoms of androstenedione are colored in cornflower blue. The color code is maintained for all figures throughout the manuscript. The distances are in Å.
enzyme. The active site, thus, is buried deep within the roughly
spherical molecule near its geometrical center. Androstenedione
binds with its !-face oriented towards the heme group and C19 of
the methyl group positioned at a distance 4.0Å from the Fe-atom
(Figs. 2 and 3). The refined Fe-position is displaced roughly 0.2Å
away from the heme plane towards the ligand Cys437. The 17-keto
oxygen of the substrate is ideally situated at a distance 2.8Å from
the backbone amide nitrogen of Met374 to accept a proton and
make a hydrogen bond. The 3-keto oxygen O1 at the other end is
at 2.6Å from the carboxylate O"2 of the Asp309 side chain, sug-
gesting protonation of the carboxylate moiety and the formation
of a hydrogen bond. The geometries of these two hydrogen bonds
are such that 3-keto O1 and the water oxygen atom lie roughly in
the carboxylate plane. Furthermore, this water molecule is situ-
ated at 3.6Å from the guanidinium group of the Arg192 side chain,
which is salt-bridged to Glu483 (not shown). Twowater molecules
were found hydrogen-bonded to each other and also to the Ser478
side chain OH, which in turn donat s its proton to His480 N"1
(Ser478OH· · ·N"1His480: 2.9Å; not shown), further away from the
active site. Moreover, the Ser478 side chain is linked via these two
watermolecules toArg192by aweakhydrogenbondof length3.4Å
(Fig. 3).
The steroid-bindingpocket that snuggly fits an androstenedione
molecule isdelineatedbyaconfluenceof tightpackinghydrophobic
residues from various parts of the polypeptide chain. The residues
contributing to the catalytic cleft are Ile305, Ala306, Asp309 and
Thr310 from I-helix, Phe221 and Trp224 from F-helix, Ile133 and
Phe134 from the B′–C loop, Val370, Leu372 and Val373 from the
K–!3 loop, Met374 from !3, and Leu477 and Ser478 from the
!8–!9 loop. Additionally, 4 arginine and 1 tryptophan side chains
are involved in binding polar interactions with the heme propi-
onate moieties, as described earlier. Of these, the NH1 atom of
Arg115 approaches O2 (of 17-keto) of androstenedione from a dis-
tance of 3.4Å (Fig. 3).
The hydrophobic residues and porphyrin rings of heme sur-
round and pack against the steroid backbone from all sides at
van der waals distances. Side chains of residues Arg115, Ile133,
Phe134, Phe221, Trp224, Ala306, Thr310, Val370, Val373, Met374
and Leu477 have direct van der waals contacts with the bound
androstenedione molecule. Among these, Ile133, Phe134, Phe221,
Trp224 and Leu477 approach the substrate from the #-face of
androstenedione and follow the contour and puckering of the
steroid backbone, while Arg115, Ala306, and Met374 make con-
tacts at its edge and Thr310, Val370, and Val373 on its !-face. The
combined surface creates a pocket just right in volume and shape
to tightly enclose androstenedione [37]. This is particularly true
for the #-face of the ligand where the van der waals surfaces of the
large hydrophobics Phe134, Phe221, nd Trp224, dictate the shape.
The volume of the binding pocket is estimated to be no more than
400Å3, considerably smaller than those in 3A4 and 2D6 [11,12].
The only significant opening to the pocket is at the bottom right
cornerwhere 3watermolecules, having hydrogen bonds toAsp309
and Ser478, are located (Fig. 3). This leads to a channel that exits to
theexterior of theprotein surface. The salt bridgingArg192–Glu483
side chain pair as well as those of Asp309 and Ser478 line the
channel, right underneath the surface [37]. It is possible that this
channel, although too narrow at points to let steroids through, per-
mits the passage of the substrate and the product, owing to the
flexibility of the surrounding tertiary structure.
Pro308 plays a key role in the architecture of the active site.
The first 5 amino-terminal turns (Arg293 to Ala306) of I-helix in
aromatase have a slightly different orientation—in a direction away
from the active site. Pro308 causes a bend in the backbone and a
shift in the helix axis, bringing it back more towards the active site
to follow its normal course. As a result, some extra space, where
the 5th turn of the helix (Met303 to Ala307) otherwise would have
b en, is created accommodating the 3-keto end of the A-ring. In a
normal course of I-helix, the 5th turnwould have a steric clashwith
this end of the substrate [37]. Furthermore, as previously discussed,
in addition to thebulkyhydrophobic residues anddifferences in the
F-helix that greatly restrict the available space, the catalytic cleft in
aromatase is further constricted by the altered location and length
of the !8–!9 loop that contributes important residues Ser478 and
Leu477 to the active site (Fig. 3).
3.4. Structural perspective on the mechanism of aromatization
In a three-step catalytic process that requires 3mol of O2, 3mol
of NADPH, and the flavoprotein CPR for transferring electrons from
NADPH, aromatase converts androgens to estrogens. There is a gen-
eral agreement among previously proposed models that the first
two steps are typical P450hydroxylation reactions. Themechanism
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 The steroid-binding pocket that fits an androstenedione molecule is delineated 
by a confluence of tight packing hydrophobic residues. The hydrophobic residues and 
porphyrin rings of heme pack tightly against the steroid backbone. The side chains of 
residues Arg115, Ile133, Phe134, Phe221, Trp224, Ala306, Thr310, Val370, Val373, 
Met374 and Leu477 make direct van der Waals contacts with the bound substrate. 
Ile133, Phe134, Phe221, Trp224 and Leu477 approach the substrate from the α-face and 
follow the contour and puckering of the steroid backbone, while the side chains of 
Arg115, Ala306 and Met374 make contacts at its edge, and Thr310, Val370 and Val373 
on the β-face. The combined surface creates a pocket that encloses androstenedione 
very tightly (Figure 1.8).33 The volume of the binding pocket is estimated to be no more 
than 400Å3, which is considerably smaller than in other xenobiotic-metabolizing human 
P450s.28,31  
 In summary, the crystal structure of aromatase revealed to be a highly tuned 
molecular machine of estrogen production. This important and recent discovery will be 
useful in the structure-based design development of new compounds.28,33 
 
 
 
 
 
 
 
 
 
 
Antiproliferative Activity of New Compounds. The six
potent 2-alkynyloxy derivatives 4−9, as well as EXM and LTZ
as controls, were assayed for their antiproliferative properties in
the breast cancer cell MCF-7-Tet-off-3βHSD1-Arom (MCF-7a;
see Experimental Section). The results are summarized in
Figure 3c,d, and the EC50 values are given in Table 1. More
detailed antiproliferation data and individual dose response
curves for the new inhibitors and the controls are provided in
Table S2 (Supporting Information). The proliferative activity of
the MCF-7a cells is first evaluated by treating the cells with E2,
TST, and ASD. All three compounds effectively stimulate the
growth of the MCF-7a cells in a concentration-dependent
manner (Figure 3c), confirming that these cells express both a
functional estrogen receptor and an active aromatase. E2 (EC50
= 55 pM) is more potent than either TST (EC50 = 99 pM) or
ASD (EC50 = 3.6 nM) in growth stimulation, indicating that
there is a time lag for the synthesis of E2 from TST (via the
aromatase pathway) and ASD (via the aromatase-17β-
hydroxysteroid dehydrogenase type 1 pathway) in these breast
cancer cells. The maximum concentration of E2 and TST
required to stimulate MCF-7a cell proliferation in our cell-
based assay system is determined to be 1 nM (Figure 3c); this
concentration is used for subsequent proliferation inhibition
assays.
Figure 3d summarizes the results from the antiproliferative
activity assay of the 2-alkynyloxy aromatase inhibitors 4−9 in
the MCF-7a cells in comparison with the activities of LTZ and
EXM. The data show that the newly designed inhibitors abolish
the TST-stimulated proliferation of MCF-7a cells in a dose
dependent manner. The number of MCF-7a cells nearly
doubles in response to 1 nM TST treatment. However, the
addition of aromatase inhibitors 4−9 progressively inhibits the
stimulatory activity of TST as a function of concentration
(Figure 3d). The EC50 values of 4−9 are 1.7, 0.03, 3.4, 5.4, 15.7,
and 0.3 nM, respectively (Table 1). Of these inhibitors, 4, 5,
and 9 show 2.6-fold (p < 0.040), 119.6-fold (p < 0.010), and
14.7-fold (p < 0.012) antiproliferative activities, respectively,
against TST-stimulated cell growth when compared to the
steroidal AI EXM (EC50 = 5.6 nM). Thus, the structure−
activity relationship of these compounds in the cell-based
antiproliferation assay parallels their enzyme inhibitory proper-
ties in the cell-free system.
Aromatase−Androstenedione Complex Structure at
2.75 Å. The newly refined structure has yielded a better model
than the 2.90 Å structure (PDB code 3EQM)6 in terms of
overall quality and the refinement parameter statistics (Table
S3, Supporting Information). Inclusion of the higher resolution
data enabled rebuilding of some of the weakly defined loop
regions and inclusion of additional solvent atoms into the
model. The residues Ser267 to Cys275 in the G−H loop have
clearer electron densities than the previous map and are rebuilt
Figure 2. Design considerations for the new inhibitors derived from
the binding interactions and exposure of the ligands to the enzyme
interaction spaces: (a) ASD; (b) EXM. In (a) and (b) derived from
the X-ray structures, the residues lining the binding pocket making
hydrophobic and hydrogen-bonding contacts are shown (hydrophobic,
green; acidic, red; basic, blue; polar, purple; sulfur-containing, yellow).
Exposure at the C4 and C6 positions of the steroid to the access
channel opening is indicated. Also shown schematically in (a) is a
water molecule trapped between Asp309 and Arg192 side chains,
postulated to have a role in the proton relay network and enolization
of 3-keto.6
Scheme 1. Synthesis of C6β-2-Alkynyloxy Derivatives of ASDDa
aShown are chemical structures of newly synthesized C6β-alkoxy-substituted androsta-1,4-diene-3,17-dione compounds 2−9.
Journal of Medicinal Chemistry Article
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Figure 1.8 - Binding interactions and exposure of ligands to the enzyme 
interaction spaces with androstenedione33 
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 A.4. Breast cancer treatment 
 Although there have been recent declines in breast cancer mortality rates in 
some European Union countries, breast cancer still remains of key importance to public 
health not only in Europe but also worldwide. 
 The major decision about the treatment to follow is determined by the patient 
and by the physician, after being considered the biological characteristics of the tumor, 
the age of the patient and the risks and benefits from each treatment. Therefore, the 
therapeutic strategies available are: surgery, chemotherapy, radiation therapy, targeted 
therapy and hormonal therapy.  
 
 
 A.4.1. Surgery 
 The main objective of breast cancer surgery is the removal of the tumor itself 
and to assess the stage of the disease. The techniques usually performed are 
lumpectomy and simple or total mastectomy. 
 
 
 A.4.2. Chemotherapy  
 There are many factors that influence the outcome of chemotherapy such as the 
size of the tumor and the number of lymph nodes affected. Drugs like doxorubicin 
(Adriamycin®) are used to weaken and destroy cancer cells within the body, being also 
used to shrink cancer that has metastasized. In most cases, combinations of drugs are 
more effective than one drug alone for breast cancer treatment.8  
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 A.4.3. Radiation therapy 
 This procedure is used to destroy cancer cells that eventually have remained in 
the breast, chest wall or underarm area after surgery. It might also be needed after 
mastectomy when cancer is larger than 5 cm in size or when it is dissiminated in the 
lymph nodes. Radiotherapy might be applied externally or internally, depending on the 
type, stage and location of the tumor. In the last decades, this therapy has become an 
accurate targeted process, which allowed reducing side effects and treatment time.8 
  
 
 A.4.4. Targeted therapy 
 In about 15-30% of breast tumors there is an over-production of protein HER2 
(Human epidermal growth factor receptor 2), which allows the tumor to grow faster. 
Monoclonal antibodies that target this protein, like trastuzumab (Herceptin®), offer a 
survival benefit for women who have breast cancer that overexpress HER2. Hence, all 
invasive breast cancers should be tested for the gene that encodes the HER2 protein to 
identify women that would benefit from this therapy.8 
 
 
 A.4.5. Hormonal therapy 
 Many studies have shown that endocrine therapy plays an important role in the 
treatment of hormone-dependent breast cancer, being used in most of the cases in 
complement with the above-mentioned approaches. There are two major hormonal treatment 
modalities to prevent the effects of estrogens in the growth of tumors:24 (1) the use of 
estrogen antagonists to block the action of the estrogens on its receptor, and (2) the use of 
inhibitors of the biosynthesis of estrogens, to reduce their circulating levels (Figure 1.9).  
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 A.4.5.1. Estrogen Receptor Antagonists 
 One of the breakthroughs in breast cancer treatment was the discovery of drugs 
that targeted the ER, also called antiestrogens. These compounds compete for binding to 
the ER and reduce the number of receptors available for binding to endogenous 
estrogens. This approach has proven to be very effective in estrogen-dependent breast 
cancers. There are two types of antiestrogens: SERMs (Selective Estrogen Receptor 
Modulators) and SERDs (Selective Estrogen Receptor Downregulators). SERMs are 
chemically diverse compounds but with a conformational similarity that allow them to 
bind to ER, presenting both selective agonist or antagonist action on several target 
tissues depending on its content on ER.34 SERDs block estradiol action and induce 
receptor downregulation by causing its degradation.  
 Tamoxifen (Figure 1.10) was the first antiestrogen drug for breast cancer 
treatment approved in the 1970s and is the SERM most widely used.13,35 Like other 
SERMs, Tamoxifen exerts an agonist effect on the ER of some tissues, while acting as 
Figure 1.9 - Strategies for hormonal therapy 
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antagonist on others. For this reason, it is quite effective as ER antagonist in the 
treatment of hormone receptor-positive breast cancer, both in pre and postmenopausal 
women. However, the agonist effects in the ER of the uterus and vascular system, after 
prolonged usage, causes an increased risk of endometrial cancer and 
thromboembolism.12,36 On the other side, the agonist effect in the bone ER, prevents 
bone loss and osteoporosis. Other examples of recent SERMs are raloxifene and 
toremifene, which are structurally related to tamoxifen.37 
 
 
 
 
 
 
 
 
 Fulvestrant (Figure 1.11) is a SERD compound that has an affinity for the ER 
approximately 100 times higher than tamoxifen. Besides, it has no estrogen-like activity 
on the uterus, and has the capacity to block completely the stimulatory activities of both 
agonists and antagonists, like tamoxifen. The clinical efficacy of fulvestrant has been 
compared with that of tamoxifen in postmenopausal women with breast cancer, and its 
efficacy in tamoxifen-resistant breast cancer has also been demonstrated.37  
 
 
 
 
NO
Figure 1.10 - Tamoxifen 
Figure 1.11 - Fulvestrant 
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 A.4.5.2. Aromatase Inhibitors (AIs) 
 Hormonal treatment has also been focused into the reduction of estrogen levels, 
which has revealed to be a very successful approach. This is achieved by using 
aromatase inhibitors (AIs), by blocking the production of estrogens. Investigations on 
the development of aromatase inhibitors began in the 1970s and have expanded greatly 
in the past three decades.13  
 AIs do not interact directly with the ER but block the conversion of adrenal 
androgens into estrogens in peripheral tissues, including the breast tissue.36  
 The evolution of AIs has seen a transition from prototype first generation agents, 
which were not particularly potent or selective, to the actual third-generation drugs, 
which are much more effective. This last generation of compounds represent a 
significant advance in ER-positive breast cancer therapy in postmenopausal women, 
being approved both for early- and late-stage cases.38 
 AIs are traditionally subdivided into two main classes, according to their 
structure. Type I inhibitors are associated to the substrate-binding site of the enzyme 
and invariably have an androgen structure, and are usually referred to as steroidal 
inhibitors. On the other side, type II inhibitors are “nonsteroidal”, and are essentially 
azole type compounds.39 All AIs are similar in the way that they inhibit the estrogen 
synthesis which is by blocking aromatase activity. However, they have distinct 
mechanisms of action. 
 The steroidal or type I AIs can be classified as competitive or mechanism-based 
inhibitors according to the way they promote the inhibition of the enzyme, binding 
reversibly or irreversibly to its active site. Nonsteroidal or type II inhibitors are mostly 
competitive inhibitors. Thus, competitive inhibitors are molecules that compete with the 
substrate for noncovalent binding to the active site of the enzyme, decreasing the 
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amount of product formed. A mechanism-based inhibitor mimics the substrate, being 
then converted by the enzyme to a reactive intermediate, which irreversibly binds to the 
enzyme promoting its inactivation. The term “mechanism based” is used because the 
inhibitor uses the mechanism of the enzyme to be activated.13 Other denominations are 
also used for these inhibitors such as “enzyme-activated irreversible inhibitors”, 
“suicide substrates” and “suicide inactivators”, since aromatase is inactivated because of 
its own mechanism of action.38 
 On the other side, nonsteroidal AIs interact noncovalently with the heme moiety 
of the enzyme and occupy its substrate-binding site, thereby preventing binding of 
androgens to the catalytic site. This antagonism is reversible, being these AIs 
competitively displaced from the active site.38 The nonsteroidal inhibitors contain a 
nitrogen heteroatom with a free electron pair that coordinates with the heme iron (Fe3+) 
mimicking the C-10 methyl group of steroids. Some of these inhibitors are likely to be 
less enzyme specific and can inhibit other cytochrome P450-mediated hydroxylations, 
which results in significant toxicity.35  
 The evolution of AIs has seen the development of agents of both type I and type 
II classes that have progressively increased in both specificity and potency, within each 
new generation. 
 
 
 First-Generation Drugs 
 First-generation AIs were used without the knowledge at that time that they had 
anti-aromatase properties, as was the case of testololactone and aminoglutethimide 
(Figure 1.12).  
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 Testololactone (Teslac®) was initially used as androgen, based on the conviction 
that existed at that time, that androgens might counteract the action of estrogens. It is 
structurally related to testosterone and became available for studies in the early 1960s.40 
Segaloff et al.40 performed the first clinical study and reported on the effectiveness of 
the drug in advanced breast cancer. It demonstrated a very low rate of toxic effects and 
did not present virilism or other hormonal activity present in testosterone. It was only in 
1975 that Siiteri and Thompson41 discovered that this compound had aromatase 
inhibitory activity. It was used for over two decades as a treatment for breast cancer 
since it was found to inhibit aromatase.25 
 
 
 
 
  
   
 
 Aminoglutethimide (Cytadren®) was originally an antiepileptic agent that was 
removed from the market due to serious side effects, namely renal failure.13,40 It first 
entered in preliminary clinical trials in advanced breast cancer as a result of the 
observation that it inhibited adrenal steroidogenesis, being introduced as a form of 
chemical adrenalectomy.39  
 Aminoglutethimide was the prototype for the nonsteroidal aromatase 
inhibitors,40 being referred to as the first-generation AI. Although it was an important 
AI, it was clear that it was far from being an ideal agent. The drug was only partially 
effective in supressing plasma estrogen levels, and it lacked specificity since it also 
Figure 1.12 - Testololactone (left) and aminoglutethimide (right) 
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inhibited a number of other steroidogenic CYP-450 enzymes, requiring a concomitant 
administration of corticosteroids. This resulted in significant toxicity.13,39 
 
 
 Second-Generation Drugs 
 Second-generation inhibitors were developed with greater selectivity and 
potency than their first-generation counterparts. Among the second-generation AIs that 
reached the clinic, the most notables were the steroidal, formestane, and the 
nonsteroidal, fadrozole (Figure 1.13).  
 
 
 
 
 
 
  
  
 Formestane (Lentaron®) was one of about 200 compounds that were specifically 
designed and assayed as AIs by Harry and Angela Brodie in the 1970s, which revealed 
to be a potent inhibitor of aromatase.39,42,43 It is structurally related to androstenedione, 
the natural substrate of the enzyme, having a hydroxyl group at C-4. Due to this 
inhibitory activity it was indeed used for breast cancer treatment in postmenopausal 
women.44 
 Formestane competes rapidly with androstenedione for the active site of the 
enzyme initiating a time-dependent reactive process which results in either covalent or 
O
O
OH
N
N
N
Figure 1.13 - Formestane (left) and fadrozole (right) 
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very tight binding to the enzyme, causing its inactivation.42 It appeared to be converted 
by the enzyme to a reactive intermediate that bound irreversibly to aromatase.39 This 
kind of inhibitor presents lasting effects, because new enzyme synthesis is required to 
overcome this mode of inhibition. Hence, it is not necessary the continued presence of 
the drug to maintain inhibition and the probability of toxic side effects are reduced.35,42 
Formestane was administrated as a suspension by intramuscular injection because, when 
given orally, it had poor biological activity due to glucuronidation of the critical 4-
hydroxy group through the first-pass liver metabolism, which results in its elimination 
from the body.39  
 Formestane is about 60-fold more potent than aminoglutethimide.39 It is also 
more effective than tamoxifen, and it does not have estrogenic activity on other tissues 
as tamoxifen.25 
 
 Fadrozole (Afema®) is the representative compound of second-generation type II 
inhibitor. This compound is an imidazole analog of aminoglutethimide, but shows 
higher potency, inhibiting aromatase in vitro 200 to 400 times higher.45 Another 
interesting difference when compared to the first generation drugs is that, at 
concentrations that maximally inhibit the enzyme, it had relatively small effects on 
other cytochrome P450-related enzymes. This means that with fadrazole there is no need 
for corticoid replacement.39  
 Although fadrozole is a highly potent compound, it has a relatively short half-
life, which is responsible for its lower in vivo activity when compared with other 
triazole derivatives, that are cleared more slowly.46  
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 Third-Generation Drugs 
 Among the recent third-generation of AIs, the most significant ones include type 
I, exemestane, and type II, anastrazole and letrozole (Figure 1.14).  
 
 
 
 
 
 
  
 
 
 These molecules are substantially more potent than aminoglutethimide in 
inhibiting aromatase activity in vitro (Table 1.1). For the first-generation drug it is 
necessary a micromolar concentration while for the second- and third-generation drugs 
the active concentration ranges the nanomolar scale. Their superior pharmacokinetic 
profiles also mean that they are even more effective in vivo.39 
 
 Exemestane (Aromasin®) is an orally active, irreversible steroidal inhibitor 
developed by Di Salle and Lombardi to overcome the unfavourable metabolism and 
poor oral availability of formestane.47,48 Exemestane entered in preclinical development 
in 1986, and successfully performed clinical trials during the 1990s led to FDA 
approval in 1999 for the treatment of advanced breast cancer in postmenopausal 
women.48 It differs from nonsteroidal inhibitors in that it leads to irreversible inhibition 
of aromatase, probably by covalent binding to the enzyme. This derivative of 
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Figure 1.14 - Exemestane (left), letrozole (middle) and anastrazole (right) 
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androstenedione is recognized as a false substrate by the enzyme and processed through 
the normal catalytic mechanism to a transformed product, which covalently binds to and 
irreversibly inactivates the substrate-binding site of the enzyme, an effect also known as 
“suicide inhibition”.49 The irreversible nature of its inhibitory activity is responsible for 
the long-lasting effect (3 to 5 days according to the dose) on estrogen biosynthesis.48 
Treatment with this steroidal compound has been shown to be well tolerated and 
chronic treatment was found to suppress plasma estrogen levels by 85 to 95% when the 
drug was administered at a dose ≥10 mg per day.50 It also shows a great potential to be 
more effective as first-line treatment than other substances, including antiestrogens and 
nonsteroidal AIs.48 
 Exemestane undergoes a complex metabolism, being the first step the reduction 
of the 17-keto group to give the 17β-hydroxy derivative (the primary metabolite to be 
identified in plasma), followed by the P450-catalyzed oxidation of the 6-methylidene 
group with formation of many secondary metabolites (Figure 1.15).53,54 These 
metabolites were found to be either inactive or less potent than exemestane.48,53,55-57 
However, the 17β-hydroxy derivative was further studied by Goss and collaborators58 
which found that it produced similar effects to exemestane, such as, bone sparing and 
favorable changes in circulating lipid levels. Buzzetti et al. have synthesized some 
potential metabolites through oxidation of the 6-methylidene group.47 Recently, some 
new exemestane metabolites were detected in urine by gas chromatography coupled to 
mass spectrometry.53  
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Table 1.1 - Comparison of aromatase inhibitory activity of first, second and third 
generation drugs39,51,52 
 
 
Placental 
microsomes 
IC50 (nM) 
Breast cancer 
homogenates 
IC50 (nM) 
Inhibitiona) 
(%) 
Aminoglutethimide 3000 4500 90.6 
Anastrazole 12 10 96.7 
Letrozole 12 2.5 98.9 
Formestane 50 30 91.9 
Exemestane 50 15 97.9 
 
a) Activity determined in vivo; drugs were given orally with exception for formestane that was 
administered intramuscularly. 
 
  
 Nonsteroidal third-generation, anastrazole (Arimidex®) and letrozole (Femara®) 
are reversible, imidazole-based potent AIs and with high specificity to aromatase. These 
new agents are 100-3000 times more active than aminoglutethimide, and inhibit whole-
body aromatization by greater than 96%.13 Both agents have shown to cause profound 
suppression of plasma estrogen levels in postmenopausal women.59 Since they do not 
interact significantly with other P450 enzymes, no substantial suppression of cortisol, 
progesterone and aldosterone levels is evident.13 Besides, they have few side effects and 
low toxicity when compared with other generation nonsteroidal inhibitors.35  
 
 Anastrazole, which was the first AI from the third-generation drugs to enter into 
clinical trials, in an in vitro system, revealed to be a potent inhibitor of human placental 
aromatase (200 times more potent than aminoglutethimide and twice more potent than 
formestane). Treatment with anastrazole does not change lipid profiles, and studies have 
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confirmed that it has fewer thromboembolism and ischemic cerebrovascular events, and 
it does not demonstrate androgenic, progestogenic or estrogenic effects.60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.15 - Proposed metabolic pathways for exemestane (3α/β-HSD = 3α/β-hydroxysteroid-dehydrogenase) 
5α/β-Reductase 
17β-Hydroxyexemestane 
 
3α/β-HSD 
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 Letrozole is more potent and effective, suppressing plasma estrogen 
concentration to undetectable levels. It has proven to be superior in several aspects to 
the other drugs having survival benefits and better tolerability.61 A cross-over study of 
letrozole and anastrazole revealed that treatment with the first one supressed levels of in 
vivo aromatization below the detection limit of the assays in all patients, while this 
degree of inhibition with anastrazole was only achieved in one case. Essentially, 
letrozole achieves a greater aromatase inhibition at its lower dose (0.5 mg, daily) when 
compared with anastrazole at its higher dose (10 mg, daily).59,61 This suggests that 
letrozole might translate into more effective therapy than anastrozole for 
postmenopausal women.62 
 Clinically, letrozole produces tumor remission in postmenopausal women with 
breast cancer resistant to other endocrine treatments and chemotherapy.39  
  
 Third-generation AIs have their efficacy in breast cancer demonstrated, being 
the treatment of choice for the advanced disease, as well as for the adjuvant setting, the 
preoperative setting and even with potential in chemoprevention.63 
 
  
 Resistance to Aromatase Inhibitors 
 Whilst substantial number of patients with breast cancer benefit from treatment 
with AIs, others do not and, even in responding patients, remissions are not usually 
permanent and disease returns in a resistant form.64 Overall, the long-term use of 
antihormonal therapy can result in the development of resistance.35  
 Once AIs play their role by causing estrogen deprivation, many of the 
mechanisms by which resistance occurs are likely to be shared by other forms of 
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endocrine deprivation. These mechanisms include the loss of ERs with the treatment,65 
the outgrowth of hormone-intensive cells, the ineffective estrogen suppression and/or 
endocrine compensation, and a switch to dependence on other mitogens.39,66 
 Irrespective of the cause of the phenotype of aromatase, certain tumors may be 
more sensitive/resistant to individual AIs. Since steroidal and nonsteroidal AIs have a 
different mechanism of action, it is not observed cross-resistance. Potential explanations 
for this lack of cross-resistance include: the nature of the interaction with the enzyme 
active site, differential sensitivities of aromatase variants to specific compounds, 
androgen-agonistic effects, and inherent differences in potencies among AIs.38,67 
Furthermore, this lack of cross-resistance between distinct AIs offers the possibility of 
its sequential use in advanced disease.36 
 
 
 Advantages/Disadvantages of Aromatase Inhibitors 
 Aromatase inhibitors have revealed several advantages over other endocrine 
therapies, such as:39 
i. The actions of AIs are not totally irreversible and estrogen levels return to 
normal on discontinuation of treatment; 
ii. AIs specifically decrease the estrogen production, while surgical ablation of 
endocrine organs will affect the normal production of other steroid hormones. For this 
reason, AIs have fewer side effects and lower morbidity; 
iii. AIs have the potential to totally block estrogen production since 
biosynthesis is not restricted to endocrine glands but occurs in many other tissues, such 
as breast cancer.  
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 On the other side, specific AIs also present some disadvantages in the treatment 
of estrogen-dependent breast cancers:39 
i. They do not affect estrogens exogenously derived or levels of other types of 
steroids with estrogenic activity; 
ii. They are unproven to be effective in premenopausal women once they 
cannot stop the ovaries from producing estrogen due to the hypophyseal feedback 
mechanism;  
iii. They increase significantly musculoskeletal symptoms, arthralgia, 
osteopenia, osteoporosis and fracture rate, since estrogens have a major role in the 
maintenance of bone mass;12,25  
iv. Although no significant changes in cardiovascular events have been 
described, a trend toward its increase is of concern;25 
v. They may induce cellular resistance, by long-term estrogen deprivation.25,35 
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 AIM OF THE WORK 
 
 Recent data has shown significant success in improving the survival rates among 
breast cancer patients by using aromatase inhibition therapy. This can be explained by 
the more insightful choice of the appropriate drugs for each patient, based on the 
clinical information available and by using more potent drugs, such as exemestane, 
anastrazole and letrozole.  
 Third-generation AIs appear to be extremely potent and highly specific 
inhibitors of the enzyme, showing strong anti-tumor effects in postmenopausal women, 
and being well tolerated. However, they still present some side effects, such as increase 
of bone loss, joint pain and cardiac events.68 In addition, after some years of usage they 
can develop cellular resistance.51 For these reasons it is necessary to discover new drugs 
that allow to surpass the referred limitations. These new molecules can also allow 
studying the mechanism of enzyme inhibition and can help to clarify the aromatization 
mechanism of aromatase, which still remains unknown. 
 The recent elucidation of the 3D-structure of aromatase and the establishment of 
the molecular basis of the enzyme-substrate interaction36 allowed us a more rational 
design of AIs. The design, synthesis and biological study of the new substrate- and 
structure-based inhibitors in this thesis would greatly contribute to understand the 
interactions of the enzyme with the inhibitors and to establish new SAR.  
 Based on this, the aim of the work was to design and synthesize new steroidal 
AIs for subsequent biochemical and biological evaluation, and in some cases to do 
molecular modelling studies, in order to establish new and solid SAR.   
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1.1. DERIVATIVES OF EXEMESTANE 
 
1.1.1. Design and synthesis  
Exemestane (3) (Scheme 1.1), chemically described as 6-methylenandrosta-1,4-
diene-3,17-dione, is the only steroidal AI in the market being orally active, long-lasting 
and safe for the treatment of hormone-responsive breast cancer in postmenopausal 
women.48  
As described before, exemestane is extensively metabolized (Figure 1.15). 
Frequently, these metabolites are still active compounds and there is a huge interest in 
studying them biochemically and biologically. Hence, we were interested in 
synthesizing some selected exemestane derivatives. By this reason, our first challenge 
began with the synthesis of exemestane itself. 
   
 
Synthesis of Exemestane 
Buzzetti et al., in the US patent 4,808,616, disclosed the synthesis of 
exemestane for the first time in 1989.69 They considered its preparation by 
dehydrogenation of 6-methylenadrosta-4-ene-3,17-dione using 2,3-dichloro-5,6-
dicyanobenzoquinone (DDQ) and anhydrous dioxane as solvent. The starting material 
6-methylenadrosta-4-ene-3,17-dione was prepared by reaction of androstenedione with 
formaldehyde acetal and phopshoryl chloride, according to the general method of 
Annen et al.70  
  Other synthetic strategies were disclosed in order to overcome the disadvantages 
and drawbacks of this method, specially the low yields and high price of DDQ as well 
as purification processes, which were not affordable in a scaled up synthesis. Therefore, 
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a practical approach, using the commercially available dehydrotestosterone, disclosed a 
curious Mannich reaction on a cross-conjugated dienone moiety by directly introducing 
the methylidene group at the C-6 position using, for this matter, paraformaldehyde and 
dimethylamine in isoamylic alcohol. Exemestane was then obtained after the Jones 
oxidation of the 17β-hydroxyl group of its precursor.48,71 Another strategy developed 
also made use of androstenedione as starting material and it also involved the 
intermediate 6-methylenadrosta-4-ene-3,17-dione, but using other reagents to prepare it, 
and being followed by three other reactions until the production of exemestane.48 Other 
groups explored other approaches studying the influence of an acid catalyst with the 
dehydrogenation agent,72 and others even studied this approach using also at least one 
co-oxidant in the dehydrogenation reaction.73,74  
 In this thesis, we decided to attempt the synthesis of exemestane (3) using a two-
step strategy (Scheme 1.1).69 Hence, we used androstenedione (1) as the starting 
material to which the 6-methylidene group was introduced. We followed the method 
developed by Annen et al.,70 who succeeded in performing this transformation in an 
one-step reaction overcoming the former synthesis that had many steps. Once prepared 
the 6-methylidene derivative (2), a subsequent dehydrogenation using DDQ47 was made 
in order to achieve exemestane (3). However, in our hands we did not succeed in this 
step ending up by obtaining compound 4 (Scheme 1.1). Marcos-Escribano et al.74 have 
also reported the same problem we encountered. In general, the 1,2-dehydrogenation of 
steroidal 4-en-3-ones with DDQ predominates in the presence of weak acids, or in 
uncatalyzed reactions, while the 6,7-dehydrogenation occurs in the presence of strong 
acids. In fact, the reaction of androstenedione (1) with DDQ in benzene or dioxane, 
under reflux, leads to the 1,2-dehydrogenated derivative as the major one.74 However, 
when these conditions were applied to compound 2 the reaction proceeded with the 
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desired 1,2-dehydration but, besides that, it was also observed an isomerization of the 
exocyclic C-6 double bond forming the most stable conjugated system leadind to 
derivative 4.  
  
 
Scheme 1.1 - Attempt to synthesize exemestane (3) from androstenedione (1) 
 
 
 
 
 
 
 
 
 
Reagents and Conditions: (i) anhydrous sodium acetate, formaldehyde dimethyl acetal, 
phosphoryl chloride, anhydrous chloroform, reflux, 10 h; (ii) DDQ, anhydrous dioxane, reflux, 
11 h 10 min. 
 
 
The structure of compound 2, which is a key synthetic precursor of exemestane, 
was characterized by X-ray analysis and its ORTEP view is shown in Figure 1.16.75 
Results from the single-crystal diffraction revealed that it adopts a 1α-sofa 
conformation, slightly distorted towards a 1α,2β-halfchair. The pseudo-torsion angle 
C19-C10…C13-C18 indicates that the structure of 2 is slightly twisted. It was observed 
that the 6-methylidene group is in a beta equatorial position with an angle of 63.8(2)º 
relative to the plane of the molecule.  
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Synthesis of Derivatives of Exemestane 
Due to the huge clinical interest of exemestane and since it is extensively 
metabolized being some of the metabolites active, we decided to synthesize some 
epoxide derivatives that are proposed as potential metabolites in the metabolic pathways 
for exemestane.48,53-55 Besides, we have already observed for other potent AIs that the 
substitution of double bonds by epoxide functions, which have similar bond geometries, 
allowed the molecule to maintain planarity and to exhibit strong aromatase inhibitory 
activity.76,77 Because of this, we have synthesized the epoxide derivatives 5 and 6 of 
exemestane. 
Two different reaction conditions for the epoxidation reaction were explored in 
order to obtain distinct epoxide derivatives of exemestane (Scheme 1.2).  
For the epoxidation of the 6-exomethylidene group, we subjected exemestane to 
treatment with performic acid generated in situ.78 Buzzetti et al.47 also synthesized 
compound 5 using different reaction conditions (m-chloroperbenzoic acid). For the 
Figure 1.16 – ORTEP view of the molecular structure of compound 2 obtained by X-ray analysis75 
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oxidation of the C-1/C-2 double bond we used alkaline hydrogen peroxide,79 which 
allowed obtaining the respective epoxide 6.  
 We have also been interested in preparing a 3-deoxy-derivative based on the fact 
that formerly our team has concluded that the presence of the carbonyl group at C-3 was 
not mandatory to bind the inhibitors to the enzyme.80 With this idea in mind, we 
subjected exemestane to the reaction conditions of Hanson et al.81 using sodium 
borohydride in a mixture of trifluoroacetic acid, acetonitrile, acetic acid and 
dichloromethane to promote the deoxygenation of the C-3 carbonyl group. This reaction 
allowed the preparation of compound 8 along with compound 7, which is the main in 
vivo metabolite of exemestane (Scheme 1.2). 
 
 
 1.1.2. Chemistry 
Androstenedione (1) (Scheme 1.1) was prepared through the oxidation of 
testosterone with a solution of chromium trioxide in aqueous sulphuric acid (Jones 
reagent), as reported by Rasmusson and Arth,82 in 98% yield. 
The direct γ-alkylenation of enone 1 was achieved by reaction with phosphoryl 
chloride and formaldeyde dimethyl acetal.70 After 10 h at reflux, a mixture of several 
products was formed, being compound 2 isolated by silica gel column chromatography, 
in 17% yield. 
Compound 2 (Scheme 1.1) was then subjected to a reaction with DDQ in order 
to promote the dehydrogenation at C-1/C-2,47 and therefore produce exemestane (3). 
The reaction conditions allowed indeed the dehydrogenation at the mentioned position 
of the A-ring. However, they also promoted the isomerization of the 6-methylidene 
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double bond with formation of compound 4, which was isolated in the pure form by 
silica gel column chromatography, in 98% yield, as a white solid.  
 
 
Scheme 1.2 - Synthesis of derivatives of exemestane (3)  
 
 
 
 
 
 
 
Reagents and Conditions: (i) H2O2, HCOOH, dichloromethane, rt, 96 h; (ii) H2O2, NaOH, 
methanol, rt, 24 h; (iii) CF3COOH, CH3COOH, CH3CN, NaBH4, anhydrous dichloromethane, 
rt, 11 h. 
 
 
The synthesis of compound 5 (Scheme 1.2) was made by treating exemestane 
(3) with performic acid in dichloromethane, at room temperature, for 96 h.78,80 The 
crude mixture was then purified by column chromatography affording the desired 
epoxide 5, in 21% yield. In other fraction, a mixture of 5 with its 6α-isomer was 
obtained in a 65:35 proportion, respectively.  
Although the C-6 epoxide derivative of exemestane is already described, its 
stereochemistry had not been established. Therefore, two-dimensional NOESY 
experiments were used to assign the C-6 stereochemistry of compound 5. The most 
significant correlation to be studied was between the H-atoms of groups C-6 -O-CH2 
and 19-CH3 (Figure 1.17). For the 6α-isomer it was observed a strong correlation 
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between the H-atoms of the C-6 -O-CH2 and 19-CH3 groups, which implies that these 
H-atoms are spatially close enough to correlate. Hence the C-6 -O-CH2- will be pointing 
towards the beta face of the molecule being the epoxide functional group with alpha 
stereochemistry. For the 6β-isomer 5, it was not observed any correlation between the 
C-6 -O-CH2- and 19-CH3 H-atoms. This observation together with the study of the 
chemical shifts for the 19-CH3 H-atoms, which are shifted downfield when compared 
with that of the 6α-isomer, due to the higher influence of the electronegativity of the 
oxygen atom, allows one to conclude that the more abundant and isolated compound is 
the 6β-isomer 5.   
 
 
 
 
 
  
 
 
 The synthesis of epoxide 6 (Scheme 1.2) was performed by treatment of a 
methanol solution of exemestane (3) with an alkaline oxidizing solution of 35% 
hydrogen peroxide in a 4 N sodium hydroxide solution.79 The reaction was carried out 
at room temperature during 24 h and the crude product was purified by column 
chromatography affording the desired epoxide 6 in 11% yield.  
 Despite the reaction has not been complete, only compound 6 was detected.  
Figure 1.17 - Compound 5 (6β-isomer) and its 6α-isomer showing NOESY correlations (dashed line – absence of 
correlation; full line – strong correlation) 
6β-Epoxide isomer (compound 5) 6α-Epoxide isomer  
19 19 
6 6 
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 NOESY experiments were also used to unequivocally identify compound 6 
(Figure 1.18). The most significant signal analyzed was the correspondent to the 
resonance of 1-H atom at 3.58 ppm. It was observed a strong correlation between this 
H-atom and the H-atoms of group 19-CH3, which reveals that the 1-H must be assuming 
the beta configuration allowing an enhanced spatial proximity towards the C-19 angular 
methyl group (Figure 1.18). Hence, the isolated isomer will be the 1α,2α-epoxide 
compound 6.    
 
 
 
 
 
 
 
The reaction of exemestane (3) (Scheme 1.2) with a mixture of sodium 
borohydride in trifluoroacetic acid, glacial acetic acid and acetonitrile was performed in 
a nitrogen atmosphere.81 It led to a mixture of several compounds, being 7 and 8 the 
two main products, which were isolated through column chromatography. Compound 7 
was isolated in higher yield (39%) as a pure white solid residue and compound 8 was 
isolated in 12% yield.  
As the 1H NMR studies did not allow to unequivocally elucidate the position of 
the double bonds within the A-ring in compound 8, two-dimentional COSY 
experiments were performed. The most relevant signals analyzed in COSY spectrum 
were: the signal of the H-atoms from -CH2 group in C-3 at 2.77 ppm and the signals of 
the H-atoms of the double bonds at 5.66 ppm, 5.70 ppm and 5.92 ppm (Figure 1.19). 
Figure 1.18 - Compound 6 showing NOESY correlations (full line – 
existence of correlation) 
1 
19 
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The analysis of the spectrum showed a significant correlation between the two H-atoms 
of the C-3-methylidenegroup and the H-atoms resonating at 5.66 and 5.70 ppm, and a 
weaker correlation with the H-atom resonating at 5.92 ppm. This correlation pattern is 
consistent with the structure of compound 8 (Figure 1.19).   
 
 
 
 
 
 
 
 
1.1.3. Biochemistry and biology 
 Inhibition of aromatase activity by the synthesized steroids (5, 6 and 7) was 
evaluated in human placental microsomes by a radiometric assay in which tritiated 
water, released from [1β-3H] androstenedione into the incubation medium, was used as 
an index of estrogen formation.83 A screening assay was performed in human placental 
microsomes and the results obtained are shown in Table 1.2 as a percentage of 
inhibition (%). The assay was performed for all compounds at 2 µM, against an assay 
carried out in the absence of the inhibitor. The aromatase inhibitor formestane at 0.5 µM 
concentration (99.65 ± 0.06%) was used as reference.84,85 
 The IC50 of these compounds was also evaluated in MCF-7aro cells, an ER+ 
aromatase-overexpressing human breast cancers cell line, using the same radiometric 
assay, as reported in previous works of our group.84,85  
Figure 1.19 - Compound 8 showing COSY correlations (dashed line – weak correlation; 
full line – strong correlation) 
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 In addition, cell proliferation and cell viability were evaluated, also in MCF-7aro 
cells, according previous works of our group.84,85 All derivatives revealed to promote a 
decrease in both cell proliferation and cell viability. However, compound 6 promotes 
this effect in a more efficient way, even surpassing exemestane itself (unpublished 
results).  
 
 
Table 1.2 - Percentage of aromatase inhibition and IC50 values of tested compounds in 
human placental microsomes a) and in MCF-7aro cells b)  
 
 
 
 
 
 
 
 *Results for the IC50 of exemestane (3) described in the literature.47 
 
 
1.1.4. Structure-activity relationships discussion and conclusions  
 As pointed out before, exemestane is metabolized in vivo into active compounds. 
In this work, it were synthesized some potential metabolites of exemestane by 
substituing the double bonds of the A- and B-rings by epoxide groups (compounds 5 
and 6) and by reducing the C-17 carbonyl group to a hydroxyl group (compound 7). 
Looking at compounds 5 and 6 (Figures 1.17 and 1.18 and Table 1.2), we observed that 
the substitution of the double bond, both in the C-6 exocyclic and in C-1/C-2 position, 
Compounds 
Aromatase Inhibitiona) (%) 
± SEM 
IC50a) 
(µM) 
IC50b) 
(µM) 
5 93.64 ± 0.89 0.67 0.70 
6 86.78 ± 0.99 1.04 0.75 
7 - - 4.20 
Formestane (9) 99.65 ± 0.06 0.042 - 
Exemestane (3)* - 0.027 0.90 
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by the epoxide group, led to derivatives less potent in microsomes but even more potent 
in MCF-7aro cells than exemestane (3), being the exocyclic substitution (compound 5) 
slightly more potent, with an IC50 of 0.67 µM, in microsomes, and 0.70 µM in MCF-
7aro cells, than the substitution at C-1/C-2 (compound 6), with an IC50 of 1.04 µM and 
0.75 µM, in microsomes and MCF-7aro cells, respectively. In these two molecules it 
was maintained the integrity of the C-17 carbonyl group, which is known to be 
important to reach maximum aromatase inhibitory activity. In compound 7, this group 
was transformed into a hydroxyl group and a significant decrease in activity was 
observed (IC50 of 4.20 µM) in MCF-7aro cells. This decreasing of activity was already 
observed in other aromatase inhibitors for the same transformation. We believe that, 
contrary to what happens with the carbonyl group, the hydroxyl group does not allow 
the establishment of the hydrogen bond with Met374 residue of the active site of the 
enzyme (Figure 1.7), which is essential for a strong inhibitory activity. 
 When it was studied the cell viability and cell proliferative effects of the 
synthesized molecules (5, 6 and 7), we observed that they induced a decline in cell 
viability and proliferation in a more efficient way than exemestane. When the two 
epoxide inhibitors were compared, we observed that compound 6, although slightly less 
potent in inhibiting aromatase than 5, was the most effective derivative in reducing the 
cell viability and proliferation. This reveals that other mechanisms of cell death than 
aromatase inhibition may be involved, requiring further studies to elucidate the 
biological effects observed (unpublished results).   
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1.2. DERIVATIVES OF FORMESTANE 
 
1.2.1. Design and synthesis 
 Formestane (9) (Scheme 1.3), chemically described as 4-hydroxyandrost-4-ene-
3,17-dione, was the first selective aromatase inhibitor to become available in the clinic. 
Due to the high activity of this molecule and to the fact that its C-4 acetoxy derivative 
have also revealed to be a strong aromatase inhibitor,43 we decided to prepare several 
other C-4 ester derivatives related to formestane in order to study their activity against 
aromatase (Scheme 1.3).87 Moreover, an interesting feature related to breast cancer 
concerns the existence of an elevated expression of the enzyme cyclooxygenase 2 
(COX-2) in the tumor tissues. Based on this, it was hypothesized that the inhibition of 
COX-2 might decrease carcinogenesis by decreasing cell proliferation, angiogenesis 
and metastasis and increasing apoptosis.86-88 Further, epidemiologic studies suggest that 
the use of nonsteroidal anti-inflammatory drugs (NSAIDs), such as acetylsalicylic acid, 
protects against breast cancer development. Hence, we felt that it would be interesting to 
develop C-4 acetoxy and acetylsalicyloxy derivatives of formestane (9) (Scheme 1.3).76 
In the case of the C-4 acetylsalicyloxy derivative, we intended to combine in the same 
steroidal structure, the dual capacity of aromatase and COX-2 inhibition. Hence, the 
acetyl derivatives 10 and 12 were prepared through classical acetylation conditions from 
the corresponding alcohols using the respective acyl chloride.  
 Based on the rationale that the presence of the carbonyl group at C-3 is not 
mandatory to bind the molecule to the enzyme,80 we were also interested in preparing 
the corresponding C-3 deoxyderivatives 11, 13a and 14. For this, compounds 10 and 12 
were submitted to a Clemmenson-type reduction with zinc dust in acetic acid solution. 
This allowed to obtain, respectively, compounds 11 and 13a in mixture with 13b. In 
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order to achieve compound 14, we subjected formestane to the reaction conditions of 
Hanson et al.81 where it was used sodium borohydride in a mixture of trifluoroacetic 
acid, acetonitrile, acetic acid and dichloromethane to promote the deoxygenation of the 
C-3 carbonyl group. However, this only allowed to isolate 14a. 
 
 
Scheme 1.3 - Synthesis of derivatives of formestane (9) 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Reagents and Conditions: (i) acetyl chloride, anhydrous pyridine, rt, 21 h 50 min; (ii) o-
acetylsalicyloyl chloride, anhydrous pyridine, rt, 24 h 40 min; (iii) Zn dust, acetic acid, rt; (iv) 
CF3COOH, CH3COOH, CH3CN, NaBH4, anhydrous dichloromethane, rt, 45 min. 
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 1.2.2. Chemistry 
 Compound 9 was treated with acetyl chloride in anhydrous pyridine leading, 
after crystallization, to the pure compound 10, in 72% yield. Subsequently, compound 
10 was treated with zinc dust in acetic acid solution leading to a mixture of 5α- and 5β-
epimers, which after crystallization with petroleum ether allowed the isolation of the 
desired pure 5α-epimer, compound 11.  
 Treatment of 9 with o-acetylsalicyloyl chloride in anhydrous pyridine led, after 
purification by column chromatography, to a main fraction (one single TLC spot), 
which after NMR analysis revealed to be composed by a mixture of compounds 10 and 
12, in a 40:60 proportion, respectively. The formation of compound 10 probably 
resulted from an interestingly intramolecular transesterification occurred in 12, 
according to the proposed mechanism (Scheme 1.4). This may involve the formation of 
a cyclic intermediate, which then opens through alkaline catalysis leading to formation 
of 10 and salicilic acid. Further purification of this mixture by another column 
chromatography, using a different mixture of solvents, allowed the isolation of the pure 
compound 12. Treating 12 with zinc dust in acetic acid solution led to an inseparable 
epimeric mixture of 13a, and its 5β-epimer (13b) in a 70:30 proportion, respectively 
(NMR analysis). 
 The reaction of formestane (9) with the reductive mixture of sodium 
borohydride in trifluoroacetic acid, glacial acetic acid and acetonitrile was performed 
under a nitrogen atmosphere, in order to attempt the preparation of the 3-deoxy 
derivative 14.81 However, instead of 14, a mixture of compounds was obtained from 
which 14a was isolated through a column chromatography as a white solid, in 65% 
yield. 
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Scheme 1.4 - Proposed mechanism for the intramolecular transesterification of 12 to 
obtain derivative 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.3. Biochemistry  
 Inhibition of aromatase activity by the synthesized steroids 11 and 12 was 
evaluated in human placental microsomes as mentioned formerly (Section 1.1.3). A 
screening assay was performed and the results obtained are shown in Table 1.3 as a 
percentage of inhibition (%).76 
 
 
1.2.4. Structure-activity relationships discussion and conclusions  
 As pointed out previously, some recent studies suggest that the use of NSAIDs, 
such as acetylsalicylic acid, protects against breast cancer development.86-88 
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Additionally, the C-4 acetoxy derivative 10 of formestane (9), the first steroidal AI 
clinically used also revealed to be a strong inhibitor.89 In this manner, a new AI 
(compound 12) based on 9 was designed and synthesized, by esterification of its C-4 
hydroxyl group with the acetylsalicylic acid moiety. However, the C-4 acetylsalicyloxy 
derivative 12 showed a pronounced decrease in aromatase inhibition when compared 
with its precursor 9. 
 
  
Table 1.3 - Percentage of aromatase inhibition of tested compounds in human placental 
microsomes76  
 
 
 
 
 
 
 *Data for compound 10 described in the literature.89 
 
 
 The results obtained suggest that the presence of bulky substituents in C-4 
diminishes the aromatase inhibitory activity, which is consistent with the short volume 
of the binding pocket of aromatase. The C-4 acetoxy derivative 11 also showed a 
dramatic reduction in the aromatase inhibitory activity (Table 1.3), when compared with 
that of 10 showing that the C-3 carbonyl group would be potentially important, in this 
case. This decrease in activity can be also due to the displacement of the 4,5 double 
bond to the 3,4 position, reinforcing the importance of having planarity in the A,B-ring 
Compounds Aromatase Inhibition (%) ± SEM 
  10* 81 
11 33.90 ± 1.68 
12 68.73 ± 3.53 
Formestane (9) 99.65 ± 0.06 
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junction at C-5 as previously observed by our group.76,80,90 This hypothesis might be 
corroborated when we compare 11 with the C-4 acetoxy derivative of Δ4-olefin (Figure 
1.20), which is a strong competitive inhibitor (IC50 = 0.66 µM).77,91 It is also interesting 
to compare the activity of 11 with that of Δ3-olefin 27a (Scheme 1.6 – Section 1.3.2). 
We observed a decrease in the activity when we go from Δ3-olefin 27a to its C-4 
acetoxy derivative 11. In this case, the introduction of a C-4 acetoxy group did not 
maintain the aromatase inhibitory activity, in contrary to that observed for 10 relatively 
to 9.  
 
 
 
 
 
 
 
 
 Further studies in COX-2 inhibition were not performed due to the weak 
aromatase inhibitory activity of compound 12. 
 
 
 
  
Figure 1.20 - Structure of 4-acetoxyandrost-4-en-17-one 
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1.3. A- AND D-RING MODIFIED DERIVATIVES OF ANDROSTENEDIONE 
 
1.3.1. C-3 Hydroxyl Derivatives of Androstenedione and Testosterone 
 
 1.3.1.1. Design and synthesis 
 After the elucidation of the active site of the enzyme aromatase and the 
establishment of the structural bases of the enzyme-substrate interaction,28 a more 
rational design of new AIs was allowed. Among other interactions, aromatase 
establishes two main hydrogen bonds with the oxygen atoms of the carbonyl groups at 
C-3 and C-17 of androstenedione.28 From a previous study, it was concluded that the 
presence of the carbonyl group at C-3 is not absolutely necessary to allow the binding of 
steroid molecules to the enzyme.80 Other authors described strong aromatase inhibitors 
without the C-17 carbonyl group.92 Recently, our group also confirmed those facts and 
postulated that it is necessary, at least, one carbonyl group (C-3 or C-17) in order to 
allow the binding of steroid molecules to aromatase.90  
In this work, we were interested in studying steroid molecules as aromatase 
inhibitors in which the carbonyl group at C-3 (a hydrogen bond acceptor) of 
androstenedione, was replaced by a hydroxyl group (a hydrogen bond donor) and also 
in which the two carbonyl groups (C-3 and C-17) were replaced by two hydroxyl 
groups. The design of these compounds was based in the structure of the substrates of 
the enzyme, androstenedione and testosterone (substrate-based design), and in the 
interactions of these substrates with the enzyme. The effect of the stereochemistry of the 
hydroxyl group at C-3 was also explored (Scheme 1.5). For this purpose, we studied 
reduction conditions of the carbonyl group by using two different hydride reagents, 
sodium borohydride and lithium tri-t-butoxy aluminum hydride, in order to obtain 
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compound 16 from compound 15. Compound 17 was in turn prepared from the 
commercially available compound 21. Reduction of testosterone acetate derivative 18, 
with sodium borohydride gave an isomeric mixture of 3α (10%) and 3β (compound 19). 
The effect of different functional groups at C-17, such as carbonyl (compound 20), 
hydroxyl (compound 16) and acetyl (compound 19), was also studied for the series of 
3β-OH derivatives. 
 
 
Scheme 1.5 - Synthesis of C-3 hydroxyl derivatives of androstenedione (1) and 
testosterone (15)  
 
 
 
 
 
 
 
 
Reagents and conditions: (i) NaBH4, methanol, rt; (ii) (t-butoxi)3AlLiH, tetrahydrofuran, reflux, 
8 h 20 min; (iii) (CH3CO)2O, pyridine, rt, 21 h 25 min. 
  
 
 
3α isomer (10%) 
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 1.3.1.2. Chemistry 
 The synthesis of derivative 16 was performed from 15 through two different 
methods (Scheme 1.5), in an attempt to achieve stereoselectivity in the reduction of the 
C-3 carbonyl group. In the first approach, testosterone (15) reacted with sodium 
borohydride, in methanol, at room temperature yielding a mixture of the 3β- and 3α- 
isomers, which after crystallization afforded 21% of compound 16 (Method A). In the 
second method, testosterone (15) was refluxed in tetrahydrofuran with lithium tri-t-
butoxyaluminum hydride.93 However, this reduction also led to a mixture of the 3β- and 
3α-isomers, which after crystallization gave a similar amount of compound 16 (Method 
B). Testosterone (15) was also converted to its acetate derivative 18, by acetylation with 
acetic anhydride, in 84% yield (Scheme 1.5).94 Compound 18 was then reduced with 
sodium borohydride, leading to a mixture of the 3β- (compound 19) and 3α-epimers  
(90:10 respectively, NMR and HPLC). Attempts to isolate 3β-isomer by crystallization 
led however to enrichment of the obtained mixture in the 3α-isomer. Compound 17 was 
obtained quantitatively from the commercially available compound 21, by reduction 
with sodium borohydride in methanol, at room temperature (Scheme 1.5).  
 
 
1.3.1.3. Biochemistry and biology  
 Inhibition of aromatase activity by the synthesized steroids (16, 17, 19, 20 and 
21) was evaluated in human placental microsomes as mentioned formerly (Section 
1.1.3). The screening assay was performed in human placental microsomes and the 
results obtained are shown in Table 1.4 as a percentage of inhibition (%).76 
 For the most potent inhibitor of this series, steroid 20, the IC50 was determined 
in human placental microsomes and also in MCF-7aro cells as described formerly 
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(Section 1.1.3), and the kinetic studies to characterize the type of binding to the active 
site of the enzyme and the apparent inhibition constant, were also performed (Table 
1.5). This steroid revealed to be a powerful competitive inhibitor.76 
 The effect of derivative 20 in cell viability and cell proliferation was assessed in 
MCF-7aro cells. Compound 20 inhibits aromatase in MCF-7aro cells.95 It was also 
observed that 20 induced a significant decrease in cell viability and proliferation in a 
dose- and time-dependent maner.95,96 To evaluate if the biological effect of 20 in MCF-
7aro cells was depend on ER, it was also studied the effect in an ER- human breast 
cancer cell line SK-BR-3. It was also observed a decrease in their viability, which 
means that 20 induces its effect in cells in a ER-independent way.95 
 
 
Table 1.4 – Aromatase inhibition of tested compounds in human placental 
microsomes76  
 
 
 
 
 
 
 
 
   
 * 90% was the best purity achieved 
 
 
 
 
Compounds Aromatase Inhibition (%) ± SEM 
16 56.82 ± 5.59 
17 6.59 ± 2.00 
  19* 4.60 ± 0.40 
20 93.14 ± 2.36 
21 60.84 ± 2.61 
Formestane (9) 99.65 ± 0.06 
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Table 1.5 – IC50 determined in human placental microsomes a) and in MCF-7aro cells 
b) and kinetic studies for the most potent inhibitor76,95 
 
Compounds 
IC50 
(µM)a) 
IC50 
(µM)b) 
Type of 
Inhibition 
Vm 
(mol/min./µg prot) 
Ki 
(µM) 
Real Affinity 
(Km/Ki) 
 (nM) 
20 0.183 0.600 competitive 0.225 ± 0.025 0.100 1.026 ± 0.026 
Formestane (9) 0.042 - - - - - 
 
 
1.3.1.4. Structure-activity relationships discussion and conclusions  
 It is known that aromatase establishes two main hydrogen bonds with the 
carbonyl functions at C-3 and C-17 of its natural substrate 1.28 Nevertheless, it was 
observed that the presence of the carbonyl group at C-3 is not mandatory to bind steroid 
molecules to the enzyme aromatase and to get aromatase inhibition.80 The C-17 
carbonyl group, however, seems to have a more important role in steroidal AIs. In any 
case, at least one of the referred carbonyl groups must exist in order to allow the binding 
of steroid molecules to the enzyme aromatase.90  
 In this chapter, several steroid molecules were studied as AIs, in which the 
carbonyl group at C-3 (a hydrogen bond acceptor) of the substrate of the enzyme (1), 
was replaced by a hydroxyl group (a hydrogen bond donor). In another group of 
compounds, the two carbonyl groups (C-3 and C-17) were replaced by two hydroxyl 
groups. Looking at compounds 20 and 21 (Scheme 1.5 and Tables 1.4 and 1.5), we 
observed that the substitution of the C-3 carbonyl group of 1 by a C-3 hydroxyl group, 
maintaining the C-17 carbonyl group, led to a potent AI when the C-3-OH group 
assumes the 3β stereochemistry. Compound 20 revealed to be a very strong aromatase 
inhibitor, with an IC50 of 0.180 µM and 0.600 µM in microsomes and in MCF-7aro 
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cells, respectively, and having also a high affinity to the enzyme (Ki of 0.1 µM) (Table 
1.5). The C-3α-OH analog 21 was not as good AI as 20. Changing the two C-3 and C-
17 carbonyl groups of 1 by hydroxyl groups, a dramatic decrease in the activity was 
observed (compounds 16 and 17), particularly if the C-3-OH assumes the 3α 
stereochemistry (compound 17) (Table 1.4). This decrease was also observed for other 
compounds submitted to the same type of transformation in C-17.90 The lack of both C-
3 and C-17 carbonyl groups in 16 and 17 can explain the inability of these steroids to 
bind conveniently to the enzyme with the consequent loss of activity. As the C-3-OH 
stereochemistry seems to play an important role in the aromatase inhibitory capacity of 
this kind of compound, a molecular docking study in the aromatase active site was 
performed for compounds 20 and 21.  
 Molecular modelling studies revealed the ability of both compounds to establish 
one hydrogen bond (1.8Å) between the C-17 carbonyl group and the Met374 residue. 
Accordingly, the different aromatase recognition of 20 and 21 can be addressed to the 
hydrogen bond network of C-3-OH. In the former case, 20 donates and accepts two 
hydrogen bonds with Thr310 (2.1Å) and Ile305 (2.4Å), respectively, (Figure 1.21), and 
in the latter case, 21 establishes only one hydrogen bond with Asp309 residue (2.1Å) 
(data not shown).  
 Concerning compound 19 (Scheme 1.5), the substitution of the C-17 hydroxyl 
group by the C-17 acetoxy group dramatically reduces the aromatase inhibitory activity 
(Table 1.4). The acetoxy moiety, that is a bulky group, may cause steric hindrance at the 
enzyme active site. This is in accordance with previous studies90 and is consistent with 
the short volume (400Å3) of the aromatase binding pocket, as recently described, which 
only accommodates molecules with the appropriate dimensions and with small 
substituents.28 
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Figure 1.21 - Best pose of inhibitor 20 within the aromatase binding pocket shown as a transparent cartoon. 
The ligand is represented as a yellow carbon polytube model. The heme and the labelled residues interacting via 
hydrogen bonds are, respectively, displayed by cyan and magenta carbon poytubes models. Hydrogen bonds are 
depicted as dashed black lines, and their distances are measured in Å.   
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1.3.2. A-Ring Olefins and Epoxides Derivatives of Androstenedione 
 
 1.3.2.1. Design and synthesis 
An important role in the manifestation of biological activity towards aromatase 
is played by the A-ring. Hence, there are some important features to attend when 
designing and synthesizing new compounds as AIs, like the pattern of substitution 
among the several positions and the stereochemistry at C-5 in the A,B-ring fusion. 
These will in turn be of huge influence in the planarity of A-ring, one of the most 
important features to allow a better fitting of steroids in the active site of the 
enzyme.77,91,97 
In our recent studies we also noticed that some planarity in the A-ring and in the 
A,B-ring junction is important for the inhibitory activity of steroids against 
aromatase.80,90 This planarity can be conferred by a double bond or by an epoxide 
function both containing similar bond geometries. Recently, we were interested in 
studying the influence of the position of the double bond or the epoxide function along 
the A-ring, in aromatase inhibitory activity. For this, we prepared two series of steroid 
compounds: Δ4, Δ3, Δ2 and Δ1-olefins (compounds 25, 27a, 29 and 34, respectively) and 
4,5-, 3,4-, 2,3- and 1,2-epoxides (compounds 26a, 28, 30 and 35, respectively) (Scheme 
1.6) and studied their inhibitory activity against aromatase. 
 
For the synthesis of the Δ4-olefin 25 (Scheme 1.6), we followed a strategy 
already used by Numazawa et al.98 where androstenedione (1) was subjected to a 
protection reaction of its C-3-carbonyl group followed by a reduction using sodium 
metal in liquid ammonia.  
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In the meanwhile, we have developed another synthetic strategy based on the C-
3 deoxygenation of testosterone acetate 36,81 followed by the acetate group hydrolysis, 
ending with the hydroxyl group oxidation (Scheme 1.6). Although this new strategy 
involves another step when compared with the former one, its overall yield is much 
better (62% vs 38%) and it does not form by-products.   
 For the synthesis of the Δ3-olefin 27a we followed the method of Mckenna et 
al.99 formerly optimized by our group, where androstenedione (1) was reduced with 
zinc dust in glacial acetic acid at reflux temperature (Scheme 1.6).100  
 For the preparation of the Δ1-olefin 34 we used a four step approach developed 
by Bowers et al.101 which involved an initial reduction of the enone 31 with lithium tri-
t-butoxy aluminium hydride, followed by reaction of the formed allylic alcohol 32 with 
thionyl chloride and then, lithium aluminium hydride giving compound 33a in mixture 
with 33b, which were oxidized with Jones reagent to compound 34 and 29 (Scheme 
1.6). We have also intended another alternative strategy to obtain the Δ1-olefin 34. 
Hence, we adapted the one used by Numazawa et al. for the synthesis of Δ4-olefin 25, 
which involved the C-3 carbonyl group protection followed by reduction with sodium 
metal in liquid ammonia.98 However, in this case, right in the first step of the strategy, 
the reaction of protection of the C-3 carbonyl group with ethane-1,2-dithiol, it was 
observed the production of several compounds being the desired protected one obtained 
only in very small yield which was an obstacle to proceed with this strategy.  
  
 The 4,5-, 3,4-, 2,3- and 1,2-epoxides were prepared using Δ4, Δ3, Δ2 and Δ1-
olefins, respectively, as starting materials (Scheme 1.6). For these syntheses, the 
referred olefins were treated with performic acid generated in situ, which allowed the 
formation of the desired epoxides.100 For 2,3-epoxide 30 it was also used the technique 
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formerly used by Campbell et al.102 where the oxidation reagent was peracetic acid 
instead of the performic acid, in order to try to increase the yield.  
 We were also interested in synthesizing the Δ4-olefin 25 (Scheme 1.6) using the 
four step strategy from Bowers et al.,101 previously used in the synthesis of the Δ1-
olefin 34. Surprisingly, in this case, instead of compound 25, it was obtained the Δ3,5-
diene 40 (Scheme 1.7).94 
 Preparation of compound 40, which is also an AI, was previously described by 
different synthetic strategies.103-108 However, this is the first time it is prepared by this 
way. Hence, it was performed the C-3 carbonyl reduction of testosterone acetate 
derivative (18) using lithium tri-t-butoxy aluminium hydride, followed by reaction of 
the obtained 37 with thionyl chloride, giving 38, which by hydrolysis with lithium 
aluminium hydride afforded 39. Jones oxidation of 39 led to 40. 
 
 
 1.3.2.2. Chemistry  
Androstenedione (1) was prepared through Jones oxidation of testosterone (15) 
as described before (Section 1.1.2). Protection of the C-3 carbonyl group of 
androstenedione (1) was undertaken by treatment of 1 with ethane-1,2-dithiol in 
anhydrous tetrahydrofuran and in the presence of anhydrous p-toluenesulfonic acid 
(Scheme 1.6).109 The crude product obtained was purified by column chromatography 
affording the protected compound 22 in 84% yield. Desulfurization of compound 22 
with sodium-ammonia in anhydrous tetrahydrofuran,98 afforded compound 25 in 46% 
yield and compound 23 in 26% yield.  
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Scheme 1.6 - Synthesis of A-ring olefin and epoxide derivatives of androstenedione (1)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagents and conditions: (i) CrO3, H2SO4, acetone, rt; (ii) Zn dust, acetic acid reflux, 15 min; 
(iii) H2O2, HCOOH, dichloromethane, rt; (iv) CH3COOOH, CH3COONa.3H2O, chloroform, rt, 
7 h 30 min; (v) HSCH2CH2SH, pTSA, anhydrous tetrahydrofuran, rt, 4 h; (vi) Na, NH3, 
anhydrous tetrahydrofuran, -65 ºC, 25 min; (vii) (t-butoxi)3AlLiH, anhydrous tetrahydrofuran, 
      + 
5β isomer  
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reflux, 3 h 15 min; (viii) SOCl2, benzene, 5-8 ºC, 3 h 15 min; (ix) AlLiH4, diethyl ether, reflux, 
10 h 30 min; (x) CrO3, H2SO4, acetone, 0 ºC; (xi) (CH3CO)2O, pyridine, rt, 21 h 25 min; (xii) 
NaBH4, CF3COOH, CH3COOH, CH3CN, dichloromethane, rt, 3 h 30 min; (xiii) 2% NaOH, 
dioxane/water, rt, 52 h. 
 
  
 The crude material resulting from the treatment of compound 25, in 
dichloromethane, with performic acid was purified by column chromatography allowing 
the isolation of one main fraction (one TLC spot). NMR analysis of this fraction 
revealed to be a mixture of the isomers 26a and 26b, in 66:34 proportion. Further 
purification by column chromatography allowed the isolation of the pure compound 26a 
in 38% yield and 26b in 63%. Compound 23 was treated in the same way as compound 
25, allowing to obtain a fraction which after NMR analysis revealed to be an 
inseperable mixture of the two 4,5-epoxide isomers 24a and 24b (Scheme 1.6).  
In agreement with a previous description of our group,80 a Clemmenson-type 
reduction of 1 with zinc dust in acetic acid solution gave a mixture of 5α- (27a) and 5β-
epimers (27b) from which the 27a was isolated by n-hexane crystallization, in 60% 
yield. Treatment of 27a with performic acid in dichloromethane led to the epoxide 
derivative 28, in 96% yield (Scheme 1.6).80  
 Compound 30 was synthesized from the commercially available 29 using two 
different protocols: with performic acid, Procedure A,90 and with peracetic acid, 
Procedure B (Scheme 1.6).102 As the starting material 29 was only available in 92% 
purity (it is supplied in a 92:8 inseparable mixture with its isomer 27a), the resulting 
2,3-epoxide 30 was also obtained in the same purity (92%) (NMR and HPLC analysis), 
by both procedures.   
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Scheme 1.7 - Synthesis of aromatase inhibitor 40 from 15  
 
 
 
 
 
 
Reagents and conditions: (i) (CH3CO)2O, anhydrous pyridine, rt, 21 h 25 min; (ii) (t-
butoxi)3AlLiH, anhydrous tetrahydrofuran, reflux, 3 h 30 min; (iii) SOCl2, benzene, 5-8 ºC, 5 h 
30 min; (iv) AlLiH4, ethyl ether, reflux, 8 h; (v) CrO3/pyridine, pyridine, rt, 19 h. 
 
  
Compound 34 was prepared following a described strategy.101 Treatment of 
enone 31 with lithium tri-t-butoxy aluminum hydride led to the desired allylic alcohol 
32, in 94% yield (Scheme 1.6). The allylic alcohol 32 was then treated with thionyl 
chloride in benzene. From this reaction, an untractable crude (TLC, NMR and LC-MS 
control) was obtained, which was used as starting material in the next reaction. 
Treatment of this crude with lithium aluminium hydride led, after conventional workup, 
followed by column chromatography, to an isomeric mixture (one TLC spot) of 
compounds 33a and its Δ2-isomer 33b (90:10, NMR analysis) (Scheme 1.6).  
An attempt to separate compounds 33a and 33b was made using a neutral 
alumina column chromatography and n-hexane/dichloromethane. However, the isolated 
fractions, subjected to 1H NMR analysis, always revealed to be isomeric mixtures with 
variable compositions (from 25:75 to 90:10 of 33a and 33b, respectively). The 
oxidation of the isomeric mixture (90:10) of these compounds was then performed 
+ traces of 
 3α-isomer 
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using Jones reagent, giving a mixture of 29 and 34. This mixture was then subjected to 
a laborious purification process by column chromatography and consecutive 
recrystallizations, allowing the isolation of Δ1-olefin 34 in the required purity for further 
biological studies (96% by LC-MS control).  
 
Although the formation of the Δ2-isomer 33b has not been previously referred in 
the followed synthetic strategy,101 our results revealed that isomerisation of the double 
bound from the Δ1- to the more stable Δ2-position occurred in a considerable extension. 
In fact, the Δ1- and Δ2-isomers (34 and 29) revealed similar physico-chemical 
properties, presenting the same Rf values over several chromatography solvents, and 
similar crystallization conditions. Moreover, as they have the same exact mass, it was 
difficult to distinguish them by mass spectrometry and elemental analysis techniques. 
Facing these difficulties, the complete diagnosis of the double bond position in these 
compounds could only be achieved by NMR spectroscopy. The Δ1-isomer 34 presents 
two proton signals at 5.52 ppm (2-H) and 5.83 ppm (1-H) for the olefinic H-atoms, 
whereas the Δ2-isomer 29 presents only one common typical multiplet around 5.9 ppm, 
for the two olefinic 2-H and 3-H atoms, allowing the accurate identification of both 34 
and 29. Therefore, the NMR analysis appears to be the most adequate technique to 
follow the formation of these compounds.  
Treatment of 34 with a solution of performic acid in dichloromethane allowed to 
prepare and isolate compound 35 in 15% yield. 
In order to also obtain the Δ4-olefin 25 through a different strategy, to overcome 
the low yield of the first strategy described, it was applied the same approach of the four 
step pathway used for the Δ1-olefin. However, in this case, instead of Δ4-olefin we 
obtained the Δ3,5-diene 40 (Scheme 1.7). For this, testosterone (15) was converted into 
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its acetate derivative 18, in 84% yield. Treatment of 18 with lithium tri-t-
butoxyaluminum hydride, in the conditions previously described, led to the Δ4-3β-
allylic alcohol 37 with traces of its 3α-isomer. Treatment of this mixture with thionyl 
chloride in benzene, contrarily to what was expected, gave the Δ3,5-diene 38, according 
to the proposed mechanism (Scheme 1.8). Therefore, considering an E1 elimination 
mechanism, an allylic cation would be formed from the chlorosulfinate ester 
intermediate 37’. This is a particularly stable tertiary allylic cation that favours the 
elimination reaction to form 38 (Scheme 1.8). On the other side, a SN2 nucleophilic 
substitution displacement would provide a C-3 allylic chloride 37’’ with inversion of 
configuration, which could also afford compound 38 through the same allylic cation 
formed by the E1 mechanism (Scheme 1.8). As observed, both mechanisms concur for 
the formation of the stabilized tertiary allylic cation, explaining diene 38 as the only 
product formed. 
To complete the synthetic strategy, the diene 38 was treated with lithium 
aluminium hydride giving the Δ3,5-diene derivative 39, which after oxidation with 
chromium trioxide in pyridine110 led to Δ3,5-diene 40. The classical Jones reaction did 
not allow the oxidation of compound 39. This approach allowed to find a new way to 
prepare compound 40, which is also an AI.108 
As the 1H NMR did not allow to unequivocally elucidate the position of the 
diene C=C bonds in the A,B-ring system, two-dimensional COSY experiments of 
compound 38 were performed. The most relevant signals analysed in the COSY 
spectrum were for the three olefinic H-atoms at 5.9, 5.6, and 5.4 ppm; for the 17α-H 
atom at 4.5 ppm; and for the 18-CH3 and 19-CH3 H-atoms at 0.82 and 0.95 ppm, 
respectively (Figure 1.22). The 17α-H atom correlates with 18-CH3 H-atoms (3J), which 
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resonates at 0.82 ppm, therefore the resonance at 0.95 ppm is unequivocally due to 19-
CH3 H-atoms.  
 
 
Scheme 1.8 - Proposed mechanism for the formation of 38  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Focusing on the three olefinic H-atoms and concerning the Δ3,5-diene isomer 38 
(Figure 1.22), the C-4 H-atom will correlate strongly with the C-3 H-atom and weakly 
with the C-6 H-atom. In fact, we observed that an olefinic H-atom at 5.9 ppm (the 4-H) 
strongly correlates with another olefinic H-atom at 5.6 ppm (the 3-H) (3J); the same 
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olefinic H-atom at 5.9 ppm has a very weak correlation with an olefinic H-atom at 5.4 
ppm (the 6-H) (4J) and there is no observable correlation between the olefinic H-atoms 
at 5.6 ppm (the 3-H) and 5.4 ppm (the 6-H) (5J), respectively (Figure 1.22). Therefore, 
the signal at 5.6 ppm unequivocally belongs to C-3 H-atom, the signal at 5.9 ppm to C-4 
H-atom, and the signal at 5.4 ppm to C-6 H-atom, which is in agreement with the 
structure of compound 38. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Since the former strategy did not turn out as we expected, Δ4-olefin 25 was 
prepared by a new alternative synthetic strategy, which is depicted in Scheme 1.6. In 
Figure 1.22 - Expansion of the COSY spectrum of compound 38 in the region of the olefinic H-atoms (bold line – 
strong correlation; plain line – weak correlation; dashed line – absence of correlation). Each olefinic H-atom is 
identified in the figure. It is also highlighted the strong correlation (full arrow), between 4-H and 3-H, and the 
very weak one (dashed arrow), between 4-H and 6-H 
 
4-H 
3-H 
6-H 
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this case, testosterone (15) was converted to its acetate derivative 18 with acetic 
anhydride, in 84% yield. Then compound 18 was treated with a mixture of sodium 
borohydride in trifluoracetic acid, glacial acetic acid and acetonitrile in nitrogen 
atmosphere,81 giving compound 36 in 99% yield. This compound was then submitted to 
a base-catalyzed hydrolysis giving quantitatively compound 23, which was then 
subjected to Jones oxidation leading to the desired Δ4-olefin 25, in 75% yield. This new 
strategy has the advantage of allowing a better overall yield without the formation of 
isomers, hence with easier purification procedures.  
 
 
1.3.2.3. Biochemistry and biology 
 Inhibition of aromatase activity by the synthesized steroids (25, 26a, 26b, 27a, 
28, 29, 30, 34 and 35) was evaluated in human placental microsomes as mentioned 
formerly (Section 1.1.3). The results obtained are shown in Table 1.6 as a percentage of 
inhibition (%).76 
 For the most powerful AIs 25, 26a, 26b, 27a, 28, 29 and 30 the IC50 in human 
placental microsomes was determined, and kinetic studies, to characterize the type of 
binding to the active site of the enzyme and the apparent inhibition constant, were also 
performed (Table 1.7). These steroids revealed to be competitive inhibitors of 
aromatase.76  
 Previously described values for the IC50 and Ki for compound 40 were also 
presented in Table 1.7.108 
 For compounds 25, 26a and 29 the IC50 was also determined in MCF-7aro cells 
as described formerly (Section 1.1.3) (Table 1.7).95  
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 Additionally, the effect of derivatives 25, 26a and 29 in cell viability and cell 
proliferation was assessed in MCF-7aro cells. These compounds inhibit aromatase in 
MCF-7aro cells causing a significant decrease in their viability and proliferation in a 
dose- and time-dependent manner, being compound 25 the most efficient while 29 is the 
less potent in decreasing cell viability.95,96  
 To evaluate if the biological effects of 25, 26a and 29 in MCF-7aro cells were 
ER-dependent or not, they were also studied in the ER- human breast cancer cell line 
SK-BR-3. All compounds induced a decrease on the viability of SK-BR-3 cells in a 
dose-dependent manner, suggesting that these AIs can induce their effects in cells in an 
ER-independent manner. Results indicate that compounds 25 and 26a induced a 
decrease in MCF-7aro cell viability in an aromatase-dependent way but ER-independent 
manner, whereas for compound 29 the reduction was both aromatase- and ER-
independent.95  
 The biological effects of compounds 25 and 26a were also investigated in 
LTEDaro cells (long-term estrogen deprivation human breast cancer cell line) that 
represent a good model to study AI acquired resistance. It was also observed a decrease 
in these cells viability being compound 25 the most efficient. An interesting observation 
was that exemestane, the only steroidal AI in clinical use, which was used as a 
reference, has no effect in this cell line,95 revealing compound 25 to be very promising 
as a drug for resistant breast cancer. 
 
 
1.3.2.4. Structure-activity relationships discussion and conclusions  
As reported before, some planarity in the A-ring and in the A,B-ring junction 
reveals to be important for steroids to have anti-aromatase activity.80,90  This planarity 
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could be achieved by introducing double bonds or epoxide functions into the A-ring, 
both possessing similar bond geometries. In this part of the work, we were interested in 
studying the effect of the double bonds and the epoxide groups in several positions 
along the A-ring, in aromatase inhibitory activity.  
 
 
Table 1.6 – Aromatase inhibition of tested compounds in human placental 
microsomes76  
 
 
 
 
 
 
 
  
 
 
 
 Considering the A-ring olefins (25, 27a, 29 and 34) and the corresponding 
epoxides (26a, 28, 30 e 35) (Scheme 1.6), it was observed that 4,5-olefin 25 and 1,2-
olefin 34 are better AIs than the corresponding epoxides 26a and 35, respectively 
(Tables 1.6 and 1.7). Interestingly, and on the contrary, the 3,4-epoxide 28 and the 2,3-
epoxide 30 are better AIs than the corresponding olefins 27a and 29 (Tables 1.6 and 
1.7). We believe that this is probably due to the possibility of the oxiran oxygen atom of 
Compounds Aromatase Inhibition (%) ± SEM 
25 97.84 ± 0.19 
26a 84.59 ± 0.51 
26b 84.54±0.62 
27a 95.90 ± 0.60 
28 96.40 ± 0.10 
29 72.05 ± 2.60 
30 70.70 ± 4.25 
34 55.99 ± 1.86 
35 40.01 ± 2.05 
Formestane (9) 99.65 ± 0.06 
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the epoxide 28 and 30, which is near the C-3 atom, may resemble the C-3 carbonyl 
oxygen of the aromatase substrate 1, allowing it to establish hydrogen bonds with 
aromatase active site residues and contributing for a strong binding of the inhibitor with 
aromatase. In fact, this hypothesis was already explored in a recently published work of 
our group, for the 3α,4α-epoxy-5α-androstan-17β-ol.90 Computer-assisted molecular 
modelling studies also indicate epoxide 28 as being able to accept two hydrogen bonds 
with the aromatase. Notably, they are both established with the Thr310 residue (Figure 
1.23), in particular with the NH (2.4Å) backbone and OH side chain (2.3Å). 
Interestingly, in the lowest energy pose, inhibitor 28 fits the receptor core adopting an 
inverted positioning when compared with aromatase substrate 1, keeping the C-19 
methyl group in the opposite side of the heme group.76 
 When we compare 4,5-epoxides 26a and 26b, we see that, contrary to what 
usually happens, in this particular case the beta stereochemistry still allows a derivative 
with enhanced inhibitory activity (IC50 = 0.530 vs 0.970 µM) (Tables 1.6 and 1.7). This 
must be a consequence of the similar conformations that the steroidal A-ring adopts in 
both epoxides.  
 Another observation related with SAR of A-ring olefins and epoxides is that 
when the double bond is closer to the A,B-ring junction in C-5, the highest aromatase 
inhibition is reached (Tables 1.6 and 1.7), confirming that the planarity in the C-5 A,B-
ring junction is very important to aromatase inhibition. In fact, among the studied olefin 
and epoxide compounds, 4,5-olefin 25 showed the best aromatase inhibition. 
Numazawa et al. had already described this compound as a very strong aromatase 
inhibitor.98 Among the epoxides, compound 28 showed the best aromatase inhibitory 
activity (IC50=0.145 µM). 
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Table 1.7 – IC50 determined in human placental microsomes a) and in MCF-7aro cells 
b) and kinetic studies for the most potent inhibitors of this series76,95 
 
Compounds 
IC50a) 
(µM) 
IC50b) 
(µM) 
Type of 
Inhibition 
Vm 
(mol/min./µg 
prot) 
Ki 
(µM) 
Real Affinity 
(Km/Ki) (nM) 
25 0.135 5.0 - - - - 
26a 0.970 8.5 competitive 0.015 ± 0.001 0.086 0.636 ± 0.058 
26b 0.530 - - - - - 
27a 0.225 - competitive - 0.050 - 
28 0.145 - competitive - 0.038 - 
29 
30 
1.733 
1.150 
12.5 
- 
competitive 
- 
0.200 ± 0.010 
- 
9.501 
- 
0.012 ± 0.002 
- 
40* 0.340 - competitive - 0.058 - 
Formestane (9) 0.042 - - - - - 
 
* Results described in the literature.108 
   
  
It is known that the introduction of additional double bonds into androstenedione 
based compounds gives derivatives with enhanced inhibitory activity.111 However, 
when we compare the biochemical results of compound 27a with that of 40 (Table 1.7), 
which has an additional double bound in C-5/C-6, we observed a decrease in potency 
(IC50 = 0.225 vs 0.340 µM).  
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Figure 1.23 - Best pose of inhibitor 28 within the aromatase binding pocket shown as transparent cartoon. The 
ligand is represented as a yellow carbon polytube model. The heme and the labelled residues interacting via 
hydrogen bonds with 28 are, respectively, displayed by cyan and magenta carbon polytube models  
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1.3.3. Derivatives of 5α-Androst-3-en-17-one 
  
 1.3.3.1. Design and synthesis 
 From previous studies of our group and in order to justify the strong activity of 
the 3,4-epoxide 28 (Scheme 1.6) when compared with the other A-ring epoxides, it was 
postulated that its oxiran oxygen atom could resemble the C-3 carbonyl group of 
androstenedione76,90,112 in establishing a hydrogen bond with residues of the active site 
of aromatase.28,113 To further explore this hypothesis we decided to synthesize the 
cyclopropane derivative 41 (Scheme 1.9). For this we used the Rawson and Harrison 
method114 where the Δ3-olefin was set to react with a mixture of zinc dust and cuprous 
chloride in anhydrous diethyl ether with methylidenediiodide. 
   
 On the other side, based on the importance of the C-17 carbonyl group in 
steroidal AIs,80,90 it was also performed a chemical modification by substituting the C-
17 carbonyl oxygen atom of compound 27a by its sulfur isoster 42 (Scheme 1.9). This 
was achieved by using Lawesson’s reagent, which allows the chemical conversion of 
carbonyl to thiocarbonyl compounds.115 
 
 
 1.3.3.2. Chemistry 
 The method of Simmons and Smith116 allows the stereospecific addition of an 
unsubstituted methylidenegroup to an olefin to obtain the corresponding cyclopropane 
derivative. In this method, the methylidenediiodide and a zinc-copper couple in 
anhydrous diethyl ether is usually used. The method of preparation of this couple is an 
important fact in determining its reactivity towards methylidenediiodide. Although this 
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is a convenient and very used method to promote this entry, in fact the experimental 
procedure requires the preparation of a rather irreproducible zinc-cooper reagent. 
Therefore, Rawson and Harrison114 developed a method where it was not required a 
separate preparation of the zinc-copper couple, making use of the fact that a mixture of 
zinc dust with a cuprous halide is even more effective. By this reason, we selected this 
later method to prepare compound 41. 
 
 
Scheme 1.9 - Synthesis of aromatase inhibitors 41 and 42 from 27a 
 
  
 
 
 
Reagents and conditions: (i) Zn, CuCl, CH2I2, I2, anhydrous diethyl ether, reflux, 90 h; (ii) 
Lawesson’s reagent, anhydrous toluene, reflux, 7 h. 
  
 
For this, olefin 27a was subjected to a reaction with a mixture of zinc dust and 
cuprous chloride in anhydrous diethyl ether with methylidenediiodide, under a nitrogen 
atmosphere, in ultra-sound at reflux temperature (Scheme 1.9). After 10 h of reaction, 
the TLC control revealed the presence of a product with slightly higher Rf when 
compared to the starting material. The reaction proceeded in the referred conditions for 
a total of 90 h, with further addition of reagents for several times. Even so, the reaction 
was never complete. The residue obtained after work up was purified through silica gel 
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column chromatography, which allowed isolating 10.7 mg (20% yield) of the pure 
compound 41.  
 The elucidation of the stereochemistry of the cyclopropane ring of derivative 41 
was achieved by NOESY experiments. The α-H atom of the -CH2- cyclopropyl group 
presents the strongest correlation with the geminated β-H atom and also correlates with 
5α-H and 1α-H atoms. The α-H atom with the signal at -0.12 ppm showed the following 
correlations: a very strong one with the H-atom resonating at 0.65 ppm, which 
corresponds to the β-H atom of the -CH2- cyclopropane ring; a moderate correlation 
with the H-atom resonating at 0.55 ppm, which corresponds to the 5α-H atom, and a 
weak correlation with the 1α-H atom resonating at 0.88 ppm (Figure 1.24, in green). On 
the other hand, the β-H atom from the -CH2- cyclopropane ring presents a strong 
correlation with the geminal α-H atom and strong correlations with 3β-H and 4β-H 
atoms (Figure 1.24, in red). These two H-atoms correlate strongly with each other, and 
3β-H atom also correlates with 2α-H and 2β-H atoms and in a smaller intensity with 1β-
H atom (Figure 1.24, in blue). In the spectrum, it were observed strong correlations 
between the H-atoms resonating at 0.35 and 0.80 ppm, which corresponds to 3β-H and 
4β-H atoms. The H-atom resonating at 0.35 ppm has other correlations: a strong one 
with H-atom resonating at 1.66 ppm, a moderate one with H-atom at 1.37 ppm, and a 
weak one with H-atom at 0.59 ppm. By this reason, the signal at 0.35 ppm was 
unequivocally attributed to the 3β-H atom and that at 0.80 ppm to the 4β-H atom. On 
the other side, signals at 1.66, 1.37 and 0.59 ppm are due to the resonance of 2β-H, 2α-
H and 1β-H atoms, respectively. On the other hand, 1α-H atom correlates with 2α-H and 
2β-H atoms, although in a stronger way with 2α-H atom (Figure 1.24, in grey). In 
summary, the main resonance signals for the most important H-atoms of the 
cyclopropryl derivative 41 are at: -0.12 ppm for the α-H atom of the -CH2- cyclopropyl 
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group; 0.35 ppm for 3β-H atom; 0.55 ppm for 5α-H atom, 0.65 ppm for β-H atom of the 
-CH2- cyclopropyl group, and 0.80 ppm for 4β-H atom. 
 
 
 
  
 
 
 
 
 
 
 The synthesis of compound 42 was performed under anhydrous conditions with 
Lawesson’s reagent through thionation of the C-17 carbonyl group of 27a (Scheme 1.9). 
The reaction occurred during 7 h, as reported for other compounds,115 however in our 
case it was never complete. After this period of time, the reaction mixture was worked 
up with a prior elimination of Lawesson’s reagent by an aluminium oxide neutral 
column chromatography. This chromatographic procedure constitutes an additional step 
to the conventional work up and it was implemented after observing that there was an 
undesirable reaction of Lawesson’s reagent with the silica gel, leading to a complete 
decomposition of the product, when the crude was directly chromatographed through a 
silica gel column. After the reagent elimination, the crude product was then finally 
purified by silica gel column chromatography affording thione 42, in 54% yield. 
 
 
Figure 1.24 - Compound 41 showing NOESY correlations (bold line – strong 
correlation; plain line – moderate correlation; dashed line – weak correlation)  
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1.3.3.3. Biochemistry and biology 
 Inhibition of aromatase activity by the modified steroids was evaluated as 
mentioned formerly (Section 1.1.3.). A screening assay was performed and the results 
are shown as a percentage of inhibition (%) for compounds 41 and 4276 (Table 1.8). The 
IC50 was also determined for compound 41 in human placental microsomes and in 
MCF-7aro cells (unpublished results) (Table 1.8). 
 
 
Table 1.8 – Aromatase inhibition for compounds 41 and 42 in human placental 
microsomes and IC50 determined in human placental microsomes a) and in MCF-7aro 
cells b) for compound 41 
 
 
 
 
 
 
 
1.3.3.4. Structure-activity relationships discussion and conclusions  
 In Scheme 1.9, we developed the synthesis of the cyclopropane derivative 41 
from the olefin 27a. Our expectation was that this cyclopropane derivative 41 would be 
less potent than 3,4-epoxide 28, in order to justify the strong activity of this epoxide 
through the establishment of a hydrogen bond in the active site of aromatase. However, 
and interestingly, derivative 41 revealed to have higher anti-aromatase activity than 
epoxide 28 (IC50=0.110 vs 0.145 µM) (Tables 1.7 and 1.8). We think that in this case, 
Compounds 
Aromatase Inhibition (%)  
± SEM 
IC50a)  
(µM) 
IC50b) 
 (µM) 
41 95.35 ± 0.57 0.110 1.880 
42 41.45 ± 2.05 - - 
Formestane (9) 99.65 ± 0.06 0.042 - 
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some direct van der Waals contacts between the cyclopropane ring and the side chains 
of some aminoacids, must be more determinant for the interaction of the inhibitor with 
the active site of aromatase than the hydrogen bond that can be established between the 
oxiran oxygen atom of epoxide 28 and residues of the active site, hence justifying the 
higher inhibitory activity of 41. Compound 41 is effectively the most potent AI 
synthesized and evaluated that is described in this thesis.  
 
 Compound 42 was designed based on the isosterism concept by performing the 
chemical substitution of the C-17 carbonyl oxygen atom by the corresponding sulfur 
atom. It was observed that this transformation resulted in a loss of the aromatase 
inhibitory activity, which prompted us to conclude that the sulfur atom was not as able 
as the oxygen atom to establish a hydrogen bond with the Met374 residue, in the 
aromatase active site.  
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1.4. C-6 METHYL DERIVATIVES OF ANDROSTENEDIONE 
 
1.4.1. Design and synthesis 
 From SAR studies based on steroidal androstanes with alkyl and phenyl groups 
in the C-6 position, it was accepted that the referred substituents were beneficial for 
achieving aromatase inhibitory activity. It was believed that a hydrophobic binding 
pocket of the enzyme would interact with these groups, favoring aromatase 
inhibition.111,117-121 However, when the 3D structure of aromatase, in a complex with its 
substrate androstenedione, was elucidated, no peculiar binding pocket near the C-6 
region was found. Nevertheless, a shallow hydrophobic crevice was observed to 
accommodate the extra C-6-methylidene group of exemestane (Figure 1.14), being this 
group surrounded by the side-chain atoms of Thr310, Val370 and Ser478 (Figure 1.25), 
when its molecule was built into the active site of aromatase.28,33  
 
  
 
 
 
Figure 1.25 - Modelling of exemestane (C atoms in magenta) after being built in the active site of aromatase, 
showing that it superimposes very well with androstenedione (C atoms in blue) (left image), with detail of the 
access channel (right image)28,33 
hydrogen is too far from this carbonyl (6.2 A˚) to be abstracted in such
a manner. It points at and is close to the haem Fe (4.2 A˚), and is
probably removed after the Fe-peroxy nucleophilic attack on the 19-
aldehyde (Fig. 3b) as previously proposed3,5,6.
To examine how a mechanism-based steroidal inhibitor could
interfere with the aromatization process, an exemestane (Aromasin;
one of the three aromatase inhibitors approved by the US Food and
Drug Administration) molecule was built into the active site (Fig. 3c)
by using the androstenedione backbone. The two steroids super-
impose quite well (root mean square (r.m.s.) deviation about 0.2 A˚),
except for differences in puckering of the A-rings. The extra C6-
methylidene group in exemestane is accommodated in a shallow
hydrophobic crevice surrounded by the side-chain C atoms
Thr 310-Cc, Val 370-Cc2 and Ser 478-Cb, at the mouth of the
active-site access channel (described below). The distance between
the methylidene C and Cc-Thr 310 is 3 A˚, shorter than the van der
Waals contact distance. Indeed, a slight adjustment of these side
chains on the binding of exemestane is highly likely. The clamping
of C6-methylidene in a hydrophobic surrounding, resulting in entro-
pic gain and a lowering of the free energy and the dissociation con-
stant, could greatly reduce themobility of the Thr 310 side chain and/
or interfere with its ability to interact with the catalytic waters for the
creation of the active oxyferrylmoiety. Exemestanewould thus remain
tightly bound in the pocket without being hydroxylated at C19.
An access channel links the active site to the outer surface. Figure 4a
is a view of the interior of a semi-transparent solvent-excluded sur-
face28 that also excludes the active-site region, consisting of the ster-
oid-binding pocket and haem, from the protein interior by forming a
‘pouch’-like cleft that opens only to the exterior through the channel,
at the arrowhead. The inset shows a view along this channel, revealing
the locations of three water molecules within the channel and a
glimpse of the opening to the active-site cavity. The salt-bridging
–
–
–
a
b
c
Figure 3 | Steroid–protein interactions and mechanistic implications. a, A
close-up view of the Ala 306CO???HOThr 310 pair that may function in the
aromatization of the A-ring of androstenedione. Calculated hydrogen-atom
positions of C2 of the bound androstenedione are shown. Distances are in
a˚ngstro¨ms. b, A possiblemechanism forH2b abstraction and 2,3-enolization
that could be initiated by a nucleophilic attack on C2-H2b by the
Ala 306CO???HOThr 310 pair, along with an electrophilic attack on the C3
carbonyl by a protonated Asp 309 side chain. The direction of proton flow
from the proton relay network through Asp 309 carboxylate to the substrate
is indicated by arrows. Involvement of a catalytic water in H2b abstraction is
a possibility. The backbone carbonyl of the Ala 306CO???HOThr 310 pair
aided by a potential catalytic water molecule, or the water oxygen itself (as
indicated by dotted arrow) could act as the nucleophile. H1b abstraction is
drawn as proposed previously6. c, Modelling of an exemestane molecule (C
atoms in magenta) after the experimental positioning of androstenedione.
The short van derWaals contact distance (3 A˚) between the C6-methylidene
carbon and Cc of Thr 310 is indicated by a black line.
a
b
Figure 2 | Views of the active site of aromatase. a, A van der Waals
interaction surface cast by the protein and haem atoms at the active site. The
semi-transparent surface, coloured green for hydrophobic interactions and
magenta for polar interactions, closely resembles the shape, size and
puckering of the steroid backbone. This figure was prepared withMOE. b, A
view along the I-helix axis from its N-terminal end. The disruption to the
helicity of the backbone at residues Pro 308-Asp 309-Thr 310 causes the helix
axis to displace by about 3.5 A˚, allowing the side chain of Asp 309 to interact
with the 3-keto oxygen of the steroid. The deviation from helicity could be
stabilized by a strong Ala 306CO???HOThr 310 (2.8 A˚) hydrogen bond, as
well as by Asp 309 peptide CO???water (3.4 A˚) interaction as indicated.
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Antiproliferative Activity of New Compounds. The six
potent 2-alkynyloxy derivatives 4−9, as well as EXM and LTZ
as controls, were assayed for their antiproliferative properties in
the breast cancer cell MCF-7-Tet-off-3βHSD1-Arom (MCF-7a;
see Experimental Section). The results are summarized in
Figure 3c,d, and the EC50 values are given in Table 1. More
detailed antiproliferation data and individual dose response
curves for the new inhibitors and the controls are provided in
Table S2 (Supporting Information). The proliferative activity of
the MCF-7a cells is first evaluated by treating the cells with E2,
TST, and ASD. All three compounds effectively stimulate the
growth of the MCF-7a cells in a concentration-dependent
manner (Figure 3c), confirming that these cells express both a
functional estrogen receptor and an active aromatase. E2 (EC50
= 55 pM) is more potent than either TST (EC50 = 99 pM) or
ASD (EC50 = 3.6 nM) in growth stimulation, indicating that
there is a time lag for the synthesis of E2 from TST (via the
aromatase pathway) and ASD (via the aromatase-17β-
hydroxysteroid dehydrogenase type 1 pathway) in these breast
cancer cells. The maximum concentration of E2 and TST
required to stimulate MCF-7a cell proliferation in our cell-
based assay system is determined to be 1 nM (Figure 3c); this
concentration is used for subsequent proliferation inhibition
assays.
Figure 3d summarizes the results from the antiproliferative
activity assay of the 2-alkynyloxy aromatase inhibitors 4−9 in
the MCF-7a cells in comparison with the activities of LTZ and
EXM. The data show that the newly designed inhibitors abolish
the TST-stimulated proliferation of MCF-7a cells in a dose
dependent manner. The number of MCF-7a cells nearly
doubles in response to 1 nM TST treatment. However, the
addition of aromatase inhibitors 4−9 progressively inhibits the
stimulatory activity of TST as a function of concentration
(Figure 3d). The EC50 values of 4−9 are 1.7, 0.03, 3.4, 5.4, 15.7,
and 0.3 nM, respectively (Table 1). Of these inhibitors, 4, 5,
and 9 show 2.6-fold (p < 0.040), 119.6-fold (p < 0.010), and
14.7-fold (p < 0.012) antiproliferative activities, respectively,
against TST-stimulated cell growth when compared to the
steroidal AI EXM (EC50 = 5.6 nM). Thus, the structure−
activity relationship of these compounds in the cell-based
antiproliferation assay parallels their enzyme inhibitory proper-
ties in the cell-free system.
Aromatase−Androstenedione Complex Structure at
2.75 Å. The newly refined structure has yielded a better model
than the 2.90 Å structure (PDB code 3EQM)6 in terms of
overall quality and the refinement parameter statistics (Table
S3, Supporting Information). Inclusion of the higher resolution
data enabled rebuilding of some of the weakly defined loop
regions and inclusion of additional solvent atoms into the
model. The residues Ser267 to Cys275 in the G−H loop have
clearer electron densities than the previous map and are rebuilt
Figure 2. Design considerations for the new inhibitors derived from
the binding interactions and exposure of the ligands to the enzyme
interaction spaces: (a) ASD; (b) EXM. In (a) and (b) derived from
the X-ray structures, the residues lining the binding pocket making
hydrophobic and hydrogen-bonding contacts are shown (hydrophobic,
green; acidic, red; basic, blue; polar, purple; sulfur-containing, yellow).
Exposure at the C4 and C6 positions of the steroid to the access
channel opening is indicated. Also shown schematically in (a) is a
water molecule trapped between Asp309 and Arg192 side chains,
postulated to have a role in the proton relay network and enolization
of 3-keto.6
Scheme 1. Synthesis of C6β-2-Alkynyloxy Derivatives of ASDDa
aShown are chemical structures of newly synthesized C6β-alkoxy-substituted androsta-1,4-diene-3,17-dione compounds 2−9.
Journal of Medicinal Chemistry Article
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 In a recent work, Ghosh et al.33 have determined the crystal structures of 
inhibited complexes of aromatase with steroidal C-6-substituted 2-alkynyloxy 
compounds. It was found that, the linear C-6-alkynyloxy side chains protrude into an 
access channel cavity immobilizing the catalytic residues, which resulted in very potent 
inhibitors of aromatase. Numazawa et al.118-121 have synthesized C-6 alkyl derivatives 
and one of its most potent inhibitors was the 3-deoxy derivative of androstenedione 
with a C-6α methyl group. With all this information in mind, we decided to develop 
new molecules based in two of our better AIs, the Δ3-olefin 27a and the 3,4-epoxide 28, 
but with an additional methyl group in its C-6α position, in order to try to increase its 
inhibitory activity. 
 Therefore, we embarked on the preparation of these compounds through the 
synthesis presented in Scheme 1.10.  
 
 
1.4.2. Chemistry 
The direct γ-alkylenation of enone 1 was achieved by subjecting this to reaction 
with phosphoryl chloride and formaldehyde dimethyl acetal.70 After 9 h of reflux a 
mixture of several products was formed, being compound 2 isolated after silica gel 
column chromatography, in 17% yield.  
In order to try to prepare 44 and as a first approach, we followed the most recent 
strategy from Buzzetti et al.47 where compound 2 isomerizes to 43 and then 43 is 
catalytically reduced to compound 44. However, in our hands, when it was attempted 
the isomerization of the 6-methylene-4-en-3-one system of 2 into the 6-methyl-4,6-dien-
3-one of 43 with 5% palladium charcoal (Pd-C), in refluxing ethanol, under benzyl 
alcohol addition,122 there was no successful reaction. For this reason, compound 44 was 
Chapter I 
Steroidal Aromatase Inhibitors as Anti-tumors 
 81 
then prepared by another catalytic reduction of 2, in order to selectively reduce its C-6 
methylidene group.123 Therefore, compound 2 was subjected to reflux in a solution of 
ethanol containing cyclohexene, as hydrogen donor, in the presence of 5% Pd-C 
catalyst. The reaction was followed by UV, since λmax of the starting material 2 is 260 
nm while the λmax of the desired product 44 is 240 nm. After 3 h, the reaction was 
complete and the residue obtained after filtration of the catalyst was purified by silica 
gel column chromatography, which allowed isolating derivative 44 in 71% yield. A 
Clemmenson-type reduction of 44, with zinc dust in a glacial acetic acid solution, at 
reflux temperature afforded an isomeric mixture of 5α- and 5β-olefins 45a and 45b 
(1.7:1, by NMR). Attempt to separate these isomers was made by silica gel column 
chromatography allowing to obtain the pure compound 45b. In the case of 45a, the best 
purity achieved was 90%, after two subsequent chromatographic columns. 
Subsequently, the whole mixture of olefins 45a and 45b was treated with performic acid 
generated in situ, giving a mixture of epoxides 46a and 46b. This mixture was then 
purified by silica gel column chromatography, which allowed isolating the pure 3α,4α-
epoxide 46a, in 44% yield, and the pure 3β,4β-epoxide 46b, in 29% yield.  
  
 
1.4.3. Biochemistry  
 Inhibition of aromatase activity by the synthesized steroids (45a and 46a) was 
evaluated in human placental microsomes as formerly mentioned (Section 1.1.3). The 
results obtained are shown as a percentage of inhibition (%), in Table 1.9. The IC50 for 
both steroids was also determined (Table 1.9) (unpublished results). 
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Scheme 1.10 - Synthesis of aromatase inhibitors 45a and 46a from androstenedione (1)  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Reagents and conditions: (i) anhydrous sodium acetate, formaldehyde dimethyl acetal, 
phosphoryl chloride, anhydrous chloroform, reflux, 9 h; (ii) cyclohexene, 5% Pd-C, ethanol, 
reflux, 3 h 15 min; (iii) zinc dust, glacial acetic acid, reflux, 5 h; (iv) H2O2, HCOOH, 
dichloromethane, rt, 9 h 30 min.  
 
 
 1.4.4. Structure-activity relationships discussion and conclusions  
 Compounds 45a and 46a revealed to be very active (IC50 = 0.560 and 0.175 µM, 
respectively) (Table 1.9), although slightly less potent than the corresponding 
derivatives without the C-6 alkyl substituent, 27a and 28 (IC50 = 0.225 and 0.145 µM) 
(Table 1.7). Contrarily to that observed by Numazawa et al.118-121 for the Δ4-olefin, our 
C-6α methyl derivative 45a revealed to be a weaker AI when compared with the 
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corresponding olefin 27a. As it has been observed for compounds 27a and 28, where 
the epoxide derivative 28 was more potent than the respective olefin 27a, also for these 
C-6α methyl derivatives, the epoxide 46a is more potent than the corresponding olefin 
45a. This reinforces the hypothesis that the oxiran oxygen atom in the 3,4 position 
could resemble the C-3 carbonyl oxygen atom of the aromatase substrate 
androstenedione (1), hence establishing hydrogen bonds with aromatase active site 
residues which contributes for a stronger inhibition of the enzyme.  
 
 
Table 1.9 – Aromatase inhibition and IC50 of tested compounds in human placental 
microsomes 
 
 
 
 
 
  
Compounds Aromatase Inhibition (%) ± SEM IC50 (µM) 
45a 93.47 ± 1.06 0.560 
46a 96.72 ± 0.37 0.175 
Formestane (9) 99.65 ± 0.06 0.042 
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1.5. C-7 ALLYL DERIVATIVES OF ANDROSTENEDIONE 
 
1.5.1. Design and synthesis 
 Many studies suggest that the presence of alkyl or phenyl groups in the C-6 or 
C-7 positions of the steroidal androstane scaffold is beneficial for achieving aromatase 
inhibitory activity.111,124-128 It was believed that this activity was due to the existence of 
a hydrophobic binding pocket in this region of the enzyme and that it would interact 
with those groups leading to a more effective ligand-enzyme interaction. Surprisingly, 
when recently the 3D structure of aromatase was elucidated,28 no particular binding 
pocket near the C-6 and C-7 region of androstenedione was found. Although, it was 
identified a narrow hydrophobic cleft that accommodated the extra C-6-methylidene 
group of exemestane. The recent work of Ghosh and collaborators33  has revealed the 
development of very potent C-6-substituted steroidal AIs whose linear side chains 
protruded into the access channel cavity, resulting in a very efficient inhibition of the 
enzyme. In addition, Brueggemeier and co-workers124-127 have also reported the 
synthesis of many effective C-7α-substituted androstanes as AIs, having the most part 
of the substituents a phenyl moiety. Labrie et al.128 have also described a rather active 
AI with an allyl functional group in the C-7α position. Moreover, evidence from 
previous reported works127,129 show that the aromatase inhibitory activity is similar 
when the same kind of substituent is in position C-6 or C-7 of a given steroidal 
framework.  
 Keeping this in mind, we have been interested in performing the synthesis of 
derivatives of 7α-allylandrostenedione (50) (Scheme 1.11) where two main structural 
features were considered: the introduction of a double bond in C-1 position and the 
reduction of the carbonyl group at C-3 position. The introduction of a double bond in  
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C-1 position was based on the rationale that the A-ring planarity in steroidal AIs is 
important for aromatase inhibition, as reported in previous works,76,80,90 and also 
because it has been established that the introduction of a double bond at C-1/C-2 of 
androstenedione affords AIs that causes mechanism-based inactivation of 
aromatase.29,74,130,131 In fact, the aromatization process of androstenedione 
encompasses the C-1 and C-2 hydrogen atoms elimination,132 as observed in Figure 1.5. 
There are also several studies revealing that, in some AIs, the C-3 carbonyl group, 
present in the natural substrate of the enzyme, is not essential for aromatase 
inhibition.76,77,80,91 For this reason, we have designed and synthesized a series of 7α-
allyl derivatives according to the strategy depicted in Scheme 1.11. Further, for each set 
of derivatives it was studied the influence of the functional group (carbonyl, hydroxyl or 
acetyl) at C-17 position in aromatase inhibitory activity. 
 
 
1.5.2. Chemistry 
 Testosterone (15) was converted into its acetate derivative 18, in 84% yield. 
Dehydrogenation of 18 with chloranil was undertaken in an anhydrous environment, 
leading to a brown-greenish solid residue.133 This residue was then purified by silica gel 
column chromatography affording the dienone 47, in 58% yield. Subsequently, a 
Sakurai reaction was performed in 47 with allyltrimethylsilane and titanium 
tetrachloride, at controlled atmosphere and temperature, in order to introduce the allyl 
group at the C-7α position.128,134 After work-up, an oily crude was obtained which was 
purified over silica gel column chromatography allowing the isolation of the 7α-allyl 
derivative 48, in 56% yield. Compound 48 was next submitted to alkaline hydrolysis 
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giving the alcohol 49, in 96% yield. This was subsequently oxidized using Jones 
reagent, leading to ketone 50 in 73% yield after insolubilization in diisopropylether. 
 In order to obtain the 3-deoxo derivative 51, the reaction of 48 with a mixture of 
sodium borohydride in a mixture of trifluoracetic acid, glacial acetic acid, acetonitrile 
and dichloromethane was performed under a nitrogen atmosphere81 giving, after 
column chromatography, the almost pure compound 51. An analytical sample of this 
compound was obtained by ethanol/water crystallization. Compound 51 was then 
submitted to base-catalyzed hydrolysis, at room temperature, giving a crude product 
which, after column chromatography allowed obtaining a fraction containing alcohol 
52, with traces of inseparable impurities. Treatment of this fraction with Jones reagent 
gave rise, after column chromatography, to the pure ketone 53, in 79% yield. 
Compound 52 was then further reobtained, in its pure form, as a white solid, in 29 % 
yield, by reduction of ketone 53 with sodium borohydride in ethanol.135 
 Aiming to prepare the Δ1-derivative 54, compound 49 was treated with DDQ 
and benzoic acid in refluxing toluene.136 After several filtrations and purification by 
silica gel column chromatography, the alcohol 54 was isolated in 50% yield. Compound 
54 was then treated with acetic anhydride in pyridine giving a crude product that after 
ethyl acetate/n-hexane crystallization led to acetate 55. Jones oxidation of 54 led, after 
column chromatography purification, to the pure ketone 56, in 88% yield. 
 
 
1.5.3. Biochemistry  
 Inhibition of aromatase activity by the modified steroids was evaluated as 
previously mentioned (Section 1.1.3.). A screening assay was performed and the results 
are shown as a percentage of inhibition (%) for all compounds (Table 1.10).137 
Chapter I 
Steroidal Aromatase Inhibitors as Anti-tumors 
 87 
 For steroids 50, 53, 54 and 56 the IC50 was determined, and kinetic studies, to 
characterize the type of binding to the active site of the enzyme, and the apparent 
inhibition constant were also performed (Table 1.11). All these steroids revealed to be 
competitive inhibitors of aromatase.137 
 
 
1.5.4. Structure-activity relationships discussion and conclusions 
 Regarding the 7α-allyl-3-deoxo-4-androstenes 51, 52 and 53, it was observed 
that the 3-deoxo analog 53 is slightly less potent than 50 (IC50 = 0.75 vs 0.59 µM) 
(Table 1.11) showing that, in this case, the C-3 carbonyl group appears to be important 
for aromatase inhibitory activity. In addition, when one substitutes the C-17 carbonyl 
group of 53 by a hydroxyl group, as in 52, the activity also decreased, as expected 
(Table 1.10). In this case, no C-3 or C-17 carbonyl group is present, being therefore 
difficult the binding of the inhibitor to the enzyme active site. Substituting the C-17 
carbonyl group of 53 by an acetate group, as in 51, the aromatase inhibitory activity 
decreased even more (Table 1.10). This allows us to conclude that the short volume of 
the aromatase active site (400Å3),28 does not allow bulky substituents to be present in 
this position of the androstane framework if one aims to obtain strong aromatase 
inhibitors. 
 Concerning the 7α-allyl-3-oxo-1,4-androstadienes 54, 55 and 56, it was 
observed that the Δ1 analogue 56 is a very strong AI (IC50 = 0.47 µM) with great 
affinity for the enzyme aromatase (Tables 1.10 and 1.11). 
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Scheme 1.11 - Synthesis of steroidal 7α-allyl derivatives as aromatase inhibitors  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagents and conditions: (i) (CH3CO)2O, anhydrous pyridine, rt, 21 h 30 min; (ii) chloranil, 
acetic acid, toluene, reflux, 3 h; (iii) TiCl4, allyltrimethylsilane, anhydrous dichloromethane, -78 
ºC, 40 min; (iv) 2% NaOH, dioxane/water, rt, overnight; (v) Jones reagent, acetone/dioxane, 0 
ºC; (vi) CF3COOH, CH3COOH, CH3CN, NaBH4, anhydrous dichloromethane, rt, 1 h 30 min; 
(vii) 2% NaOH, dioxane/water, rt, 48 h; (viii) NaBH4, ethanol, -10 to 5 ºC, overnight; (ix) DDQ, 
benzoic acid, toluene, reflux, 34 h; (x) (CH3CO2)2O, anhydrous pyridine, rt, 33 h 15 min. 
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 Compound 56 is even more potent than 50 and also more potent than the 
corresponding 3-deoxo compound 53 (Tables 1.10 and 1.11), proving that the 
introduction of a double bond in C-1, which increases the planarity of the A-ring, is 
more beneficial for aromatase inhibition than the C-3 carbonyl group reduction, in the 
studied compounds. Compound 56 is structurally similar to exemestane (3) differing by 
the longer alkenyl group (allyl) at C-7 position, instead of the shorter one (methylidene 
group) at C-6 position of exemestane (3).  
 
  
Table 10 – Aromatase inhibition of tested compounds in human placental 
microsomes137  
 
 
 
 
 
 
 
 
 
 
 
 Surprisingly, when one substitutes the C-17 carbonyl group of 56 by a hydroxyl 
group, as in 54, the aromatase inhibitory activity is almost maintained (IC50 = 0.45 µM), 
showing 54 lower affinity to aromatase (Tables 1.10 and 1.11). In this case, the decrease 
Compounds Aromatase Inhibition (%) ± SEM 
48 10.12 ± 0.74 
49 24.74 ± 1.56 
50 83.14 ± 1.95 
51 31.33 ± 2.24 
52 52.44 ± 3.85 
53 84.29 ± 3.23 
54 87.94 ± 3.04 
55 13.01 ± 0.35 
56 94.49 ± 1.04 
Formestane (9) 99.65 ± 0.06 
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is much lower than that observed in the 3-deoxo derivatives series (53 and 52), probably 
because one carbonyl group, at C-3 position, remains in the molecule, allowing the 
establishment of hydrogen bonding with aromatase active site residues, and also 
because the A-ring planarity is increased, by the presence of the Δ1 double bond. By this 
reason, the A-ring planarity seems to assume an important role, since the same type of 
substitution in 50 to give 49, produces a dramatic decrease in the aromatase inhibition 
(Table 1.10). The substitution of the C-17 carbonyl group of 56 by an acetate group, as 
in 55, decreases the aromatase inhibitory activity (Table 1.10), even more than that 
observed in the 3-deoxo derivatives series. This dramatic decrease was also observed 
when it was made the substitution of the C-17 carbonyl group of 50 by an acetate group, 
as in 48. This effect can be due to stereochemical conflicts of these bulky groups with 
aromatase active site, because of the larger size of inhibitors 48 and 55, when compared 
with 51. 
 
 
Table 1.11 – IC50 and kinetic studies for compounds 50, 53, 54 and 56137 
 
Compounds 
IC50 
(µM) 
Type of 
Inhibition 
Vm 
(mol/min./µg prot) 
Ki 
(µM) 
Real Affinity 
(Km/Ki) (nM) 
50 0.59 competitive 0.009 ± 0.001 80.00 0.458 ± 0.042 
53 0.75 competitive 0.017 ± 0.003 60.00 0.014 ± 0.003 
54 0.45 competitive 0.004 ± 0.002 65.00 0.835 ± 0.041 
56 0.47 competitive 0.006 ± 0.001 45.00 0.926 ± 0.055 
Formestane (9) 0.042 - - - - 
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 In summary, several 7α-allyl derivatives of androstenedione were prepared and 
found to be strong aromatase inhibitors. Concerning its SAR, the presence of a double 
bond in C-1, as in 54 and 56, which increases the planarity of the steroidal A-ring, 
seems to be beneficial for aromatase inhibition. The reduction of the C-3 carbonyl 
group did not particularly favour the aromatase inhibitory activity, in some of these 
compounds, proving the importance of this group in the establishment of a hydrogen 
bond with the enzyme. The introduction of a double bond in C-1 seems to be more 
beneficial for aromatase inhibition since it increases the planarity in the A-ring. The 
substitution of the C-17 carbonyl group by a hydroxyl group usually decreases the 
aromatase inhibition, except if a double bond in C-1 is present, as in 54. The 
substitution of the C-17 carbonyl group by an acetate group dramatically decreases the 
aromatase inhibitory activity. This effect seems to be lower when the volume of the 
steroid molecule is also smaller as in 51. 
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1.6. CONCLUDING STRUCTURE-ACTIVITY RELATIONSHIPS 
  
 As main conclusions emerging from the observed results, it can be established 
that if one aims to design and synthesize an ideal steroidal AI we have to consider some 
important aspects, such as:  
- The existence of at least a carbonyl group at C-3 or C-17, but it is better if 
considering both of them. If we have to loose one of these groups, we should 
keep the C-17 carbonyl group.  
- Put enough planarity in A-ring and A,B-ring junction, through double bonds 
or other functions, like epoxides or cyclopropanes, since the planarity in this 
region is very important to inhibit aromatase. 
- Try to conjugate and extend the number of double bonds in convenient 
positions of the A and B-rings of the steroid, specially in positions C-1, C-4 
and C-6, like in exemestane. 
-  Avoid bulky groups in specific positions of the steroidal framework since 
the active site of the enzyme is small.  
- Some substituents in C-6 and C-7 positions can be beneficial to achieve 
strong aromatase inhibition. 
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1.7. EXPERIMENTAL SECTION 
  
 Melting points (mps) were determined on a Reichert Thermopan hot block 
apparatus and were not corrected.  
 IR spectra were recorded on a Jasco 420FT/IR spectrometer using a NaCl disk 
with chloroform solution and, when needed, KBr disk. 
 The 1H NMR spectra were recorded at 600 MHz, on a Varian Unity 600. The 
13C NMR spectra were recorded at 150 MHz on a Varian Unity 600. The 
characterization of CH3, CH2, CH and Cquaternary carbons was made by the APT 
technique.  Chemical shifts were recorded in δ values in parts per million (ppm) 
downfield from tetramethylsilane as an internal standard. All J-values are given in Hz.  
 ESI-MS (electrospray ionization-mass spectrometry) and LC-MS (liquid 
chromatography-mass spectrometry) sepctra were obtained with a mass spectrometer 
QIT-MS Thermo Finningan, model LCQ Advantage MAX coupled to a Liquid 
Chromatograph of High Performance Thermo Finningan. 
 Reactions were monitored by thin layer chromatography (TLC) in silica gel 60 
F254 aluminium sheets. The chromatographic separation of products was made using 
silica gel 60 (0.063-0.200 mm) columns. The TLC plates were revealed using ultra-
violet lamp (254 nm) and/or revealed by pulverization with a mixture of sulphuric 
acid/ethanol 95%, followed by heating at 100 ºC.  
 Testosterone (15) was purchased from STEROID, (Cologno, Monzese, MI). 
Exemestane (3) was purchased from Sequoia Research Products (Pangbourne, United 
Kingdom). Formestane (9) was purchased from Sigma-Aldrich, Inc. (St. Louis, USA). 
3β-Hydroxyandrost-4-en-17-one (20), 3α-hydroxyandrost-4-en-17-one (21), 5α-androst-
2-en-17-one (29) and 3-oxo-5α-androst-1-en-17β-yl acetate (31) were purchased from 
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Steraloids, Inc. (Newport RI, USA). Reagents and solvents were used as obtained from 
the suppliers without further purification, except dioxane, which was dried through 
reflux and distilled from sodium;138 chloroform, dichloromethane138 and pyridine,139 
which were dried from calcium hydride, and diethyl ether from sodium.138 
 Yields have not been optimized. 
 All compounds that were evaluated biochemically and biologically possess a 
purity superior to 95%, except compounds 19 and 45a (90% purity) and compounds 29 
and 30 (92% purity). The purity was checked by HPLC (high-pressure liquid 
chromatography) with a C18-reversed phase column and water/acetonitrile 40:60 as 
solvent. The purity of individual compounds was determined from the peak areas in the 
chromatogram of the sample solution.  
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Scheme 1.1 - Attempt to synthesize exemestane (3) from androstenedione (1) 
 
 6-Methylenandrost-4-ene-3,17-dione (2).  
 A suspension of anhydrous sodium acetate (1.0 g, 12.19 mmol) in anhydrous 
chloroform (30.0 mL) containing formaldehyde dimethyl acetal (30 mL, 340.0 mmol) 
and phosphoryl chloride (1.9 mL, 20.0 mmol) was stirred at reflux temperature, for 1 h. 
After that, androstenedione (1) (773.5 mg, 2.70 mmol) was added and the mixture was 
treated dropwise with phosphoryl chloride (1.9 mL, 20.0 mmol), over a period of 3 h 30 
min, and let to stir, at reflux temperature, under a stream of dry nitrogen, for a total of 
10 h. Subsequently, the reaction mixture was allowed to cool to room temperature and, 
under vigorous stirring, a saturated aqueous solution of sodium carbonate was added 
until the aqueous layer became alkaline. This mixture was afterwards diluted with 
chloroform (200 mL) and the organic layer was washed with water (4 x 100 mL), dried 
over anhydrous MgSO4, filtered and concentrated to dryness. The obtained residue was 
purified by silica gel 60 column chromatography (hexane/diethyl ether) affording the 
pure compound 2 (134.8 mg, 17%). Further crystallization from acetone/n-hexane 
afforded an analytical sample of 2. Mp(actenone/n-hexane) 162-164 ºC [lit.,70 165 ºC]. IR 
(NaCl plates, CHCl3) υmax cm-1: 3084 (=C-H), 1738 (C17=O), 1671 (C3=O), 1599 
(C=C). 1H NMR (600 MHz, CDCl3) δ: 0.78 (3H, s, 18-H3), 1.00 (3H, s, 19-H3), 4.87 
(1H, t, =CH2), 4.97 (1H, t, =CH2), 5.79 (1H, s, 4-H). 13C NMR (150 MHz, CDCl3) δ: 
11.5 (C-18), 14.9 (C-19), 18.2, 19.5, 29.0, 31.6, 32.9, 33.0, 33.6, 36.6, 36.9, 45.3, 48.9, 
50.3, 112.4 (=CH2), 119.6 (C-4), 143.2 (C-6), 166.3 (C-5), 197.4 (C-3), 217.8 (C-17). 
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 6-Methylandrosta-1,4,6-trien-17-one (4).  
 A mixture of compound 2 (253.2 mg, 0.85 mmol) and DDQ (288.9 mg, 1.27 
mmol) in anhydrous dioxane (20 mL) was refluxed under a stream of dry nitrogen for 
11 h 10 min, time after which nearest all starting material had been transformed. The 
reaction mixture was then filtered through alumina in order to remove the oxidizing 
agent. Afterwards, the solvent was removed under vacuum and the crude product was 
dissolved in ethyl acetate (150 mL); the yellow organic layer was washed with water (3 
x 100 mL), dried over anhydrous MgSO4, and concentrated to dryness. The resulting 
dark yellow oily residue was purified by silica gel column chromatography (petroleum 
ether 40-60 ºC/diethyl ether) allowing the isolation of the pure compound 4 (247.0 mg, 
98%) as a white solid. Mp(petroleum ether 40-60 ºC/diethyl ether) 216-219 ºC [lit.,47 222 ºC]. IR 
(NaCl plates, CHCl3) υmax cm-1: 1737 (C17=O), 1763 (C3=O), 1611 (C=C). 1H NMR 
(600 MHz, CDCl3) δ: 0.98 (3H, s, 18-H3), 1.18 (3H, s, 19-H3), 1.93 (3H, m, 20-H3), 
5.89 (1H, bs, 7-H), 6.20 (1H, d, J4,2=1.6, 4-H), 6.27 (1H, dd, J2,1=10.1, J2,4=1.7, 2-H), 
7.06 (1H, d, J1,2=10.1, 1-H). 13C NMR (125 MHz, CDCl3) δ: 13.8 (C-18), 19.3 (C-19), 
20.6 (C-20), 21.2, 21.3, 31.2, 35.5, 37.2, 47.7, 48.5, 48.9, 121.8 (C-7), 127.8 (C-4), 
132.4 (C-6), 132.7 (C-2), 153.2 (C-1), 162.9 (C-5), 186.4 (C-3), 219.2 (C-17).  
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Scheme 1.2 - Synthesis of derivatives of exemestane (3) 
 
 6β-Spirooxiranandrosta-1,4-diene-3,17-dione (5).  
 To a solution of exemestane (3) (250.4 mg, 0.84 mmol) in dichloromethane (7 
mL), a solution of performic acid generated in situ by addition of HCOOH 98-100% 
(0.12 mL) to H2O2 35% (0.31 mL), was added and the reaction was stirred at room 
temperature for 29 h, time after which an equivalent amount of performic acid solution 
was added and let to react for more 67 h. The reaction was worked up by addition of 
dichloromethane (200 mL) and the organic layer was washed with 10% aqueous 
NaHCO3 (2 x 100 mL) followed by water (4 x 100 mL), dried over anhydrous MgSO4, 
filtered and concentrated to dryness, giving a white solid residue.  Purification of this 
residue by column chromatography (petroleum ether 40-60ºC/ethyl acetate) afforded the 
pure compound 5 (55.7 mg, 21%) as a white crystalline solid and a mixture of 
compound 5 and its 6α-isomer (76.1 mg of a 65:35 mixture of 6β:6α, respectively, by 
NMR).  
 
 6β-Spirooxiranandrosta-1,4-diene-3,17-dione (5): Mp (petroleum ether 40-60 ºC/ethyl 
acetate) 222-224 ºC. IR (NaCl plates, CHCl3) νmax cm-1: 3045 (=CH2), 1722 (C=O), 1662 
(C=C), 1053 (C-O). 1H NMR (600 MHz, CDCl3) δ: 0.96 (3H, s, 18-H3), 1.37 (3H, s, 19-
H3), 2.79 (1H, d, Ja-b=4.2, -CHa-O-), 3.13 (1H, d, Jb-a=4.2, -CHb-O-), 6.15 (1H, d, J4-
2=1.8, 4-H), 6.26 (1H, dd, J2-1=10.2, J2-4=1.8, 2-H), 7.08 (1H, d, J1-2=10.2, 1-H). 13C 
NMR (150 MHz, CDCl3) δ: 13.8 (C-18), 18.5 (C-19), 21.7, 21.9, 31.1, 32.9, 35.5, 38.9, 
44.8, 47.6, 50.3 (-CH2-O-), 50.4, 51.6, 59.6 (C-6), 124.9 (C-2), 127.4 (C-1), 155.7 (C-
4), 161.4 (C-5), 185.9 (C-3), 219.4 (C-17). ESI: 313.2 ([M+H]+, 100%).  
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 6α-Spirooxiranandrosta-1,4-diene-3,17-dione (from the 6β:6α mixture): 1H 
NMR (600 MHz, CDCl3) δ: 0.95 (3H, s, 18-H3), 1.27 (3H, s, 19-H3), 2.69 (1H, d, Ja-
b=5.7, -CHa-O-), 3.01 (1H, dd, Jb-a=5.7, -CHb-O-), 6.26 (1H, dd, J2-1=10.1, J2-4=1.8, 2-
H), 6.32 (1H, d, J4-2=1.8, 4-H), 7.04 (1H, d, J1-2=10.1, 1-H). 
Note: a and b are the –CH2 protons of the exocyclic oxiran ring. 
 
 1α,2α-Epoxy-6-methylenandrost-4-ene-3,17-dione (6).  
 To a solution of exemestane (250.4 mg, 0.84 mmol) in methanol (10 mL), in an 
ice bath, it was added dropwise a cooled solution of 35% H2O2 (0.81 mL, 34.83 mmol) 
followed by a cooled solution of 4 N aqueous NaOH  (0.61 mL, 2.44 mmol). The 
reaction was stirred at 0 ºC over 30 min, and then at room temperature for 24 h. The 
alkaline solution was neutralized by addition of 0.5 N aqueous HCl. After that, water 
(150 mL) was added and the product extracted with dichloromethane (3 x 100 mL). The 
organic layer was washed successively with 10% aqueous NaHCO3 (2 x 100 mL) and 
water (3 x 100 mL), dried over anhydrous MgSO4, filtered and concentrated to dryness 
giving a white solid residue. This residue was purified by silica gel 60 column 
chromatography (petroleum ether 40-60 ºC/ethyl acetate) affording the pure compound 
6 (28.7 mg, 11%) as a white solid. Mp (petroleum ether 40-60 ºC/ethyl acetate) 201-203 ºC. IR (NaCl 
plates, CHCl3) νmax cm-1: 3029 (=CH2), 1722 (C=O), 1675 (C=C), 1052 (C-O). 1H NMR 
(600 MHz, CDCl3) δ: 0.93 (3H, s, 18-H3), 1.18 (3H, s, 19-H3), 3.46 (1H, dd, J2β-1β=3.9, 
J2β-4=1.9, 2β-H), 3.58 (1H, d, J1β-2β=3.9, 1β-H), 4.98 (1H, dd, Ja-b=1.75, Ja-7β=1.75, 
C6=CHa), 5.08 (1H, dd, Jb-a=1.75, Jb-7β=1.75, C6=CHb), 5.88 (1H, d, J4-2β=1.9, 4-H). 
13C NMR (150 MHz, CDCl3) δ: 13.7 (C-18), 18.9 (C-19), 21.3, 21.7, 31.0, 34.9, 35.6, 
38.6, 41.3, 47.3, 47.5, 50.7, 55.1 (C-2), 60.6 (C-1), 114.6 (C6=CH2), 118.6 (C-4), 145.1 
(C-6), 163.9 (C-5), 194.3 (C-3), 219.7 (C-17). ESI: 313.4 ([M+H]+, 100%).  
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 3-Oxo-6-methylenandrosta-1,4-dien-17β-ol (7) and 6-methylandrosta-1,4,6-
trien-17β-ol (8).  
 Sodium borohydride (63.2 mg, 1.66 mmol) was added in small proportions with 
stirring and cooling to a previously cooled mixture of trifluoracetic acid (0.4 mL), 
glacial acetic acid (0.4 mL) and acetonitrile (0.4 mL). A solution of 3 (100.0 mg, 0.337 
mmol) in dry dichloromethane (8 mL) was added to the former mixture. After this, the 
reaction mixture was let to react at room temperature, with stirring and under a stream 
of nitrogen, until all the starting material had been consumed (11 h, TLC control). The 
reaction mixture was then neutralized with a solution of 10% aqueous NaHCO3 and 
extracted with dichloromethane (3 x 100 mL). The organic layer was washed with water 
(3 x 100 mL), dried over anhydrous MgSO4, filtered and concentrated to dryness giving 
a white solid residue (102.5 mg). This residue was purified by silica gel column 
chromatography (petroleum ether 40-60 ºC/ethyl acetate) affording 39.1 mg of 
compound 7 (39%) and 11.3 mg of compound 8 (12%).  
 
 3-Oxo-6-methylenandrosta-1,4-dien-17β-ol (7): Mp(petroleum ether 40-60 ºC/ethyl acetate) 
87-90 ºC. IR (NaCl plates, CHCl3) νmax cm-1: 3421 (O-H), 3037 (H-C=), 1735 (C=C), 
1656 (C=C), 1057 (C-O) . 1H NMR (600 MHz, CDCl3) δ: 0.81 (3H, s, 18-H3), 1.14 (3H, 
s, 19-H3), 3.66 (1H, dd, J17α,16α= J17α,16β=8.6, 17α-H), 4.94 (1H, t, C=CH2), 5.01 (1H, t, 
C=CH2), 6.14 (1H, t, J4,2= 1.8, 4-H), 6.23 (1H, dd, J2,1=10.2, J2,4=1.8, 2-H), 7.08 (1H, d, 
J1-2=10.2, 1-H). 13C NMR (150 MHz, CDCl3) δ: 11.1 (C-18), 19.7 (C-19), 22.4, 23.4, 
30.3, 35.8, 36.2, 40.0, 43.0, 43.8, 50.0, 50.5, 81.4 (C-17), 111.9 (C=CH2), 122.5 (C-4), 
127.6 (C-2), 145.8 (C-6), 154.6 (C-1), 167.9 (C-5), 186.6 (C-3). ESI: 299.3 ([M+H]+, 
100%).  
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 6-Methylandrosta-1,4,6-trien-17β-ol (8): 1H NMR (600 MHz, CDCl3) δ: 0.81 
(3H, s, 18-H3), 0.99 (3H, s, 19-H3), 1.81 (3H, s, 6-H3), 2.77 (2H, m, 3-H), 3.65 (1H, dd, 
J17α,16α= J17α,16β=8.4, 17α-H), 5.36 (1H, s, 7-H), 5.66 (1H, t, J4,2α= J4,2β=4.3, 4-H), 5.70 
(1H, m, 2-H), 5.92 (1H, dt, J1-2=10.0, J1-3α=J1-3β=2.0, 1-H). 13C NMR (150 MHz, 
CDCl3) δ: 11.1 (C-18), 20.0 (C-19), 20.6, 21.2 (C-20), 23.2, 27.1, 30.5, 36.5, 36.7, 37.1, 
43.6, 49.1, 49.5, 81.6 (C-17), 117.8 (C-4), 122.6 (C-2), 126.1 (C-1), 131.4 (C-5), 133.3 
(C-7), 142.4 (C-6).  
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Scheme 1.3 - Synthesis of derivatives of formestane (9) 
 
 4-Acetoxyandrost-4-ene-3,17-dione (10).  
 To a solution of 9 (750.6 mg, 2.48 mmol) in anhydrous pyridine (12.5 mL), at 0 
ºC, acetyl chloride (0.27 mL, 3.80 mmol) was added dropwise. The reaction was stirred 
for 15 min at 0 ºC and then the temperature was raised to the ambient. Three subsequent 
additions of acetyl chloride (3 x 0.1 mL) were made allowing the reaction to be 
complete (total reaction time: 21 h 50 min, TLC). The solvent was then evaporated 
under vacuum and the obtained residue was crystallized with ethyl acetate/n-hexane 
after activated charcoal decolouration giving the pure compound 10 as white crystals 
(616.1 mg, 72%). Mp(chloroform) 169-171 ºC. IR (NaCl plates, CHCl3) νmax cm-1: 3018 
(=CH), 1739 (C=O), 1680 (C=C), 1059 (C-O). 1H NMR (600 MHz, CDCl3) δ: 0.91 
(3H, s, 18-H3), 1.26 (3H, s, 19-H3), 2.23 (3H, s, CH3COO). 13C NMR (150 MHz, 
CDCl3) δ: 13.7 (C-18), 17.6 (C-19), 20.2, 20.3, 21.7, 23.9, 29.7, 31.2, 33.3, 34.6, 34.7, 
35.7, 39.1, 47.4, 50.7, 53.8, 139.2, 154.9, 168.6, 190.4 (C-3), 220.2 (C-17). 
 
 4-Acetoxy-5α-androst-3-en-17-one (11).  
 To a solution of 10 (90.3 mg, 0.26 mmol) in glacial acetic acid (7.5 mL), zinc 
dust (500.0 mg, 7.65 mmol) was added. The reaction was sonicated in an ultrasound 
bath at room temperature for 25 min, time after which an excess of zinc dust (500.0 mg, 
7.65 mmol) was added and the reaction proceeded until all the starting material had 
been consumed (2 h, TLC). Zinc was then filtered, washed with diethyl ether (50 mL) 
and the filtrate was concentrated under vacuum. To the oily residue obtained, water 
(100 mL) was added and the product was extracted with dichloromethane (3 x 100 mL). 
The organic phase was sequentially washed with 10% aqueous NaHCO3 (2 x 100 mL) 
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and water (3 x 100 mL), dried over anhydrous MgSO4, filtered and concentrated to 
dryness giving an oily residue (105.9 mg) composed by a mixture of 11 and its 5β-
epimer. Further crystallization with petroleum ether afforded the pure compound 11, as 
white crystals. Mp(petroleum ether) 116-119 ºC. IR (NaCl plates, CHCl3) νmax cm-1: 3018 
(=CH), 1737 (C=O), 1681 (C=C), 1158 (C-O). 1H NMR (600 MHz, CDCl3) δ: 0.86 
(3H, s, 18-H3), 0.88 (3H, s, 19-H3), 2.11 (3H, s, CH3COO), 5.24 (1H, dd, J3-2β=6.6, J3-
2α=3.3, 3-H). 13C NMR (150 MHz, CDCl3) δ: 12.4 (C-18), 13.9 (C-19), 20.5, 20.6, 20.7, 
21.4, 21.7, 30.1, 31.5, 33.4, 34.7, 35.8, 36.5, 47.0, 47.8, 51.3, 53.0, 112.5 (C-3), 148.8 
(C-4), 169.7, 221.0 (C-17). HRMS: m/z [M + Na]+ calcd for C21H30O3: 353.2087; 
found: 353.2080. 
 
 4-(o-Acetylsalicyloxy)androst-4-ene-3,17-dione (12).  
 To a solution of 9 (500.2 mg, 1.65 mmol) in anhydrous pyridine (6.5 mL) at 0 
ºC, o-acetylsalicyloyl chloride (492.0 mg, 2.48 mmol) was added. The reaction mixture 
was stirred at room temperature for 22 h 30 min and after that an excess of o-
acetylsalicyloyl chloride (247.4 mg, 1.25 mmol) was added. The reaction proceeded 
until complete transformation of the starting material (24 h 40 min, TLC). After 
evaporation of the solvent under vacuum, the residue was dissolved in dichloromethane 
(100 mL) and the organic layer was sequentially washed with 0.25 N aqueous HCl (4 x 
100 mL), 10% aqueous NaHCO3 (2 x 100 mL) and water (2 x 100 mL), dried over 
anhydrous MgSO4, filtered and concentrated to dryness giving a yellow oily residue 
(865.8 mg). This residue was then purified by silica gel 60 column chromatography 
(petroleum ether 40-60 ºC/ethyl acetate) allowing to separate 610.6 mg of compound 12 
in mixture with compound 10 (60:40 respectively, NMR). A portion of this mixture 
(127.7 mg) was further purified by another silica gel 60 column chromatography (n-
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hexane/diethyl ether) allowing to isolate the pure compound 12 (51.2 mg) as a white 
crystalline residue. Mp(diethyl ether/n-hexane) 183-185 ºC. IR (KBr disk) υmax cm-1: 3453 
(CHAr), 1769 (C=O ester), 1739 (C=O), 1687 (C=C), 1606 (C=CAr), 1195 (C-O). 1H 
NMR (600 MHz, CDCl3) δ: 0.92 (3H, s, 18-H3), 1.32 (3H, s, 19-H3), 2.28 (3H, s, 
CH3COO), 7.12 (1H, d, J4-3=7.8, 4-HAr), 7.32 (1H, dd, J3-4=7.8, J3-2=7.8, 3-HAr), 7.57 
(1H, dd, J2-3=7.8, J2-1=9.2, 2-HAr), 8.13 (1H, d, J1-2=9.2, 1-HAr). 13C NMR (150 MHz, 
CDCl3) δ: 13.7 (C-18), 17.8 (C-19), 20.4, 20.9, 21.7, 24.0, 29.9, 31.5, 33.4, 34.8, 34.9, 
35.7, 39.4, 47.4, 50.9, 54.0, 122.8, 123.8 (CAr-4), 125.9 (CAr-3), 132.2 (CAr-2), 134.0 
(CAr-1), 139.2, 151.1, 155.3, 162.1, 169.3, 189.8 (C-3), 219.5 (C-17). ESI: 463.7 ([M-
H]+, 100%). 
 
 4-(o-Acetylsalicyloxy)-5α-androst-3-en-17-one (13a).  
 A solution of a crude containing 12 as the main product (272.9 mg) in glacial 
acetic acid (25 mL), was sonicated with an ultrasound probe in the presence of excess of 
zinc dust (< 10 µm) (4.73 g, 17.43 mmol) until the transformation of all the starting 
material (20 min, TLC). Zinc was filtered and washed with glacial acetic acid and then 
the filtrate was concentrated under vacuum. To the oily residue obtained, water (200 
mL) was added and the product was extracted with dichloromethane (3 x 100 mL). The 
organic phase was sequentially washed with 10% aqueous NaHCO3 (2 x 150 mL) and 
water (3 x 150 mL), dried over anhydrous Na2SO4, filtered and concentrated to dryness 
giving an oily residue (242.9 mg). This residue was purified by silica gel 60 column 
chromatography (petroleum ether 40-60 ºC/ethyl acetate) allowing to isolate 101.1 mg 
of 13a in an inseparable mixture with its 5β-epimer (13b) (70:30 respectively, by 
NMR).  
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 4-(o-Acetylsalicyloxy)-5α-androst-3-en-17-one (13a): 1H NMR (600 MHz, 
CDCl3) δ: 0.87 (3H, s, 18-H3), 0.93 (3H, s, 19-H3), 2.33 (3H, s, CH3COO), 5.36 (1H, 
dd, J3-2β=6.6, J3-2α=3.3, 3-H), 7.12 (1H, d, J4-3=8.7, 4-HAr), 7.33 (1H, dd, J3-4=8.7, J3-
2=8.7, 3-HAr), 7.58 (1H, dd, J2-3=8.7, J2-1=9.6, 2-HAr), 8.07 (1H, d, J1-2=9.6, 1-HAr).  
 
 4-(o-Acetylsalicyloxy)-5β-androst-3-en-17-one (13b): 1H NMR (600 MHz, 
CDCl3) δ: 0.87 (3H, s, 18-H3), 1.05 (3H, s, 19-H3), 2.34 (3H, s, CH3COO), 5.51 (1H, 
dd, J3-2β=6.9, J3-2α=3.6, 3-H), 7.12 (1H, d, J4-3=8.7, 4-HAr), 7.33 (1H, dd, J3-4=8.7, J3-
2=8.7, 3-HAr), 7.58 (1H, dd, J2-3=8.7, J2-1=9.6, 2-HAr), 8.05 (1H, d, J1-2=9.6, 1-HAr). 
 
 3β,4β-Dihydroxy-5α-androstan-17-one (14a).  
 Sodium borohydride (62.2 mg, 1.64 mmol) was added in small portions with 
stirring and cooling to a previously cooled mixture of trifluoracetic acid (0.4 mL), 
glacial acetic acid (0.4 mL) and acetonitrile (0.4 mL). A solution of 9 (100.1 mg, 0.331 
mmol) in anhydrous dichloromethane (8 mL) was added to the former mixture. After 
this, the reaction mixture was let to react at room temperature, with stirring and under a 
stream of nitrogen, until all the starting material had been consumed (45 min, TLC 
control). The reaction mixture was then neutralized with a solution of 10% aqueous 
NaHCO3 and extracted with dichloromethane (3 x 100 mL). The organic layer was 
washed with water (3 x 100 mL), dried over anhydrous MgSO4, filtered and 
concentrated to dryness giving a white solid residue (95.7 mg). This residue was 
purified by silica gel column chromatography (petroleum ether 40-60ºC/ethyl acetate) 
affording 66.3 mg of compound 14a (65%). Mp(petroleum ether 40-60ºC/ethyl acetate) 213-216 ºC. 
IR (NaCl plates, CHCl3) νmax cm-1: 3340 (O-H), 3265 (O-H), 1747 (C=O), 1066 (C-O), 
1033 (C-O). 1H NMR (600 MHz, CDCl3) δ: 0.86 (3H, s, 18-H3), 1.05 (3H, s, 19-H3), 
Chapter I 
Steroidal Aromatase Inhibitors as Anti-tumors 
 105 
2.06 (1H, ddd, J16α,16β=18.5, J16α,15β=9.2, J16α,15α=9.2, 16α-H), 2.44 (1H, ddd, 
J16β,16α=18.5, J16β,15β=9.2, J16β,15α=9.2, 16β-H), 3.57 (1H, ddd, J3α,2β=7.2, J3α,2β=4.1, 
J3α,4α=3-4, 3α-H), 3.76 (1H, dd, J4α,3α=3-4, J4α,5α=3.1, 4α-H). 13C NMR (150 MHz, 
CDCl3) δ:13.8 (C-18), 14.7 (C-19), 19.9, 21.8, 25.6, 25.9, 31.2, 31.5, 35.0, 35.6, 35.8, 
36.8, 47.8, 48.8, 51.5, 55.3, 72.2 (C-3), 74.6 (C-4), 221.3 (C-17). 
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Scheme 1.5 – Synthesis of C-3 hydroxyl analogs of androstenedione (1) and testosterone (15)  
 
 Androst-4-ene-3β,17β-diol (16).  
 Method A. To a solution of testosterone (15) (1.0 g, 3.47 mmol) in anhydrous 
methanol (30.0 mL), sodium borohydride (350.1 mg, 9.25 mmol) was added and the 
reaction was stirred at room temperature for 1 h 20 min, after which a supplement of 
100 mg of NaBH4 was added to completely transform the starting material (2 h 40 min, 
TLC). After methanol removal under vacuum, water (100 mL) was added and the 
product extracted with ethyl acetate (3 x 200 mL). The organic layer was then washed 
with water (200 mL), dried over anhydrous MgSO4, filtered and concentrated to dryness 
giving a white solid residue (1.04 g) composed by a mixture of 16 and its 3α-epimer 17. 
Crystallization from methanol gave the pure compound 16 (214.7 mg, 21%) as white 
crystalline plates. Mp(methanol) 149-151 ºC. IR (NaCl plates, CHCl3) υmax cm-1: 3361 (O-
H), 1656 (C=C), 1051 (C-O). 1H (600 MHz, DMSO-d6) δ: 0.64 (3H, s, 18-H3), 0.98 
(3H, s, 19-H3), 3.41 (1H, ddd, J17α-16α=8.5, J17α-16β=8.5, J17α-17βOH=4.5, 17α-H), 3.90 
(1H, m, 3α-H), 4.44 (1H, d, J17βOH-17α=4.5, 17β-OH), 4.54 (1H, d, J3βOH-3α=5.4, 3β-OH), 
5.17 (1H, bs, 4-H). 13C (150 MHz, DMSO-d6) δ: 11.2 (C-18), 18.5 (C-19), 20.2, 23.0, 
29.0, 29.7, 31.5, 32.3, 35.3, 35.5, 36.4, 36.8, 42.4, 50.2, 54.2, 65.9 (C-3), 79.9 (C-17), 
125.3 (C-4), 144.2 (C-5). ESI: 289.2 ([M-H]+, 84%). 
 
 Method B. To a solution of testosterone (15) (1.0 g, 3.47 mmol) in anhydrous 
tetrahydrofuran (40.0 mL), lithium tri-t-butoxyaluminium hydride (1.15 g, 4.51 mmol) 
was added and the reaction was heated under reflux for 2 h 30 min. To completely 
transform the starting material (TLC), 874 mg of tri-t-butoxyaluminum hydride were 
added in several portions and the reaction stirred at room temperature for more 8 h 20 
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min. After methanol removal under vacuum, water (100 mL) was added and the product 
extracted with ethyl acetate (3 x 200 mL). The organic layer was then washed with 
water (200 mL), dried over anhydrous MgSO4, filtered and concentrated to dryness 
giving a white solid residue (1.04 g) composed by a mixture of 16 and 17. 
Crystallization from methanol gave the pure compound 16 (222.1 mg, 22%) as white 
crystalline plates. 
 
 Androst-4-ene-3α,17β-diol (17).  
 To a solution of 21 (10 mg, 0.035 mmol) in methanol (3 mL), sodium 
borohydride (4.64 mg, 0.123 mmol) was added and the reaction mixture was stirred at 
room temperature until all the starting material has been consumed (10 min, TLC). 
After methanol evaporation and dissolution of the residue obtained with ethyl acetate 
(50 mL), the organic layer was washed with water (3 x 40 mL), dried over anhydrous 
MgSO4, filtered and evaporated affording the pure compound 17, in quantitative yield 
as a white residue. Mp(dichloromethane/methanol) 202-205 ºC. IR (KBr) νmax cm-1: 3328 (O-H), 
1655 (C=C), 1054 (C-O). 1H NMR (600 MHz, DMSO-d6) δ: 0.66 (3H, s, 18-H3), 0.92 
(3H, s, 19-H3), 3.41-3.45 (1H, m, 17-H), 3.85 (1H, bs, 3-H), 4.29 (1H, d, J=4.8, 3α-OH 
or 17β-OH), 4.38 (1H,d, J=4.8, 3α-OH or 17β-OH), 5.30 (1H, s, J=4.2, 4-H). 13C NMR 
(150 MHz, DMSO-d6) δ: 11.1 (C-18), 18.0 (C-19), 20.7, 23.0, 27.7, 29.7, 31.3, 31.6, 
32.1, 35.4, 36.5, 36.9, 40.0, 42.4, 50.3, 53.2, 62.3 (C-3), 79.9 (C-17), 122.2 (C-4). ESI: 
289.5 ([M-H]+, 100%). 
 
 3-Oxoandrost-4-en-17β-yl acetate (18).  
 To a solution of testosterone (15) (2.0 g, 6.93 mmol) in anhydrous pyridine 
(48.0 mL), acetic anhydride (7.9 mL, 83.9 mmol) was added and the reaction was 
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stirred for 21 h 25 min, at room temperature, until all the starting material was 
consumed (TLC control). Dichloromethane (250 mL) was added and the organic layer 
was washed with 10% aqueous NaHCO3 (3 x 150 mL), 10% aqueous HCl (3 x 150 mL) 
and water (3 x 150 mL), dried over anhydrous MgSO4, filtered and concentrated to 
dryness. Crystallization of the obtained residue from ethyl acetate gave the pure 
compound 18 (1.92g, 84%). Mp(ethyl acetate) 141-142 ºC. IR (NaCl plates, CHCl3) υmax cm-1: 3018 
(=CH), 1736 (C=O), 1675 (C=C), 1248 (C-O). 1H NMR (600 MHz, CDCl3) δ: 0.82 (3H, s, 18-
H3), 1.18 (3H, s, 19-H3), 2.03 (3H, s, CH3COO), 4.58 (1H, dd, J17α-16α=9.0, J17α-16β=8.0, 17α-H), 
5.71 (1H, s, 4-H). 13C NMR (150 MHz, CDCl3) δ: 12.0 (C-18), 17.4 (C-19), 20.5, 21.1, 23.4, 
27.4, 31.4, 32.7, 33.9, 35.4, 35.7, 36.6, 38.6, 42.4, 50.2, 53.7, 82.4 (C-17), 123.9 (C-4), 170.9 (C-
5), 171.1 (OC=O), 199.4 (C3=O). 
  
 3β-Hydroxyandrost-4-en-17β-yl acetate (19). 
  To a solution of 18 (676.5 mg, 2.04 mmol) in anhydrous methanol (20 mL), 
sodium borohydride (127.5 mg, 3.37 mmol) was added and the reaction was stirred at 
room temperature until complete transformation of the starting material (45 min, TLC). 
After removal of methanol under vacuum, water (200 mL) was added and the product 
extracted with ethyl acetate (3 x 200 mL). The organic layer was washed with water 
(200 mL), dried over anhydrous MgSO4, filtered and concentrated to dryness giving a 
white solid residue (706.4 mg). This residue was purified by silica gel 60 column 
chromatography (petroleum ether 60-80ºC/ethyl acetate) affording 430.0 mg of a 90:10 
3β/3α-epimeric mixture of 3-hydroxyandrost-4-en-17β-yl acetate (NMR and HPLC 
control). An attempt to isolate by crystallization the 3β-epimer 19, just enriched the 
mixture in the 3α-epimer.  
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 3β-Hydroxyandrost-4-en-17β-yl acetate (19): 1H NMR (600 MHz, DMSO-d6) δ: 
0.76 (3H, s, 18-H3), 0.99 (3H, s, 19-H3), 1.98 (3H, s, CH3COO), 3.90 (1H, m, 3α-H), 
4.49 (1H, dd, J17α-16α=9.0, J17α-16β=8.0, 17α-H), 4.54 (1H, d, J3bOH-3α=5.5, 3β-OH), 5.19 
(1H, bs, 4-H). 13C NMR (150 MHz, DMSO-d6) δ: 11.8 (C-18), 18.4 (C-19), 20.0, 20.8, 
22.9, 27.0, 28.9, 31.4, 32.2, 35.1, 35.2, 36.2, 36.7, 41.9, 49.7, 53.8, 65.8 (C-3), 81.8 (C-
17), 125.5 (C-4), 143.9 (C5), 170.2 (OC=O). ESI: 331.0 ([M-H]+, 100%).  
 
 3α-Hydroxyandrost-4-en-17β-yl acetate (from the mixture with 19): 1H NMR 
(600 MHz, DMSO-d6) δ: 0.77 (1H, s, 18-H3), 0.92 (1H, s, 19-H3), 1.98 (3H, s, 
CH3COO), 3.85 (1H, m, 3β-H), 4.36 (1H, d, J3αOH-3β=4.4, 3α-OH), 4.50 (1H, dd, J17α-
16α=9.0, J17α-16β=8.0, 17α-H), 5.31 (1H, d, J4-3β=4.5, 4-H). 
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Scheme 1.6 – Synthesis of A-ring olefin and epoxide derivatives of androstenedione (1)  
 
Androst-4-ene-3,17-dione (1).  
To a solution of testosterone (15) (11.6 g, 40.2 mmol) in acetone (500 mL) it 
was slowly added a solution of aqueous chromium trioxide in sulphuric acid – Jones 
reagent (15 mL), until the reaction mixture acquired a persistent red coloration. After 
stirring at room temperature for 15 min, the excess of the oxidant agent was destroyed 
with methanol, until it reacquired the green coloration.  Then, it was diluted with water 
(250 mL), the acetone evaporated under vacuum and it was poured into a mixture of 
water with ice (900 mL). The white precipitate formed was filtered and dried affording 
the pure compound 1 (10.4 g, 91%). IR (NaCl plates, CHCl3) υmax cm-1: 3012 (H-C=), 
1736 (C17=O), 1662 (C3=O), 1617 (C=C). 1H NMR (600 MHz, CDCl3) δ: 0.92 (3H, s, 
18-H3), 1.22 (3H, s, 19-H3), 5.76 (1H, s, 4-H). 
 
 3,3-(Ethylenedithio)androst-4-en-17-one (22).  
 A solution of androstenedione (1) (501.0 mg, 1.75 mmol) in anhydrous THF (7 
mL) was treated with anhydrous p-toluenesulfonic acid (904.2 mg, 5.25 mmol) and 
ethane-1,2-dithiol (176 µL, 2.10 mmol). A clear slightly yellowed solution was 
obtained. The reaction mixture was then stirred at room temperature for 4 h and after 
that it was diluted with water (50 mL) and brine (20 mL) and extracted with ethyl 
acetate (3 x 100 mL). The organic layer was washed with brine (4 x 70 mL), dried over 
anhydrous MgSO4, filtered and concentrated to dryness giving a slightly yellowed 
residue was obtained. Crystallization from ethyl acetate gave the pure compound 22 
(253.6 mg) as white crystals. Purification of the crystallization mother liquor by silica 
gel 60 column chromatography (n-hexane/ethyl acetate) afforded an additional portion 
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of 22, as a white crystalline solid (total yield 84%). A minor product (37.1 mg, 5%) was 
also isolated revealing to be 3,3,17,17-bis-(ethylenedithio)androst-4-ene. Compound 22: 
Mp(n-hexane/ethyl acetate) 169-170 ºC. IR (NaCl plates, CHCl3) υmax cm-1: 3016 (=CH), 1737 
(C=O), 1647 (C=C), 663 (C-S). 1H NMR (600 MHz, CDCl3) δ: 0.87 (3H, s, 18-H3), 
1.03 (3H, s, 19-H3), 3.22-3.36 (4H, m, -SCH2CH2S-), 5.50 (1H, bs, 4-H). 13C NMR 
(150 MHz, CDCl3) δ: 13.7 (C-18), 18.5 (C-19), 20.5, 21.7, 31.3, 31.4, 31.8, 35.3, 35.8, 
36.7, 37.2, 37.9, 39.5, 40.0, 47.6, 50.9, 54.2, 65.6, 124.6 (C-4), 145.7 (C-5), 220.9 (C-
17).  
 
 Androst-4-en-17-one (25) and Androst-4-en-17β-ol (23).  
 Method A. To liquid ammonia (70 mL) at -65 ºC sodium metal (1.16 g, 50.5 
mmol) was added. To this stirred solution, compound 22 (500.2 mg, 1.38 mmol) in 
anhydrous tetrahydrofuran (10mL) was added over a period of 10 min. Ammonia was 
removed at room temperature with a stream of argon and methanol (27 mL), followed 
by chilled water (18 mL), were cautiously added affording a yellow residue. The residue 
was then acidified with a solution of 5% aqueous HCl, diluted with water (75 mL) was 
extracted with ethyl acetate (3 x 100mL). The organic layer was washed with a solution 
of 5% aqueous NaHCO3 (5 x 100 mL) and water (3 x 100 mL), dried over anhydrous 
MgSO4, filtered and concentrated to dryness giving a slightly yellowed residue. This 
crude was then purified by silica gel 60 column chromatography (n-hexane/ethyl 
acetate) yielding compound 25 (174.7 mg, 46%) as a white crystalline solid and 
compound 23 (99.4 mg, 26%) as a white solid.  
 
 Androst-4-en-17-one (25): Mp (n-hexane/ethyl acetate) 74-76 ºC. IR (NaCl plates, 
CHCl3) νmax cm-1: 3018 (=CH), 1738 (C=O), 1657 (C=C). 1H NMR (600 MHz, CDCl3) 
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δ: 0.88 (3H, s, 18-H3), 1.03 (3H, s, 19-H3), 5.32 (1H, m, 4-H). 13C NMR (150 MHz, 
CDCl3) δ: 13.7 (C-18), 19.2 (C-19), 19.4, 20.6, 21.8, 25.7, 31.5, 32.1, 32.3, 35.5, 35.8, 
37.1, 37.8, 47.7, 51.2, 54.5, 119.6 (C-4), 144.3 (C-5), 221.3 (C-17). ESI: 271.0 ([M-H]+, 
50%). 
 
 Androst-4-en-17β-ol (23): Mp (n-hexane/ethyl acetate) 143-146 ºC. IR (NaCl plates, 
CHCl3) νmax cm-1: 3278 (OH), 2959 (=CH), 1651 (C=C). 1H NMR (600 MHz, DMSO-
d6) δ: 0.65 (3H, s, 18-H3), 0.97 (3H, s, 19-H3), 3.43 (1H, ddd, J17α-16α=9, J17α-16β=9, J17α-
17βOH=5, 17α-H), 4.43 (1H, d, J17βOH-17α=5, 17β-OH), 5.24 (1H, m, 4-H). 13C NMR (150 
MHz, DMSO-d6) δ: 11.2 (C-18), 18.8 (C-19), 19.1, 20.6, 23.0, 25.1, 29.8, 31.9, 32.5, 
35.5, 36.4, 36.5, 37.2, 42.4, 50.3, 54.1, 79.9 (C-17), 118.7 (C-4), 144.2 (C-5).  
 
 3-Oxoandrost-4-en-17β-yl acetate (18). As described in Scheme 1.5. 
 
 Androst-4-en-17β-yl acetate (36).  
 Sodium borohydride (566.2 mg, 14.97 mmol) was added in small proportions 
with stirring and cooling to a previously cooled mixture of trifluoracetic acid (3.5 mL), 
glacial acetic acid (3.5 mL) and acetonitrile (3.5 mL). A solution of 18 (1.0 g, 3.03 
mmol) in anhydrous dichloromethane (18 mL) was added to the former mixture. After 
this, the reaction mixture was let to react at room temperature, with magnetic stirring 
and under a stream of nitrogen, until all the starting material had been consumed (3 h 
30min, TLC control). The reaction mixture was then neutralized with a solution of 10% 
aqueous NaHCO3 and extracted with dichloromethane (4 x 100 mL). The organic layer 
was washed with water (4 x 100mL), dried over anhydrous MgSO4, filtered and 
concentrated to dryness giving 945.0 mg (99%) of compound 36 as a white solid 
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residue. Mp(methylidenechloride/n-hexane/ethanol) 95-99 ºC. IR (NaCl plates, CHCl3) νmax cm-1: 
3024 (=CH), 1737 (C=O), 1663 (C=C), 1043 (C-O). 1H NMR (600 MHz, CDCl3) δ: 
0.80 (3H, s, 18-H3), 1.01 (3H, s, 19-H3), 2.03 (3H, s, CH3COO), 4.58 (1H, dd, J17αH-
16αH=9, J17αH-16βH=8, 17α-H), 5.29 (1H, m, 4-H). 13C NMR (150 MHz, CDCl3) δ: 12.0 
(C-18), 19.2 (C-19), 19.4, 20.9, 21.2, 23.5, 25.7, 32.4, 32.8, 35.8, 36.9, 37.1, 37.8, 42.5, 
50.5, 54.4, 82.8 (C-17), 119.3 (C-4), 144.7 (C-5), 171.2 (C=O). 
 
 Androst-4-en-17β-ol (23).  
 Method B. Compound 36 (945.0 mg, 2.99 mmol) was added to a mixture of 
dioxane/water (85:15) (90 mL) with 2% aqueous NaOH (18 mL), at room temperature. 
The reaction mixture was let to react until total transformation of the starting material (52 
h, TLC control) being after this time neutralized with a solution of 5% aqueous HCl. The 
dioxane was evaporated under vacuum leading to a white solid residue that was diluted 
with water (200 mL) and extracted with ethyl acetate (4 x 100 mL). The organic layer was 
then washed with water (4 x 100 mL), dried over anhydrous MgSO4, filtered and 
concentrated to dryness giving 819.0 mg (99%) of compound 23 as a white solid. 
 
 Androst-4-en-17-one (25).  
 Method B. Jones reagent (2.7 mL) was added dropwise to a solution of 23 
(839.8 mg, 3.06 mmol) in acetone/dioxane (60:10) (190 mL), at 0 ºC, with stirring, until 
the orange colour of the reagent remains. The excess of oxidant agent was destroyed 
with the addition of 2-propanol. The dioxane and acetone were evaporated under 
vacuum. To the remaining residue water (200 mL) was added and the resulting solution 
extracted with ethyl acetate (4 x 100 mL). The organic layer was then washed with 10% 
aqueous NaHCO3 (3 x 100 mL) and water (3 x 100 mL), dried over anhydrous Na2SO4, 
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filtered and concentrated to dryness giving a white solid residue (129.3 mg) after the 
addition of some drops of diethyl ether. This solid was then purified by silica gel 
column chromatography (hexane/ethyl acetate) affording the pure compound 25 (624.2 
mg, 75%) as a white crystalline solid. 
 
 5α-Androst-3-en-17-one (27a).  
 To a boiling solution of androstenedione (1) (1.0 g, 2.50 mmol) in glacial acetic 
acid (60 mL), zinc dust (12.0 g, 183.5 mmol) was added in two portions and after 10 
min the reaction was complete. The zinc suspension was filtered, the zinc washed with 
glacial acetic acid and the filtrate evaporated to dryness. The resulting residue was 
diluted with water (100 mL) and extracted with diethyl ether (3 x 120 mL). The organic 
layers were washed with 10% aqueous NaHCO3 (3 x 100 mL) and water (3 x 100 mL), 
dried over anhydrous MgSO4 and evaporated to dryness to give a white crystalline solid 
composed by a mixture of 5α-olefin 27a and 5β-olefin 27b. Crystallization of the 
mixture from n-hexane allowed obtaining the pure 27a (570.0 mg, 60%). 1H NMR (600, 
CDCl3) δ: 0.79 (3H, s, 18-H3), 0.87 (3H, s, 19-H3), 5.29 (1H, ddd, J4,3=9.6, J4,5α=3.8, 
J4,2α=1.9, 4-H), 5.66 (1H, ddd, J3,4=9.8, J3,2β=6.4, J3,2α=3.2, 3-H). 
 
 3β-Hydroxy-5α-androst-1-en-17β-yl acetate (32).  
 To a solution of compound 31 (500.4 mg, 1.51 mmol) in anhydrous 
tehrahydrofuran (20 mL) under nitrogen, lithium tri-t-butoxyaluminum hydride (499.7 
mg, 1.96 mmol) was added and the reaction was heated under reflux for 2 h, time after 
which an excess of lithium tri-t-butoxyaluminum hydride (99.9 mg, 0.39 mmol) was 
added. The reaction proceeded until complete transformation of the starting material (3 
h 15 min, total). After removal of the solvent under vacuum, water (200 mL) was added 
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and the aqueous layer extracted with dichloromethane (3 x 200 mL). The organic layer 
was then washed with water (200 mL), dried over anhydrous Na2SO4, filtered and 
concentrated to dryness. Crystallization from methanol/water gave the pure compound 
32 (471.5 mg, 94%) as a white solid. Mp(methanol/water) 142-144 ºC (lit.,101 142-144 ºC). 
IR υmax (NaCl plates, CHCl3) cm-1: 3388 (OH), 3024 (=CH), 1735 (C=O), 1248 (C-O). 
1H NMR (600 MHz, DMSO-d6) δ: 0.74 (3H, s, 18-H3), 0.85 (3H, s, 19-H3), 1.98 (3H, s, 
CH3COO), 4.06 (1H, m, 4α-H), 4.50 (1H, dd, J17α-16α=8.0, J17α-16β=8.0, 17α-H), 4.63 
(1H, d, J3βOH-3α=5.8, 3-OH), 5.39 (1H, d, J1-2=10.0, 1-H), 5.75 (1H, dd, J2-1=10.0, J2-
3α=2.0, 2-H). 13C NMR (150 MHz, DMSO-d6) δ: 12.0 (C-18), 15.4 (C-19), 20.2, 20.8, 
22.9, 27.0, 27.6, 30.9, 34.8, 35.3, 36.4, 37.5, 42.2, 43.0, 50.0, 50.8, 66.8 (C-3), 81.8 (C-
17), 130.6 (C-1), 135.3 (C-2), 170.2 (C=O). ESI: 333.4 ([M+H]+, 14 %). 
 
 5α-Androst-1-en-17β-ol (33a).  
 A solution of 32 (418.0 mg, 1.25 mmol) in benzene (10 mL) was kept at 5-8 ºC, 
under nitrogen, treated with thionyl chloride (0.42 mL, 5.59 mmol) and stirred for 3 h 
15 min, never allowing complete transformation of the starting material. Benzene was 
evaporated under vacuum at room temperature and an oily residue was obtained. To this 
residue, solid NaHCO3 was added followed by 10% aqueous NaHCO3 (100 mL). The 
aqueous layer was extracted with dichloromethane (3 x 100 mL) and the resulting 
organic layer was washed with water (3 x 100 mL), dried over anhydrous Na2SO4, 
filtered and concentrated to dryness giving 422.0 mg of a transparent oily residue. To a 
solution of this residue in ethyl ether (63 mL), lithium aluminium hydride (292.4 mg, 
7.66 mmol) was added cautiously, under nitrogen, and the reaction heated under reflux 
for 10 h 30 min. A saturated sodium potassium tartrate solution (150 mL) was added 
and the mixture extracted with diethyl ether (4 x 100 mL). The organic layer was then 
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washed with water (3 x 100 mL), dried over anhydrous Na2SO4, filtered and 
concentrated to dryness giving a white solid residue (one TLC spot). 1H NMR analysis 
of this residue revealed to be composed by a mixture of 33a and its Δ2 isomer (33b) in 
similar proportions. This residue was further purified by column chromatography over 
neutral alumina and n-hexane/dichloromethane as solvent giving 239.0 mg of a white 
solid (one TLC spot). 1H NMR and LC-MS analysis of this product revealed to be 
composed by 33a in 90% purity.  
 
 5α-Androst-1-en-17β-ol (33a): 1H NMR (600 MHz, DMSO-d6) δ: 0.64 (3H, s, 
18-H3), 0.80 (3H, s, 19-H3), 3.42 (1H, ddd, J17α-16α=9.0, J17α-16β=9.0, J17α-17βOH =5.0, 
17α-H), 4.42 (1H, d, J17βOH-17α=5.0, 17β-OH), 5.45 (1H, m, 2-H), 5.82 (1H, bd, J1-
2=10.0, 1-H).  
 
 5α-Androst-2-en-17β-ol (33b) (from the mixture with 33a): 1H NMR (600 MHz, 
DMSO-d6) δ: 0.63 (3H, s, 18-H3), 0.71 (3H, s, 19-H3), 3.42 (1H, ddd, J17α-16α=9.0, J17α-
16β=9.0, J17α-17βOH =5.0, 17α-H), 4.42 (1H, d, J17βOH-17α=5.0, 17β-OH), 5.56 (2H, m, 2-H 
and 3-H). 
 
 5α-Androst-1-en-17-one (34).  
 Jones reagent (0,3 mL) was added dropwise to a solution of a mixture 33a and 
33b (90:10) (100.1 mg, 0.36 mmol) in acetone (5 mL), at 0 ºC, with stirring until the 
orange colour of the reagent remains. Then, the mixture was stirred for more 3 min, 
after which the reaction was poured into water (100 mL) and the product extracted with 
dichloromethane (3 x 100 mL). The organic layer was then washed with 10% aqueous 
NaHCO3 (2 x 100 mL) and water (2 x 100 mL), dried over anhydrous Na2SO4, filtered 
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and concentrated to dryness giving a white solid residue. This residue (one TLC spot) 
was composed by a mixture of 29 and 34. Column chromatography purification (n-
hexane/diethyl ether) followed by consecutive recrystallizations from methanol gave 
compound 34 in 96% purity (LC-MS analysis).  
 
 5α-Androst-1-en-17-one (34): 1H NMR (600 MHz, CDCl3) δ: 0.86 (3H, s, 19-
H3), 0.87 (3H, s, 18-H3), 5.52 (1H, m, 2-H), 5.83 (1H, bd, J1-2=10.0, 1-H). 13C NMR 
(150 MHz, CDCl3) δ: 13.9 (C-19), 15.7 (C-18), 20.4, 21.8, 25.3, 25.9, 28.2, 30.9, 31.6, 
35.3, 35.8, 37.6, 44.6, 47.9, 51.5, 51.8, 125.4 (C-2), 135.4 (C-1), 221.3 (C-17). ESI: 
271.3 ([M-H]+, 100%).  
 
 5α-Androst-2-en-17-one (29) (from the mixture with 34): 1H NMR (600 MHz, 
CDCl3) δ: 0.78 (3H, s, 19-H3), 0.87 (3H, s, 18-H3), 5.59 (2H, m, 2-H and 3-H). 
 
 
 General procedure to obtain 4α,5α-epoxyandrostan-17β-ol (24a) and 4β,5β-
epoxyandrostan-17β-ol (24b), 4α,5α-epoxyandrostan-17-one (26a) and 4β,5β-
epoxyandrostan-17-one (26b), 3α,4α-epoxy-5α-androstan-17-one (28), 2α,3α-epoxy-
5α-androstan-17-one (30), and 1α,2α-epoxy-5α-androstan-17-one (35).  
 To a solution of the olefin (23, 25, 27a, 29 or 34) in dichloromethane, a solution 
of performic acid, generated in situ by addition of HCOOH 98-100% to H2O2 35%, was 
added. The reaction mixture was stirred at room temperature until complete 
transformation of the starting material. Dichloromethane (100 mL) was added and the 
organic layer was washed successively with 10% aqueous NaHCO3 (2 x 100 mL) and 
water (4 x 100 mL), dried over anhydrous MgSO4, filtered and concentrated to dryness. 
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The obtained residue was purified by silica gel 60 column chromatography (n-
hexane/ethyl acetate). 
 
 4α,5α-Epoxyandrostan-17β-ol (24a) and 4β,5β-epoxyandrostan-17β-ol (24b).  
 Olefin 23 (82.7 mg, 0.30 mmol); dichloromethane (4.0 mL); HCOOH 98-100% 
(0.04 mL); H2O2 35% (0.11 mL); total reaction time: 7 h (TLC). Before column 
chromatography, 83.6 mg of a white solid residue was obtained. Purification by column 
chromatography afforded 39.7 mg of an inseparable epimeric mixture (60:40, by NMR) 
of 4α,5α- (24a) and 4β,5β- (24b) epimers, respectively.  
 
 4α,5α-Epoxyandrostan-17β-ol (24a) (from the mixture with 24b): 1H NMR (600 
MHz, DMSO-d6) δ: 0.65 (3H, s, 18-H3), 1.02 (3H, s, 19-H3), 3.42-3.46 (1H, m, 17α-H), 
2.86 (1H, d, J4β-3α=4.3, 4β-H), 4.42 (1H, d, J17βOH-17α=4.8, 17β-OH).  
 
 4β,5β-Epoxyandrostan-17β-ol (24b) (from the mixture with 24a): 1H NMR (600 
MHz, DMSO-d6) δ: 0.64 (3H, s, 18-H3), 0.93 (3H, s, 19-H3), 3.42-3.46 (1H, m, 17α-H), 
2.86 (1H, d, J4α-3α=4.6, 4α-H), 4.44 (1H, d, J17βOH-17α=4.9, 17β-OH). 
 
 4α,5α-Epoxyandrostan-17-one (26a) and 4β,5β-epoxyandrostan-17-one (26b).  
 Olefin 25 (300.0 mg, 1.01 mmol); dichloromethane (15.0 mL); HCOOH 98-
100% (0.14 mL); H2O2 35% (0.44 mL); total reaction time: 10 h 45 min (TLC). Before 
column chromatography it was obtained 309.7 mg of a white solid residue. Purification 
by column chromatography afforded 111.3 mg (35%) and 183.4 mg  (58%) of 4α,5α- 
and 4β,5β-epimers 26a and 26b, respectively.  
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 4α,5α-Epoxyandrostan-17-one (26a): Mp(chloroform) 142-145 ºC. IR (NaCl plates, 
CHCl3) νmax cm-1: 1734 (C=O), 1216 (C-O-C). 1H NMR (600 MHz, CDCl3) δ: 0.88 (3H, 
s, 18-H3), 1.03 (3H, s, 19-H3), 2.46 (1H, ddd, J16β-16α=19.0, J16β-15β=9.0, J16β-15β=1.0, 
16β-H), 2.90 (1H, d, J4β-3α=4.6, 4β-H). 13C NMR (150 MHz, CDCl3) δ: 13.7 (C-18), 
15.3 (C-19), 19.2, 20.5, 21.8, 23.6, 29.3, 29.6, 31.2, 31.4, 34.7, 35.8, 36.4, 46.7, 47.7, 
51.2, 61.3, 65.3 (C-5), 220.9 (C-17). ESI: 287.1 ([M-H]+, 100%).  
 
 4β,5β-Epoxyandrostan-17-one (26b): Mp(chloroform) 148-150 ºC. IR (NaCl plates, 
CHCl3) νmax cm-1: 1738 (C=O), 1016 (C-O-C). 1H NMR (600 MHz, CDCl3) δ: 0.88 (3H, 
s, 18-H3), 1.08 (3H, s, 19-H3), 2.43 (1H, ddd, J16β-16α=19.0, J16β-15β=9.0, J16β-15β=1.0, 
16β-H), 2.94 (1H, d, J4α-3β =4.1, 4α-H). ESI: 289.3 ([M+H]+, 100%). 
 
 3α,4α-Epoxy-5α-androstan-17-one (28).  
 Olefin 27a (67.5 mg, 0.25 mmol); dichloromethane (1.0 mL); HCOOH 98-100% 
(0.05 mL); H2O2 35% (0.05 mL); total reaction time: 6 h (TLC). It was afforded 75 mg 
of 28 (96%). 1H NMR (500 MHz, CDCl3) δ: 0.79 (3H, s, 19-H3), 0.86 (3H, s, 18-H3), 
2.08 (1H, ddd, J16α-16β=19.0, J16α-15α/15β=9.5, 16α-H), 2.44 (1H, ddd, J16β-16α=19.0, J16β-
15β=5.5, J16β-15α=0.0-1.0, 16β-H), 2.71 (1H, d, J4β-5α=4.0, 4β-H), 3.17 (1H, dd, J3β-2α=3.0, 
J3β-2β=3.0, 3β-H).  
 
 2α,3α-Epoxy-5α-androstan-17-one (30).  
 Method A. Olefin 29 (100.0 mg, 0.37 mmol); dichloromethane (2.0 mL); 
HCOOH 98-100% (0.1 mL); H2O2 35% (0.3 mL); total reaction time: 6 h (TLC). 
Before column chromatography it was obtained 103.5 mg of a white solid residue. 
Purification by column chromatography (chloroform) afforded compound 30 (6.7 mg, 
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6%) in 92% purity (NMR and HPLC analysis). IR (NaCl plates, CHCl3) υmax cm-1: 
1738(C=O), 1013 (C-O-C). 1H NMR (600 MHz, CDCl3) δ: 0.78 (3H, s, 19-H3), 0.84 
(3H, s, 18-H3), 2.05 (1H, ddd, J16α-16β=19.0, J16α-15β=9.0, J16α-15α=9.0, 16α-H), 2.42 (1H, 
ddd, J16β-16α=19.0, J16β-15β=9.0, J16β-15α=1.0, 16β-H), 3.11 (1H, m, J2β-1α=6.0, J2β-3β=3.95, 
2β-H) and 3.16 (1H, m, J3β-4α =6.0, J3β-2β=3.95, J3β-4β=1.69, 3β-H). 13C NMR (150 MHz, 
CDCl3) δ: 15.6 (C-19), 16.3 (C-18), 22.8, 24.4, 30.7, 31.6, 33.1, 34.1, 36.4, 37.8, 38.5, 
38.9, 40.9, 50.2, 53.5, 53.9, 55.0 (C-2), 56.4 (C-3) and 223.9 (C-17). ESI: 287.0 ([M-
H]+, 100%). 
 
 Method B. To a stirred 9% aqueous peracetic acid solution (1.0 mL) at 10 ºC, 
trihydrated sodium acetate (79.6 mg) and olefin 29 (200.2 mg, 0.73 mmol) in 
chloroform (2 mL) were added. The reaction was then stirred at room temperature until 
complete transformation of the starting material (7 h 30 min, TLC). Dichloromethane 
(150 mL) was added and the organic layer was washed with 10% aqueous NaHCO3 
(100 mL), water (4 x 100 mL), dried over anhydrous MgSO4 and concentrated to 
dryness giving 162.9 mg of a white residue. Purification by column chromatography (n-
hexane/ethyl acetate) followed by crystallization with methanol/water gave compound 
30, also in 92% purity. 
 
 1α,2α-Epoxyandrostan-17-one (35).  
 Olefin 34 (46.4 mg, 0.17 mmol); dichloromethane (3 mL); HCOOH 98-100% 
(0.03 mL); H2O2 35% (0.07 mL); total reaction time: 9 h 30 min (TLC). Before column 
chromatography, 38.6 mg of an oily residue was obtained. Purification by column 
chromatography afforded 7.4 mg (15%) of the pure compound 35. Mp(chloroform) 119-122 
ºC. IR (NaCl plates, CHCl3) υmax cm-1: 1738 (C=O), 1049 (C-O). 1H NMR (600 MHz, 
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CDCl3) δ: 0.87 (3H, s, 18-H3), 0,92 (3H, s, 19-H3), 2.07 (1H,ddd, J16α-16β=19.0, J16α-
15α=9.0, J16α-15β=9.0, 16α-H), 2.42 (1H, ddd, J16β-16α=19.0, J16β-15β=9.0, J16β-15α=1.0, 16β-
H), 2.99 (1H, d, J1β-2β=4.0, 1β-H), 3.12 (1H, dd, J2β-1β=4.0, J2β-3α=3.0, 2β-H). 13C NMR 
(150 MHz, CDCl3) δ: 11.4 (C-18), 13.8 (C-19), 20.4, 21.7, 22.7, 23.4, 27.6, 30.4, 31.3, 
34.9, 35.8, 36.6, 37.3, 47.7, 49.0, 51.3, 52.9 (C-1), 59.1 (C-2), 221.1 (C=O). ESI: 286.9 
([M-H]+, 100%). 
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Scheme 1.7 - Synthesis of aromatase inhibitor 40 from 15  
 
 3-Oxoandrost-4-en-17β-yl acetate (18). As described in Scheme 1.5 
 
 3β-Hydroxyandrost-4-en-17β-yl acetate (37).  
 To a solution of 18 (2.0 g, 6.05 mmol) in anhydrous tetrahydrofuran (75 mL) 
under nitrogen, lithium tri-t-butoxyaluminum hydride (2.0 g, 7.86 mmol) was added and 
the reaction was heated under reflux for 2 h, time after which an excess of lithium tri-t-
butoxyaluminum hydride (500.1 mg, 1.97 mmol) was added. The reaction proceeded 
until complete transformation of the starting material (3 h 30 min, total). After removal 
of the solvent under vacuum, water (200 mL) was added and the aqueous layer 
extracted with dichloromethane (3 x 200 mL). The resulting organic layer was washed 
with water (200 mL), dried over anhydrous Na2SO4, filtered and concentrated to 
dryness giving 1.97 g of a crude mainly composed by compound 37. 1H NMR (600 
MHz, DMSO-d6) δ: 0.76 (3H, s, 18-H3), 0.99 (3H, s, 19-H3), 1.98 (3H, s, CH3COO), 
3.90 (1H, m, 3α-H), 4.49 (1H, dd, J17αH-16αH=9.0, J17αH-16βH=8.0, 17α-H), 4.54 (1H, d, 
J3βOH-3αH=5.5, 3β-OH), 5.19 (1H, bs, 4-H); 13C NMR (150 MHz, DMSO-d6) δ: 11.8 (C-
18), 18.4 (C-19), 20.0, 20.8, 22.9, 27.0, 28.9, 31.4, 32.2, 35.1, 35.2, 36.2, 36.7, 41.9, 
49.7, 53.8, 65.8 (C-3), 81.8 (C-17), 125.5 (C-4), 143.9 (C5), 170.2 (OC=O). 
 
 Androsta-3,5-dien-17β-yl acetate (38).  
 A solution of the previously obtained crude (500.4 mg) in benzene (10 mL) was 
kept at 5-8 ºC, under nitrogen, treated with thionyl chloride (0.5 mL, 6.72 mmol) and 
stirred for 2 h 25 min, time after which an excess of thionyl chloride (0.1 mL, 1.38 
mmol) was added. The reaction proceeded never allowing the complete transformation 
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of the starting material (5 h 30 min, total). Benzene was evaporated under vacuum, at 
room temperature giving an oily residue to which solid NaHCO3 (500 mg) was added 
followed by 10% aqueous NaHCO3 (100 mL). The aqueous layer was extracted with 
dichloromethane (3 x 100 mL) and the resulting organic layer was washed with water (3 
x 100 mL), dried over anhydrous MgSO4, filtered and concentrated to dryness giving a 
white solid residue. This residue was purified by silica gel 60 column chromatography 
(petroleum ether 60-80ºC/ethyl acetate) to afford 263.4 mg of the title compound 38 as 
a white crystalline residue in an overall yield of 56% from 18. Mp(petroleum ether 60-80 ºC/ethyl 
acetate) 116-119 ºC. IR υmax (NaCl plates, CHCl3) υmax cm-1: 3018 (=CH), 1736 (C=O 
ester), 1648 (C=C), 1244 (C-O). 1H NMR (600 MHz, CDCl3) δ: 0.83 (3H, s, 18-H3), 
0.96 (3H, s, 19-H3), 2.04 (3H, s, CH3COO), 4.61 (1H, dd, J17α-16α=9.0, J17α-16β=8.0, 17α-
H), 5.38 (1H, m, 6-H), 5.59 (1H, m, 3-H), 5.92 (1H, m, 4-H). 13C NMR (150 MHz, 
CDCl3) δ: 12.0 (C-18), 18.8 (C-19), 20.4, 21.2, 22.9, 23.5, 27.5, 31.3, 31.6, 33.7, 35.2, 
36.8, 42.5, 48.3, 51.2, 82.8 (C-17), 122.6 (C-6), 125.1 (C-3), 128.8 (C-4), 141.5 (C-5), 
171.2 (OC=O). ESI: 315.1 ([M+H]+, 76%). 
 
 Androsta-3,5-dien-17β-ol (39).  
 To a solution of 38 (100.8 mg, 0.32 mmol) in ethyl ether (15 mL), lithium 
aluminium hydride (76.2 mg, 2.01 mmol) was added cautiously under nitrogen and the 
reaction heated under reflux for 8 h. A saturated sodium potassium tartrate solution (150 
mL) was added and the mixture extracted with ethyl ether (4 x 100 mL). The organic 
layer was washed with water (4 x 100 mL), dried over anhydrous MgSO4, filtered and 
concentrated to dryness giving 79.4 mg (91%) of the pure compound 39 as a white 
solid.  Mp(ethyl acetate/n-hexane) 140-142 ºC. IR (NaCl plates, CHCl3) υmax cm-1: 3302 (OH), 
3021 (=CH), 1646 (C=C), 1054 (C-O). 1H NMR (600 MHz, DMSO-d6) δ: 0.67 (3H, s, 
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18-H3), 0.89 (3H, s, 19-H3), 3.45 (1H, ddd, J17α-17βOH=5.0, J17α-16α=9.0, J17α-16β=9.0, 17α-
H), 4.45 (1H, d, J17βOH-17α=5.0, 17β-OH), 5.34 (1H, m, 6-H), 5.57 (1H, m, 3-H), 5.88 
(1H, m, 4-H). 13C NMR (150 MHz, DMSO-d6) δ: 11.2 (C-18), 18.5 (C-19), 20.1, 22.4, 
22.9, 29.8, 30.8, 31.4, 33.2, 34.6, 36.3, 42.3, 48.0, 50.9. 79.9 (C-17), 122.6 (C-6), 124.5 
(C-3), 128.8 (C-4), 140.8 (C-5). ESI: 271.2 ([M-H]+, 100%). 
 
 Androsta-3,5-dien-17-one (40).  
 To a solution of 39 (62.0 mg, 0.23 mmol) in pyridine (3 mL), a pyridine solution 
(2.3 mL) of chromium trioxide (98 mg, 0.98 mmol) was added at 0 ºC. The reaction was 
stirred at room temperature for 19 h, until total transformation of the starting material 
(TLC control). The mixture was then diluted with ethyl ether (150 mL) and poured into 
water (50 mL). The organic phase was brined (6 x 150 mL), washed with water (3 x 200 
mL), dried over anhydrous MgSO4, filtered and concentrated to dryness giving a yellow 
residue which was purified by neutral column chromatography (petroleum ether 40-60 
ºC) giving 9.0 mg (38%) of pure compound 40. Mp(chloroform) 81-83 ºC [lit.,140 80-82 ºC]. 
IR (NaCl plates, CHCl3) υmax cm-1: 3018 (=CH), 1739 (C=O), 1652 (C=C). 1H NMR 
(600 MHz, CDCl3) δ: 0.91 (3H, s, 19-H3), 0.97 (3H, s, 18-H3), 5.40 (1H, m, 6-H), 5.61 
(1H, m, 3-H), 5.93 (1H, m, 4-H). 13C NMR (150 MHz, CDCl3) δ: 13.7 (C-19), 18.8 (C-
18), 20.2, 21.8, 22.9, 30.6, 31.3, 31.4, 33.7, 35.3, 35.8, 47.7, 48.5, 51.9, 122.1 (C-6), 
125.3 (C-3), 128.7 (C-4), 141.6 (C-5), 221.0 (C=O). ESI: 269.1 ([M-H]+, 99%). 
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Scheme 1.9 - Synthesis of aromatase inhibitors 41 and 42 from 27a 
 
 3α,4α-Methylen-5α-androstan-17-one (41).  
 A mixture of zinc dust <10 µm (409.7 mg, 6.26 mmol) and cuprous chloride 
(618.9 mg, 13.07 mmol) in anhydrous diethyl ether (15 mL) was stirred and heated to 
reflux, using a ultra-sound bath, under an atmosphere of anhydrous nitrogen, for 30 
min. A solution of 27a (50.0 mg, 0.18 mmol) in anhydrous diethyl ether (2 mL) was 
added to the former suspension followed by the addition of methylidenediiodide (0.3 
mL, 3.35 mmol) and iodine (14.6 mg). The reaction mixture was maintained at reflux 
for 37 h, time after which a new addition of the mixture of dust zinc (204.6 mg, 3.13 
mmol), cuprous chloride (309.3 mg, 6.54 mmol) in anhydrous diethyl ether (5 mL) with 
methylidenediiodide (0.15 mL, 1.68 mmol) and iodine (7 mg) (this mixture was kept at 
reflux temperature with stirring for 1 h prior to the addition to the reaction mixture) was 
made. The reaction proceeded in the same conditions for more 53 h. After this, the 
reaction mixture was filtered through an oxide aluminium filtration plate and washed 
with ethyl acetate (50 mL) and diethyl ether (100 mL). The filtrates were concentrated 
and the residue was diluted with diethyl ether (150 mL) and washed with 5% aqueous 
HCl (3 x 50 mL), 5% aqueous NaHCO3 (3 x 50 mL) and water (3 x 50 mL). The 
organic layer was dried over anhydrous Na2SO4, filtered and concentrated to dryness 
giving a white solid residue. This residue was then purified by silica gel column 
chromatography (hexane/ethyl acetate) that allowed obtaining the pure compound 41 in 
10.7 mg (21%). Mp(hexane/ethyl acetate) 120-123 ºC. IR (NaCl plates, CHCl3) νmax cm-1: 1708 
(C=O). 1H NMR (600 MHz, CDCl3) δ: -0.12 (1H, m, α cyclopropyl-H), 0.35 (1H, m, 
3β–H), 0.55 (1H, m, 5α-H), 0.65 (1H, m, β cyclopropyl-H), 0.80 (1H, m, 4β–H), 0.83 
(3H, s, 19-H3), 0.85 (3H, s, 18-H3), 2.05 (1H, ddd, J16α,16β=19.2, J16α,15β=J16α,15α=9.1, 
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16α-H), 2.42 (1H, ddd, J16β,16α=19.2, J16β,15β=8.9, J16β,15α=1.0, 16β-H). 13C NMR (150 
MHz, CDCl3) δ: 8.9 (C-3), 12.4 (CH2 cyclopropyl), 12.7 (C-19), 13.9 (C-18), 14.2 (C-
4), 19.3, 20.6, 21.8, 29.3, 30.9, 31.65, 32.3, 34.7, 35.1, 35.9, 47.8, 48.7, 51.5, 52.9, 
221.4 (C-17). ESI: 285.5 ([M-H]+, 100%). 
 
 5α-Androst-3-ene-17-thione (42).  
 To a solution of olefin 27a (420.7 mg, 1.46 mmol) in anhydrous toluene (30 
mL), Lawesson’s reagent (624.9 mg, 1.54 mmol) was added and the reaction mixture 
was heated under reflux for 7 h, in an inert atmosphere. The remaining Lawesson’s 
reagent was removed through a neutral alumina column leading to an orange residue, 
which was further purified by silica gel 60 column chromatography (petroleum ether 
40-60 ºC) affording the pure compound 42 (238.5 mg, 54%), as a light orange solid. 
Mp(petroleum ether 40-60ºC) 95 ºC. IR (NaCl plates, CHCl3) υmax cm-1: 3015 (=CH), 1650 
(C=C), absence of C=O (peak around 1715 in compound 8). 1H NMR (600 MHz, 
CDCl3) δ: 0.79 (3H, s, 19-H3), 0.88 (3H, s, 18-H3), 2.60 (1H, ddd, J16α-16β=22.0, J16α-
15β=9.0, J16α-15α=9.0, 16α-H), 2.93 (1H, ddd, J16β-16α=22.0, J16β-15β=9.0, J16β-15α=1.0, 16β-
H), 5.27 (1 H, ddd, J4-3=9.5, J4-5α=4.0, J4-2α=2.0, 4-H), 5.54 (1 H, ddd, J3-4=9.5, J3-
2β=6.0, J3-2α=3.0, 3-H). 13C NMR (150 MHz, CDCl3) δ: 14.5 (C-19), 20.5 (C-18), 23.7, 
26.1, 27.1, 29.9, 34.3, 36.7, 37.7, 38.3, 38.6, 48.5, 51.8, 55.7 (2 carbons), 62.1, 128.2 
(C-4), 133.7 (C-3), 274.1 (C=S). ESI: 287.2 ([M-H]+, 100%). 
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Scheme 1.10 - Synthesis of aromatase inhibitors 45a and 46a from androstenedione (1) 
 
 6-Methylenandrosta-4-ene-3,17-dione (2). As described in Scheme 1.1 
 
 6α-Methylandrost-4-ene-3,17-dione (44).  
 To a solution of 2 (402.9 mg, 1.35 mmol) and cyclohexene (0.81 mL, 7.96 
mmol) in absolute ethanol (26 mL), 5% Pd-C (80.6 mg, 0.76 mmol) was added. The 
suspension was set to reflux temperature with stirring. The UV spectra of aliquots were 
periodically determined at appropriate times and after 3 h 15 min it was observed a 
complete change from λmax 260 nm to λmax 240 nm, meaning that the starting material 
had been completely transformed. The catalyst was afterwards removed by filtration 
and the filtrate was concentrated under reduced pressure giving an oily residue. This 
residue was purified by column chromatography (hexane/ethyl acetate) allowing to 
isolate the pure compound 44 (276.4 mg, 71%) as a white solid. Mp(hexane/ethyl acetate) 164-
166 ºC [lit.,118,123 166-168 ºC, 167-169 ºC]. IR (NaCl plates, CHCl3) νmax cm-1: 3050 
(H-C=), 1739 (C=O), 1671 (C=C). 1H NMR (600 MHz, CDCl3) δ: 0.92 (3H, s, 18-H3), 
1.09 (3H, d, J=6.5, 6α-H3), 1.21 (3H, s, 19-H3), 5.80 (1H, bs, 4-H). 13C NMR (150 
MHz, CDCl3) δ: 13.7 (C-18), 18.3 (C-20), 18.4 (C-19), 20.5, 21.7, 31.3, 33.6, 33.7, 
35.0, 35.8, 35.9, 38.9, 39.7, 47.5, 50.7, 54.1, 121.6 (C-4), 173.5 (C-5), 199.6 (C-3), 
220.3 (C-17).  
 
 6α-Methyl-5α-androst-3-en-17-one (45a) and 6α-methyl-5β-androst-3-en-
17-one (45b).  
 To a boiling solution of 44 (259.3 mg, 0.863 mmol) in gacial acetic acid (40 
mL), zinc dust <10 µm (1.48 g, 22.66 mmol) was added in several portions during 1 h. 
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After 3 h another amount of zinc dust (1.48 g, 22.66 mmol) was added, within 1 h. The 
reaction proceeded with a total of 5 h 15 min, although, without total transformation of 
the starting material. The zinc suspension was filtered, the zinc was washed with glacial 
acetic acid and the filtrate evaporated to dryness. The resulting residue was then diluted 
with water (100 mL) and extracted with diethyl ether (3 x 100 mL) and ethyl acetate 
(100 mL). The organic layer was washed with 10% aqueous NaHCO3  (3 x 100 mL) and 
water (3 x 100 mL), dried over anhydrous Na2SO4, filtered and concentrated to dryness. 
The NMR analysis of this crude revealed to be composed by both isomers 45a and 45b 
in a relation of 1.7:1, respectively. This crude was then purified by silica gel column 
chromatography (hexane/ethyl acetate), which allowed isolating compound 45b in 13% 
yield as a white solid residue. A mixture of isomers 45a and 45b (193.7 mg, 78% yield) 
was also obtained. A new silica gel column chromatography of this mixture allowed 
obtaining compound 45a in 90% purity (NMR and HPLC control).  
 
 6α-Methyl-5α-androst-3-en-17-one (45a): IR (NaCl plates, CHCl3) νmax cm-1: 
3030 (H-C=), 1740 (C=O), 1651 (C=C). 1H NMR (600 MHz, CDCl3) δ: 0.80 (3H, s, 19-
H3), 0.87 (3H, s, 18-H3), 0.93 (3H, d, J=6.1, 6α-H3), 5.61 (1H, ddd, J3,4=10.0, J3,2β=6.5, 
J3,2α=3.3, 3-H), 5.67 (1H, ddd, J4,3= 10.2, J4,5α=3.9, J4,2α=2.0, 4-H). 13C NMR (150 
MHz, CDCl3) δ: 12.6 (C-19), 13.9 (C-18), 19.9 (C-20), 20.3, 21.7, 23.2, 29.5, 31.6, 
34.2, 34.7, 35.3, 35.8, 35.9, 47.8, 51.4, 52.3, 53.3, 126.2 (C-3), 127.2 (C-4), 221.4 (C-
17). ESI: 287.3 ([M+H]+, 100%). 
 
 6α-Methyl-5β-androst-3-en-17-one (45b): Mp(hexane/ethyl acetate) 84-87 ºC. IR (NaCl 
plates, CHCl3) νmax cm-1: 3025 (H-C=), 1740 (C=O), 1647 (C=C). 1H NMR (600 MHz, 
CDCl3) δ: 0.86 (3H, s, 18-H3), 0.96 (3H, d, J=6.9, 6-H3), 0.97 (3H, s, 19-H3), 2.03 (1H, 
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ddd, J16α,16β=18.9, J16α,15β=9.3, J16α,15α=9.0, 16α-H), 2.42 (1H, dd, J16β,16α=19.2, 
J16β,15β=8.8, 16β-H), 5.56 (1H, dd, J4,3=10.3, J4,5β=1.7, 4-H), 5.70 (J3,4=9.8, J3,2α=3.5, 3-
H). 13C NMR (150 MHz, CDCl3) δ: 13.8 (C-18), 14.1 (C-20), 19.3 (C-19), 20.8, 21.8, 
22.3, 22.7, 22.9, 29.3, 31.8, 34.3, 34.5, 35.6, 35.9, 40.8, 49.1, 51.1, 125.7 (C-4), 127.9 
(C-3), 221.5 (C-17).  
 
 3α,4α-Epoxy-6α-methyl-5α-androstan-17-one (46a) and 3β,4β-epoxy-6α-
methyl-5β-androstan-17-one (46b).  
 A stirred solution of a crude mixture of compounds 45a and 45b (112.4 mg, 
0.39 mmol) in dichloromethane (30 mL) was treated with a solution of performic acid, 
generated in situ by the addition of 98-100% formic acid (0.10 mL) and 30% hydrogen 
peroxide (0.21 mL), at room temperature. The reaction mixture was stirred at room 
temperature for 9 h 30 min. Dichloromethane was then added (150 mL), and the organic 
layer was washed successively with 10% aqueous NaHCO3  (100 mL) and water (4 x 
100 mL), dried over anhydrous Na2SO4, filtered and concentrated to dryness giving a 
slightly yellow oily residue. This residue was purified by silica gel column 
chromatography (hexane/ethyl acetate) allowing to isolate 52.0 mg (44%) of the pure 
3α,4α-epimer 46a as a white solid, and 34.6 mg (29%)  of the pure 3β,4β-epimer 46b.  
 
 3α,4α-Epoxy-6α-methyl-5α-androstan-17-one (46a): Mp(hexane/ethyl acetate) 153-156 
ºC. IR (NaCl plates, CHCl3) νmax cm-1: 1740 (C=O), 1013 (C-O). 1H NMR (600 MHz, 
CDCl3) δ: 0.79 (3H, s, 19-H3), 0.85 (3H, s, 18-H3), 1.07 (3H, d, J=6.4, 6α-H3), 2.43 
(1H, dd, J16β,16α=19.2, J16β,15β=8.7, 16β-H), 2.92 (1H, dd, J4β,5α=4.1, J4β,6β=1.3, 4β-H), 
3.15 (1H, dd, J3β,2β=J3β,2α=3.4, 3β-H). 13C NMR (150 MHz, CDCl3) δ: 13.8 (C-19), 13.9 
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(C-18), 19.8, 20.6, 20.9, 21.7 (C-20), 29.5, 30.8, 31.5, 34.4, 34.7, 35.9, 40.2, 47.7, 51.2, 
51.9, 52.3, 53.3 (C-4), 53.4 (C-3), 221.0 (C-17). ESI: 303.1 ([M+H]+, 100%).  
 
 3β,4β-Epoxy-6α-methyl-5β-androstan-17-one (46b): Mp(hexane/ethyl acetate) 83-87 
ºC. IR (NaCl plates, CHCl3) νmax cm-1: 1738 (C=O), 1050 (C-O). 1H NMR (600 MHz, 
CDCl3) δ: 0.84 (3H, s, 18-H3), 0.87 (3H, s, 19-H3), 1.06 (3H, d, J=6.9, 6α-H3), 2.44 
(1H, dd, J16β,16α=18.3, J16β,15β=8.7, J16β,15α=0.8, 16β-H), 2.91 (1H, d, J4α,5β=3.9, 4α-H), 
3.17 (1H, dd, J3α,2α=J3α,2β=2.5, 3α-H). 13C NMR (150 MHz, CDCl3) δ: 13.6 (C-18), 13.7 
(C-19), 18.9, 20.2 (C-20), 22.1, 28.9, 29.5, 31.6, 33.6, 35.1, 35.5, 35.80, 35.81, 35.82, 
42.6, 48.9, 51.1, 52.9 (C-4), 53.0 (C-3), 220.9 (C-17).  
  
Chapter I 
Steroidal Aromatase Inhibitors as Anti-tumors 
 131 
Scheme 1.11 – Synthesis of 7α-allyl derivatives as aromatase inhibitors 
 
 3-Oxoandrost-4-en-17β-yl acetate (18). As described in Scheme 1.5 
 
 3-Oxoandrosta-4,6-dien-17β-yl acetate (47).  
 To a solution of 18 (3.8 g, 11.50 mmol) in acetic acid (50 mL) and toluene (10 
mL), under a stream of nitrogen, chloranil (2.5 g, 10.17 mmol) was added and the 
reaction mixture was refluxed for 3 h (UV spectrophotometric control). After cooling, 
the mixture was extracted with dichloromethane (3 x 200 mL) and the organic layer was 
sequentially washed with 2.5 N aqueous NaOH, 10% aqueous NaHCO3 (3 x 150 mL) 
and water (3 x 100 mL), dried over anhydrous MgSO4, filtered and concentrated to 
dryness yielding a crude product, which was purified by silica gel chromatography 
(petroleum ether 40-60 ºC/diethyl ether) gave the pure compound 47 (2.2 g, 58%), as a 
yellow crystalline solid. Mp(ethyl acetate/n-hexane) 141-143 ºC. IR (NaCl plates, CHCl3) υmax 
cm-1: 3024 (=CH), 1734 (C=O), 1658 (C=C), 1617 (C=C), 1030 (C-O). 1H NMR 
(CDCl3, 600 MHz) δ: 0.88 (3H, s, 18-H3), 1.11 (3H, s, 19-H3), 2.05 (3H, s, CH3COO), 
4.63 (1H, dd, J17α,16α=J17α,16β=9.0, 17α-H), 5.67 (1H, s, 4-H), 6.09 (1H, d, J6,7=10.4, 6-
H), 6.12 (1H, dd, J7,6 =10.4, J7,8= 2.4, 7-H). 13C NMR (150 MHz, CDCl3) δ: 11.9 (C-
18), 16.3 (C-19), 20.2, 21.1, 23.1, 27.4, 33.8, 33.9, 36.0, 36.5, 37.3, 43.4, 48.0, 50.6, 
82.1 (C-17), 123.8 (C-7), 128.2 (C-6), 139.9 (C-4), 163.4 (C-5), 171.1 (OC=O), 199.4 
(C-3). 
 
 7α-Allyl-3-oxoandrost-4-en-17β-yl acetate (48).  
 To a solution of 47 (0.55 g, 1.67 mmol) in anhydrous dichloromethane (50 mL), 
under stirring and in an inert atmosphere, cooled at -78 °C, titanium tetrachloride (3.0 
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mL, 27.29 mmol) was added. After 5 min, a solution of allyltrimethylsilane (3.0 mL, 
18.6 mmol) in anhydrous dichloromethane (5.0 mL) was carefully added to the previous 
solution. The resulting mixture was stirred for 40 min and then allowed to warm to 30 
°C. After that, water was added, the mixture was extracted with dichloromethane (3 x 
100 mL) and the organic layer was washed with 10% aqueous NaHCO3 (2 x 100 mL) 
and water (3 x 100 mL), dried over anhydrous Na2SO4, filtered and concentrated to 
dryness yielding an oily product (0.674 g). Purification of this product by silica gel flash 
column chromatography (petroleum ether 40-60 ºC/diethyl ether) afforded the pure 
compound 48 (0.35 g, 56%). Mp(petroleum ether 40-60 ºC/diethyl ether) 150-152 ºC. IR (NaCl 
plates, CHCl3) υmax cm-1: 3012 (=CH), 1745 (C=O ester), 1722 (C=O), 1663 (C=C), 
1041 (C-O). 1H NMR (600 MHz, CDCl3) δ: 0.84 (3H, s, 18-H3), 1.20 (3H, s, 19-H3), 
2.04 (3H, s, CH3COO), 4.61 (1H, dd, J17α,16α=8.9, J17α,16β=8.2, 17α-H), 4.98 (1H, ddd, 
CH=CH2), 5.02 (1H, ddd, CH=CH2), 5.64 (1H, m, CH=CH2), 5.71 (1H, s, 4-H). 13C 
NMR (150 MHz, CDCl3) δ: 11.9 (C-18), 17.9 (C-19), 20.7, 21.1, 22.8, 27.3, 30.2, 33.9, 
35.9, 36.0, 36.1, 36.4, 38.3, 38.6, 42.5, 45.9, 46.9, 82.4 (C-17), 116.8 (C-24), 126.2 (C-
4), 136.8 (C-23), 169.2 (C-5), 171.1 (C=O), 199.1 (C-3). ESI: 369.53 ([M-H]+, 100%). 
 
 7α-Allyl-3-oxoandrost-4-en-17β-ol (49).  
 To a mixture of dioxane/water (85:15) (50 mL) with 2% aqueous NaOH (10 
mL), compound 48 (0.62 g, 1.67 mmol) was added and the resulting solution was stirred 
overnight, at room temperature, after which chilled water was added leading to the 
formation of a precipitate. This precipitate was separate by filtration, dissolved in ethyl 
acetate/dichloromethane (4:1), and the resulting solution was dried over anhydrous 
MgSO4 and concentrated to dryness yielding the pure compound 49 (0.57 g, 96%) as a 
white solid. Mp(ethyl acetate/dichloromethane) 216-218 ºC [lit.,128 208-210 ºC]. IR (NaCl plates, 
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CHCl3) υmax cm-1: 3421 (OH), 1722 (C=O), 1645 (C=C), 1061 (C-O). 1H NMR (600 
MHz, DMSO-d6) δ: 0.69 (3H, s, 18-H3), 1.16 (3H, s, 19-H3), 3.46 (1H, ddd, J17α,16α=8.5, 
J17α,16β=8.5, J17α,17β-OH=4.8, 17α-H), 4.47 (1H, d, J17β-OH,17α=4.8, 17β-OH), 4.94 (1H, 
ddd, CH=CH2), 5.00 (1H, m, CH=CH2), 5.56 (1H, s, 4-H), 5.72 (1H, m, CH=CH2). 13C 
NMR (150 MHz, DMSO-d6) δ: 11.0 (C-18), 17.4 (C-19), 20.4, 22.3, 29.6, 29.8, 33.6, 
35.2, 35.5, 35.7, 36.0, 37.8, 38.2, 42.4, 45.5, 46.4, 79.8 (C-17), 116.1 (C-22), 125.2 (C-
4), 137.4 (C-21), 169.2 (C-5), 197.5 (C-3). ESI: 327.31 ([M-H]+, 100%). 
 
 
 General procedure to obtain 7α-allylandrost-4-ene-3,17-dione (50), 7α-
allylandrost-4-en-17-one (53) and 7α-allylandrosta-1,4-diene-3,17-dione (56).   
 Jones reagent was added dropwise to solutions of 49, 52 or 54 in 
acetone/dioxane (60:10), at 0 ºC, with stirring until the orange colour of the reagent 
remains. The excess of oxidant agent was destroyed by addition of 2-propanol. The 
reaction mixture was added to water (150 mL), extracted with ethyl acetate (3 x 100 
mL) and the organic layer washed with 10% aqueous NaHCO3 (2 x 100 mL) and water 
(2 x 100 mL), dried over anhydrous MgSO4, filtered and concentrated to dryness. 
 
 7α-Allylandrost-4-ene-3,17-dione (50).  
 Jones reagent (2.6 mL); compound 49 (0.53 g, 1.61 mmol); acetone/dioxane 
(60:10) (70 mL); the residue obtained was insolubilized in diisopropylether giving the 
pure compound 50 (0.386 g, 73%) as a white crystalline compound. Mp(n-hexane/ethyl acetate) 
218-221 ºC [lit.,128 219-221 ºC]. IR (NaCl plates, CHCl3) υmax cm-1: 3076 (=CH), 1734 
(C=O), 1669 (C=C). 1H NMR (600 MHz, CDCl3) δ: 0.92 (3H, s, 18-H3), 1.22 (3H, s, 
19-H3), 5.01 (1H, ddd, CH=CH2), 5.05 (1H, ddd, CH=CH2), 5.67 (1H, m, CH=CH2), 
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5.73 (1H, s, 4-H). 13C NMR (150 MHz, CDCl3) δ: 13.5 (C-18), 17.9 (C-19), 20.5, 21.3, 
30.2, 31.1, 33.9, 35.4, 35.6, 35.9, 36.0, 38.1, 38.7, 46.7, 47.1, 47.5, 117.1 (C-22), 126.4 
(C-4), 136.4 (C-21), 168.5 (C-5), 198.9 (C-3), 220.0 (C-17). ESI: 325.13 ([M-H]+, 
100%). 
 
 7α-Allylandrost-4-en-17-one (53).  
 Jones reagent (1.1 mL); compound 52 (134.7 mg, 0.43 mmol); acetone/dioxane 
(60:10) (23 mL); the solid residue obtained (129.3 mg) was purified by silica gel 
column chromatography (n-hexane/ethyl acetate) affording the pure compound 53 
(105.6 mg, 79%) as a white crystalline solid. Mp(n-hexane/ethyl acetate) 139-142 ºC. IR (NaCl 
plates, CHCl3) υmax cm-1: 3082 (=CH), 1734 (C=O), 1640 (C=C). 1H NMR (600 MHz, 
CDCl3) δ: 0.89 (3H, s, 18-H3), 1.05 (3H, s, 19-H3), 2.44 (1H, ddd, J16β,16α=18.9, 
J16β,15β=8.5, J16β,15α=1.3, 16β-H), 4.99 (2H, m, CH=CH2), 5.28 (1H, dd, J4,3α=2.2, 
J4,3β=2.2, 4-H), 5.72 (1H, m, CH=CH2). 13C NMR (150 MHz, CDCl3) δ: 13.5 (C-18), 
19.2, 19.9 (C-19), 20.7, 21.4, 25.7, 29.5, 31.4, 35.2, 35.7, 35.7, 37.2, 37.9, 38.3, 46.9, 
47.3, 47.7, 115.8 (C-22), 122.2 (C-4), 138.0 (C-21), 140.5 (C-5), 221.1 (C=O). ESI: 
311.39 ([M-H]+, 100%). 
 
 7α-Allylandrosta-1,4-diene-3,17-dione (56).  
 Jones reagent (0.3 mL); compound 54 (25.1 mg, 0.077 mmol); acetone/dioxane 
(60:10) (10 mL); the solid residue obtained (27.5 mg) was purified by silica gel column 
chromatography (n-hexane/ethyl acetate) affording the pure compound 56 (22.1 mg, 
88%) as a white crystalline solid. Mp(n-hexane/ethyl acetate) 205-207 ºC. IR (NaCl plates, 
CHCl3) υmax cm-1: 3076 (=CH), 1737 (C=O), 1661 (C=C), 1617 (C=C). 1H NMR (600 
MHz, CDCl3) δ: 0.95 (3H, s, 18-H3), 1.26 (3H, s, 19-H3), 5.01 (1H, ddd, CH=CH2), 
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5.08 (1H, ddd, CH=CH2), 5.67 (1H, m, CH=CH2), 6.06 (1H, dd, J4,2=1.8, J4,6α=1.7, 4-
H), 6.24 (1H, dd, J2,1=10.1, J2,4=1.8, 2-H), 7.05 (1H, d, J1,2=10.1, 1-H). 13C NMR (150 
MHz, CDCl3) δ: 13.5 (C-18), 19.0 (C-19), 21.4, 21.7, 29.4, 30.9, 35.2, 35.3, 36.7, 37.7, 
43.4, 44.9, 46.3, 47.6, 117.2 (C-22), 126.5 (C-4), 127.6 (C-2), 136.1 (C-21), 154.9 (C-
1), 165.2 (C-5), 185.6 (C-3), 219.4 (C-17). ESI: 323.39 ([M-H]+, 100%). 
 
 7α-Allylandrost-4-en-17β-yl acetate (51).  
 Sodium borohydride (202.0 mg, 5.33 mmol) was added in small portions to a 
stirred and cooled mixture of trifluoracetic acid (1.24 mL), glacial acetic acid (1.24 mL) 
and acetonitrile (1.24 mL) followed by a solution of 48 (400.2 mg, 1.08 mmol) in 
anhydrous dichloromethane (20 mL). The temperature was raised up at room 
temperature and the reaction was stirred under nitrogen, until all the starting material 
had been consumed (1 h 30 min, TLC control). The reaction mixture was then 
neutralized with 10% aqueous NaHCO3, extracted with dichloromethane (4 x 100 mL) 
and the organic layer was washed with water (3 x 100 mL), dried over anhydrous 
MgSO4, filtered and concentrated to dryness giving a white solid residue (380.8 mg). 
This residue was purified by silica gel column chromatography (n-hexane/ethyl acetate) 
affording 293.8 mg of a fraction containing compound 51, which was further purified 
by crystallization from ethanol/water giving the pure 51 (26.9 mg) as clear and bright 
needle-like crystals. Mp(ethanol/water) 129-130 ºC. IR (NaCl plates, CHCl3) υmax cm-1: 3076 
(=CH), 1728 (C=O), 1041 (C-O). 1H NMR (600 MHz, CDCl3) δ: 0.81 (3H, s, 18-H3), 
1.03 (3H, s, 19-H3), 2.04 (3H, s, CH3COO), 4.59 (1H, dd, J17α,16α=8.5, J17α,16β=8.5, 17α-
H), 4.96 (2H, m, CH=CH2), 5.25 (1H, dd, J4,3α=2.3, J4,3β=2.3, 4-H), 5.69 (1H, m, 
CH=CH2). 13C NMR (150 MHz, CDCl3) δ: 11.8 (C-18), 19.2, 19.9 (C-19), 20.9, 21.2, 
22.9, 25.8, 27.4, 29.5, 35.3, 36.2, 36.7, 37.1, 37.9, 38.5, 42.6, 46.1, 47.2, 82.8 (C-17), 
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115.9 (C-24), 121.9 (C-4), 138.4 (C-23), 140.9 (C-5), 171.2 (C=O). ESI: 355.49 ([M-
H]+, 100%). 
 
 7α-Allylandrost-4-en-17β-ol (52).  
 From 51: Compound 51 (223.2 mg, 0.63 mmol) was added to a mixture of 
dioxane/water (85:15) (18 mL) with 2% aqueous NaOH (3.6 mL), at room temperature, 
and the reaction mixture was stirred until total transformation of the starting material 
(48 h, TLC control) being after this time neutralized with a solution of 5% aqueous 
HCl. The dioxane was evaporated under vacuum leading to a white solid residue that 
was then dissolved with ethyl acetate (50 mL), diluted with water (100 mL) and 
extracted with ethyl acetate (3 x 100 mL). The organic layer was washed with water (3 
x 100 mL), dried over anhydrous MgSO4, filtered and concentrated to dryness giving a 
white solid residue (209.3 mg). A portion of this residue was separated by silica gel 
column chromatography (n-hexane/diethyl ether) affording compound 52 in mixture 
with some impurities.  
  
 A pure sample of 52 was obtained from 53 by the following procedure: 
  From 53: To a stirring solution of 53 (15.3 mg, 0.049 mmol) in ethanol (3.0 
mL), under nitrogen, at -10 ºC, sodium borohydride (0.6 mg, 0.016 mmol) was added. 
The mixture was stirred for 1 h and after two subsequent additions of sodium 
borohydride (0.6 mg, 0.016 mmol; 0.7 mg, 0.018 mmol), the reaction was stirred, at 
room temperature, overnight. The reaction mixture was then cooled at -10 ºC and 3 N 
aqueous HCl was added until pH 5 to 7. Ethanol was evaporated under vacuum and the 
oily residue obtained was poured in water (50 mL) and extracted with ethyl acetate (3 x 
50 mL). The organic layer was then washed with water (3 x 100 mL), dried over 
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anhydrous MgSO4, filtered and concentrated to dryness giving a solid residue (18.2 
mg). This residue was washed with chilled n-hexane leading to the pure compound 52 
(4.4 mg, 29%) as a white solid. Mp(ethyl acetate) 140-143 ºC. IR (NaCl plates, CHCl3) υmax 
cm-1: 3297 (OH), 3076 (=CH), 1640 (C=C), 1059 (C-O). 1H NMR (600 MHz, CDCl3) 
δ: 0.77 (3H, s, 18-H3), 1.04 (3H, s, 19-H3), 3.64 (1H, dd, J17α,16α=8.6, J17α,16β=8.6, 17α-
H), 4.96 (2H, m, CH=CH2), 5.25 (1H, dd, J4,3α=2.3, J4,3β=2.3, 4-H), 5.70 (1H, m, 
CH=CH2). 13C NMR (150 MHz, CDCl3) δ: 10.9 (C-18), 19.3, 19.9 (C-19), 21.1, 22.8, 
25.8, 29.5, 30.4, 35.3, 36.2, 36.6, 37.2, 37.9, 38.8, 42.9, 46.3, 47.3, 82.0 (C-17), 115.5 
(C-22), 121.8 (C-4), 138.5 (C-21), 141.1 (C-5). ESI: 313.49 ([M-H]+, 100%). 
 
 7α-Allyl-3-oxoandrosta-1,4-dien-17β-ol (54).  
 To a stirred solution of 49 (538.7 mg, 1.64 mmol) in toluene (55 mL), DDQ 
(645.0 mg, 2.84 mmol) and benzoic acid (215.0 mg, 1.76 mmol) were added. After 18 h 
at reflux, an additional amount of DDQ (250 mg, 1.10 mmol) and benzoic acid (150 
mg, 1.23 mmol) was added and the reaction proceeded for more 16 h. The reaction 
mixture was cooled at room temperature, filtered and the resulting filtrate was 
evaporated giving an oily residue, which was dissolved with dichloromethane and then 
mixed with silica gel. This mixture was filtered through basic alumina and washed with 
petroleum ether 40-60 ºC/ethyl acetate (8:2) (250 mL). Evaporation of the filtrate 
afforded a dark residue that was purified by silica gel column chromatography 
(toluene/diethyl ether) affording compound 54 (268 mg, 50%) as a pure solid. 
Mp(petroleum ether 40-60 ºC/toluene) 175-178 ºC. IR (NaCl plates, CHCl3) υmax cm-1: 3378 (OH), 
3018 (=CH), 1652 (C=C), 1053 (C-O). 1H NMR (600 MHz, CDCl3) δ: 0.83 (3H, s, 18-
H3), 1.24 (3H, s, 19-H3), 3.65 (1H, dd, J17α,16α=8.6, J17α,16β=8.6, 17α-H), 5.00 (1H, ddd, 
CH=CH2), 5.05 (1H, ddd, CH=CH2), 5.64 (1H, m, CH=CH2), 6.06 (1H, dd, J4,2=1.8, 
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J4,6α=1.7, 4-H), 6.23 (1H, dd, J2,1=10.1, J2,4=1.8, 2-H), 7.06 (1H, d, J1,2=10.1, 1-H). 13C 
NMR (150 MHz, CDCl3) δ: 10.9, 19.1, 22.2, 22.9, 29.4, 30.2, 35.4, 36.1, 37.5, 38.2, 
43.1, 43.6, 45.2, 45.9, 81.4 (C-17), 116.9 (C-22), 126.3 (C-4), 127.5 (C-2), 136.7 (C-
21), 155.6 (C-1), 166.1 (C-5), 185.9 (C-3). ESI: 325.39 ([M-H]+, 100%). 
 
 7α-Allyl-3-oxoandrosta-1,4-dien-17β-yl acetate (55).  
 To a solution of 54 (50.0 mg, 0.15 mmol) in anhydrous pyridine (4.0 mL), acetic 
anhydride (0.2 mL, 1.79 mmol) was added and the reaction was stirred for 33 h 15 min 
at room temperature, until all the starting material had been consumed (TLC control). 
Dichloromethane (100 mL) was added and the organic layer was washed with 10% 
aqueous NaHCO3 (2 x 100 mL), 10% aqueous HCl (2 x 100 mL) and water (2 x 100 
mL), dried over anhydrous MgSO4, filtered and concentrated to dryness. The resulting 
residue was crystalized from ethyl acetate/n-hexane giving the pure compound 55 (29.6 
mg, 54%) as white needles. Mp(ethyl acetate/n-hexane) 156-159 ºC. IR (NaCl plates, CHCl3) 
υmax cm-1: 3076 (=CH), 1731 (C=O), 1661 (C=C), 1617 (C=C), 1042 (C-O). 1H NMR 
(600 MHz, CDCl3) δ: 0.87 (3H, s, 18-H3), 1.24 (3H, s, 19-H3), 2.04 (3H, s, CH3COO), 
4.59 (1H, dd, J17α,16α=8.5, J17α,16β=8.5, 17α-H), 5.01 (1H, ddd, CH=CH2), 5.05 (1H, ddd, 
CH=CH2), 5.64 (1H, m, CH=CH2), 6.04 (1H, dd, J4,2=1.6, J4,6α=1.5, 4-H), 6.23 (1H, dd, 
J2,1=10.1, J2,4=1.6, 2-H), 7.05 (1H, d, J1,2=10.1, 1-H). 13C NMR (150 MHz, CDCl3) δ: 
11.9 (C-18), 19.2 (C-19), 21.1, 22.1, 23.1, 27.3, 29.4, 35.4, 36.3, 37.5, 38.0, 42.7, 43.5, 
45.0, 45.7, 82.2 (C-17), 117.1 (C-24), 126.4 (C-4), 127.6 (C-2), 136.5 (C-23), 155.4 (C-
1), 165.9 (C-5), 171.0 (C=O), 185.8 (C-3). ESI: 367.49 ([M-H]+, 100%).  
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 INTRODUCTION 
 
 B.1. Prostate Cancer and Benign Prostate Hyperplasia (BPH): Some Facts 
 Androgens are responsible for many physiological functions in both males and 
females. Their action is mediated by specific intracellular hormone receptors expressed 
in androgen responsive cells,141 being essential for sex-determination and mature sexual 
development in men.142 Among the several organs responsible for androgen production, 
testes produce these hormones in the greatest amount.143 Testosterone (T), the major 
circulating androgen, is secreted by Leydig cells of the testes under the stimulation of 
pituitary-derived luteinizing hormone (LH).141 The effects of these hormones in male 
accessory sex organs are mediated primarily through the reduction of T to 
dihydrotestosterone (DHT).144 DHT is more potent than T in stimulating most of the 
androgen actions in the prostate, binding with greater affinity with androgen receptor.145 
 Despite their physiological role, androgens also play an important part in the 
genesis and progression of prostate cancer and benign prostate hyperplasia (BPH).146-
149 Besides these actions, an excessive accumulation of DHT may likewise cause male 
pattern baldness, acne, alopecia in men and hirsutism in women.150  
 Prostate cancer is typically a slow growth tumor that affects older men, being the 
average age at time of diagnosis of 70 years old. It is the most frequently diagnosed 
cancer and the leading cause of cancer death in the United States and United Kingdom 
(Figure 2.1).2 There has been a significant increase in the clinical detection of prostate 
cancer due to the progressive nature of the disease and to the increase in life expectancy 
of the male population.151 
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 BPH is a leading disorder of the elderly male population where there is an 
enlargement of the prostate gland due to an over-proliferation of the stromal and 
glandular elements of the prostate. The incidence of BPH is about 50% of males at the 
age of 50, 70% at the age of 70 and 90% of males by the age of 80, being the major 
responsible for men morbidity.145,153  
   
 
 B.2. Androgens and 5α-Reductase Enzyme 
 The conversion of T to DHT (Figure 2.2) is made by a microssomal steroid 5α-
reductase enzyme (3-oxo-steroid-4-ene dehydrogenase), which works in a two 
membrane enzyme system together with NADPH, at the level of prostatic stromal and 
basal cells.145,149,152  
  
 
 
 
important cancer in 1984 (29% of all cancers) is now in third
position (12% of male cancers), while prostate cancer now
comprises 29% of the total, having comprised only 11% of the
total in 1984. Stomach cancer, the fifth most common type of
cancer in 1984 no longer figures in the top 10 (it ranks 12th, with
o2% of the total), and melanoma (14th with just under 1% of male
cancer in 1984) is predicted to become the fourth most common
male cancer accounting for 4.6% of cases in 2030.
Comparison with Nordpred predictions
We also used the Nordpred package (with a power-5 link and
5-year step functions for age, period and cohort) to project
rates until 2023–2027. Comparison of 2052 age–sex–site–period-
sp cific projections (for all sit s other th n breast a prostate,
for ages 40þ years for all sites except for testis, and for ages
15–79 years for testis) were made (Table 2). The median of the
observed absolute differences increased from 9% for 2008–2012 to
14% for 2023–2027. The 95th percentile (i.e., the 488th largest of
the 513 comparisons in each 5-year calendar period) of the
distribution of disagreement was about four times greater than
the median (Table 2).
These results can be compared with those obtained by using the
data until 2002 in Nordpred to predict results for 2003–2008 and
comparing these with the observed data. Here the median absolute
disagreement was 7% and the 95th percentile 28%.
DISCUSSION
The observed data were annual incidence rates, for GB, by cancer
site, sex and 5-year age group from 1975 to 2007. The rates were
converted to numbers of cases for the United Kingdom by
multiplying by the ratio of the respective populations. Compared
with the actual incidence (number of recorded cases) in the United
Kingdom in 2007, the difference between observed and modelled
numbers of cases (using GB rates applied to the UK population)
waso1.5% for all sex/site combinations. In Table 1, we present the
projected changes in ASRs and in the numbers of cases of cancer
between 2007 and 2030. These can be used to split the change in
numbers between changes due to changing rates and changes due
to changing population. Thus, for instance, the 11% increase in
male stomach cancer cases is accompanied by a 33% fall in rates,
so that the effect of the population change is to increase numbers
by 66% (¼ [100þ 11]/[100#33]#1).
We have deliberately shown results on a linear rather than a
logarithmic scale because of the greater uncertainties in predicting
cancers in the young. For ovarian cancer, for instance, cancers in
young women are likely to be germ cell with very different risk
factors from epithelial cancer in older women; therefore, there is
no reason to suspect that cohort effects seen in those aged 15–29
years will carry forward to ages 35–49 years. Rates of melanoma,
ovarian cancer, endometrial cancer (corpus uterus) and testicular
cancer (not shown in Figure 2) are all non-negligible in those aged
25–49 years, and our model is seen to fit these observed data well.
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Figure 4 Pie charts of the most common cancers in women and men in 1984, 2007 and predicted in 2030. The areas of the pies are proportional to the
numbers of cases (scaled separately for men and women).
Table 2 Agreement between our (spline) model projections and those
of the Nordpred (step function) model
Period
Median percentage
absolute disagreement
95th percentile
absolute disagreement
2008–2012 9 35
2013–2017 10 40
2018–2022 10 37
2023–2027 14 66
UK cancer projections
M Mistry et al
1801
British Journal of Cancer (2011) 105(11), 1795 – 1803& 2011 Cancer Research UK
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Figure 2.1 - Pie charts of the most common cancers in men in 1984, 2007 and predicted for 2030, in the United 
Kingdom2 
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 In the proposed chemical mechanism for the above mentioned conversion 
(Figure 2.3),145,149,150,152 it is considered the formation of a binary complex between the 
enzyme and NADPH, followed by the formation of a ternary complex with the substrate 
T. A delocalized carbocation is formed due to the activation of the enone system by a 
strong interaction with an electrophilic residue (Enz+) present in the active site. Enolate 
of DHT is formed by the direct hydride ion transfer from NADPH to the α face of the 
delocalized carbocation leading to a selective reduction at C-5. This enolate, which is 
coordinated with the formed NADP+ on the α face, is then attacked by a proton on the 
β-face at C-4 giving the ternary complex Enz-NADP+-DHT. Binary NADP+-enzyme 
complex is formed after departure of DHT and finally the release of NADP+ leaves the 
enzyme free for further catalytic cycles.  
 
 
 
Figure 2.2 - Reduction of testosterone to dihydrotestosterone by 5α-reductase 
OH
O
OH
O HNADPH NADP+ 
5α-Reductase 
Testosterone Dihydrotestosterone 
Figure 2.3 - Mechanism for 5α-reduction of testosterone 
δ+ 
 
δ- 
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 The crystal structure of 5α-reductase is not yet known due to the unstable nature 
of the enzyme not allowing its isolation and purification. Nevertheless, the modern 
molecular biology techniques allowed the identification of two different types of 5α-
reductase enzyme: type I and type II.145,152 They differ in several aspects, such as, size, 
molecular weight, localization, etc. The comparison of the properties of the two 
isoenzymes is summarized in Table 2.1.  
 Recently, a third type of 5α-reductase enzyme (type III) has been identified in 
hormone-refractory prostate cancer cells, and it is known that it also converts T to DHT, 
being active at pH 6.9. It is indeed a ubiquitous enzyme in mammals.145  
  
 
Table 2.1 – Properties of human type I and type II 5α-reductase145,152,154  
 
Properties Type I 5α-reductase Type II 5α-reductase 
Amino acids 259  245  
Molecular weight (Da) 29 462 27 000 
Optimal pH 6-8.5 5-5.5 
Biochemical properties Hydrophobic Hydrophobic 
In vitro inhibition by 
Finasteride 
 
IC50 = 410 nM 
 
IC50  = 9.4 nM 
In vitro inhibition by 
Dutasteride 
 
IC50 = 2.4 nM 
 
IC50 = 0.5 nM 
Location Peripheral skin, hair 
follicles 
Prostate, male external 
genitalia 
Selectivity to the inhibitors Inhibitors with 4-methyl-4-
aza functionalities are very 
potent 
4-Aza, 6-aza and charged 3-
substituents derivatives are 
very selective 
 
 
Chapter II 
Steroidal 5α-Reductase Inhibitors as Anti-tumors and as Drugs for the Treatment of BPH 
 
 147 
B.3. 5α-Reductase Inhibitors  
 Based on the fact that the problems of the prostate are frequently associated to 
high DHT levels, the inhibition of 5α-reductase enzyme becomes a logical approach for 
their treatment. Hence, a large number of molecules have been synthesized as potential 
5α-reductase inhibitors over the past years. In addition, several compounds may act as 
androgen receptor antagonists by preventing the natural ligands of the androgen 
receptor, such as T and DHT, from binding to the receptor. Combination of these two 
therapeutical approaches provides effective androgen receptor blockage.145 
 5α-Reductase inhibitors (RIs) are classified as steroidal and nonsteroidal, based 
on their structure. 
  
 
 B.3.1. Steroidal 5α-Reductase Inhibitors  
 The first inhibitors synthesized were designed upon modifications of the natural 
substrate T. One of the main modifications was the substitution of one carbon atom of 
the A-, B-, C- and D-rings of the steroid framework by a nitrogen heteroatom leading to 
the discovery of potent inhibitors of human 5α-reductase, such as 4-azasteroids, 6-
azasteroids and 10-azasteroids. Therefore, there are several categories among these 
azasteroids, depending on the position of the nitrogen atom.145,152,155,156   
 Other derivatives, with a carboxylic acid group at the C-3 position were studied. 
They were designed to mimic the enzyme-bound enolate intermediate (Figure 2.3) by 
incorporating sp2-hybridized centers at C-3 and C-4. Nitro, sulphonic acid, phosphonic 
acid and phosphinic acid derivatives also proved to be efficient inhibitors of 5α-
reductase.145 
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 Other categories of steroidal inhibitors developed were: 4-substituted, with 
cyano and trifluoromethyl groups, 16-methyl substituted derivatives, 6-methylidene 
derivatives, as well as other oximes and tetrahydrooxazin-2-ones derivatives.145   
 Among the azasteroid derivatives developed, two of them, finasteride and 
dutasteride, are nowadays clinically used.  
 
 Finasteride (Proscar®) was the first 5α-reductase inhibitor to be approved by the 
US Food and Drug Administration (FDA) (Figure 2.4). This inhibitor blocks the 
reduction of T through the inhibition of type II 5α-reductase isoenzyme in a very potent 
fashion, when compared to the inhibition of the type I (9.4 nM versus 410 nM of IC50, 
respectively) (Table 1). At clinical dose, 5 mg/day, it causes a decrease of 65-80% of 
DHT levels in the plasma and studies have demonstrated an improvement in the 
symptoms of BPH.145 The decrease in the DHT production results in an average 
reduction in the prostate volume of 20-25% over one year.157 Finasteride and closed 
analogs are mechanism-based inactivators of type II 5α-reductase.145 It is usually used 
in combination with an α-blocker* since it is expected to have additive benefit in the 
treatment of the symptomatic BPH.157 Although, the Prostate Cancer Prevention Trial 
(PCPT) has demonstrated a reduced prevalence of prostate cancer with 
finasteride,151,158,159 it has not been approved by the FDA to be used for prevention of 
prostate cancer (www.drugs.com/pro/finasteride), since it leads to the development of 
high grade prostate cancers.160  
                                                
* α-Blockers – one of the classes of drugs used in BPH treatment; compounds such as doxazosin, 
alfuzosin and tansulosin are selective α1-andrenergic receptor blockers that have lower side effects; their 
effect occurs through reducing smooth muscle tone in the prostate.157 
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 Lately, in 2002, the FDA approved dutasteride (Avodart®) (Figure 2.5), which is 
currently available as a drug for the treatment of prostate diseases such as BPH and 
prostate cancer, and also for acne, male pattern baldness and hirsutism.161  
 
 
 
 
 
 
 
  
 
 Dutasteride has emerged as the most potent dual inhibitor being highly selective 
towards type I and II 5α-reductase isoenzymes (Table 2.1), not binding to the androgen 
receptor. It reduces DHT levels over 90% following one year of oral administration,162 
and in spite of being a time-dependent inhibitor, it is 60 more potent than finasteride 
with a surprisingly long half-life.141,145 Being a dual inhibitor, dutasteride is more 
beneficial than selective type II inhibitors since it does not allow the escape of DHT 
Figure 2.4 - Finasteride 
Figure 2.5 - Dutasteride 
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formed through the type I isoenzymes. This provides a greater efficacy and consistency 
in the suppression of DHT production. Dutasteride is usually well tolerated with 
exception to what is reported in some literature where it is described that it alters libido 
and erectile dysfunction.161  
 Although the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) 
trial has presented a decrease in the absolute prostate cancer risk, dutasteride has not 
been approved by the FDA to be used for prevention of prostate cancer, since it also 
leads to the development of high grade prostate cancer.151,159,163  
  
 
 B.3.2. Nonsteroidal 5α-Reductase Inhibitors 
 A number of classes of nonsteroidal RIs have emerged over the last years. Due 
to the potential interaction with other enzymes or receptors with hormonal action 
exhibited by steroidal compounds, the research towards the discovery of nonsteroidal 
inhibitors has gained some importance in the last years.145,163  
 Nonsteroidal RIs can be classified according to their structure. Their design is 
based on (aza)steroidal inhibitors, generally by removing one or more rings from the 
(aza)steroidal structure. These derivatives are generally thought to act by mimicking T, 
being competitive inhibitors of 5α-reductase. They include benzo[f]quinolinones, 
pyridones and quinolinones, benzo[c]quinolinones and benzo[c]quinolizinones which 
mimic 4-azasteroid, 6-azasteroid and 10-azasteroid inhibitors, respectively, and also 
indol derivatives.145,156 Among these latest derivatives (the indol group), compound 
FK-143 (Figure 2.6) was disclosed as a potent dual inhibitor145,164-166 being expected to 
be available for clinical use in the treatment of BPH. 
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Figure 2.6 - FK-143 
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 AIM OF THE WORK 
 
 Although finasteride and dutasteride are the only two 5α-reductase inhibitors 
clinically used nowadays, the research in this field has been very active over the last 40 
years and many molecules have been prepared, some of them with very promising 
results. Though the most recent research of these inhibitors has been focused on 
azasteroidal derivatives, in fact the first inhibitors designed were based on modifications 
of the natural substrate of the enzyme, T.  
 Since the diseases of the prostate have a huge incidence in the older men, and 
once the population is aging, it seems really important to continue searching for new 
5α-reductase inhibitors, with higher potency but with less side effects such as decrease 
in bone and muscle mass, and impotency. Therefore, we focused on the design, 
synthesis and on the establishment of new SAR of new RIs. With these molecules, we 
intend to investigate the biological effects of the most potent screened compounds. It is 
our hope to contribute for the development of new potent RIs.  
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2.1. STEROIDAL C-17 CARBOXY DERIVATIVES 
 
2.1.1. Design and synthesis 
 In the A-ring of T, the C-3 carbonyl group works presumably as an H-bond 
acceptor from a residue in the enzyme, which would donate a hydrogen to stabilize the 
intermediate enolate. In addition, it has been described the importance of a sp2-
hybridized center at C-3 and C-4 for the 5α-reductase inhibitory activity.145 Further, it 
was also observed that the enzyme tolerated a wide variety of side chains at the 17β-
position,167 and the presence at C-17β of lipophilic side chains, containing amide or 
ester groups, enhances potency by binding to a lipophilic pocket on the enzyme.145 
Besides this, previous studies have highlighted the importance of the 3-keto-Δ4-
androstan-17β-carboxamide steroids as RIs. 149,168,169  
 Based on this, we were interested in designing and synthesizing steroids keeping 
the 3-keto-Δ4 moiety in the A-ring, as in T, and having a carboxamide, carboxyester or 
carboxylic acid function at the C-17β position (Scheme 2.1).  
  The rationale particularly focuses on the synthesis of derivatives of finasteride 
(Figure 2.4) and dutasteride (Figure 2.5) obtained by combining in the same molecule, 
the A-ring of the substrate T with the C-17β carboxamide group of the referred RIs 
(Scheme 2.1).  
 
 Compound 1 (Scheme 2.1) was used as starting material in the synthesis of these 
derivatives and itself was previously described as a potent inhibitor of 5α-reductase, for 
the microsomal enzyme of human skin.145,152,170,171  
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Scheme 2.1 - Synthesis of 5α-reductase inhibitors from 4-androsten-3-one-17β-
carboxylic acid (1) 
 
 
 
 
 
 
 
 
 
 
 
Reagents and conditions: (i) CF3COOH, CH3COOH, CH3CN, NaBH4, anhydrous 
dichloromethane, rt, 3 h 30 min; (ii) dimethylformamide, triethylamine, tert-butylamine, or n-
propylamine, or n-hexylamine, or 2,5-bis-(trifluoromethyl)aniline, BOP, dichloromethane, rt; 
(iii) 1st: SOCl2, anhydrous tetrahydrofuran, anhydrous pyridine, rt, 40 min; 2nd: 2,5-bis-
(trifluoromethyl)aniline, anhydrous tetrahydrofuran, anhydrous pyridine, 66 ºC, 5 h. 
 
 
 The rationale behind the design of compound 2 was to study the effect of the 
absence of the C-3 carbonyl group in the inhibition of the enzyme, maintaining the 
carboxylic acid function at the C-17β. This compound was prepared by reaction 
conditions of Hanson et al.81 where it was used sodium borohydride in a mixture of 
trifluoroacetic acid, acetonitrile, acetic acid and dichloromethane. 
 Concerning the amides 3, 4, 5 and 6 (Scheme 2.1), they combine in the same 
molecule, the A-ring of the substrate T and different C-17β carboxamide groups, 
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namely the C-17β carboxamide group of finasteride (compound 3) and the C-17β 
carboxamide group of dutasteride (compound 6). The other amides, with different N-
alkyl chain lengths (4 and 5), were synthesized in order to evaluate the effect of the 
chain length in the enzyme inhibition. Amide derivatives 3 to 5 were prepared by 
reacting 1 with tert-butylamine, n-propylamine or n-hexylamine, in dimethylformamide 
(DMF) and dichloromethane, using triethylamine as catalyst and the coupling agent 
(benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP). 
The attempt to prepare amide 6 by this procedure, led to carboxyester 7. Amide 6 was 
then prepared by reaction of 1 with thionyl chloride followed by reaction of the 
resulting acyl chloride with 2,5-bis-(trifluoromethyl)aniline.  
 
 
2.1.2. Chemistry 
 The synthesis of compound 2 (Scheme 2.1), which is the C-3 deoxygenated 
derivative of 1, was performed by submitting 1 to a reduction with sodium borohydride 
in a mixture of trifluoroacetic acid, glacial acetic acid, and acetonitrile giving 2, in 71% 
yield.81  
 The amides 3, 4 and 5 (Scheme 2.1) were obtained in 69%, 54% and 35% yield, 
respectively, by reacting carboxylic acid 1 with tert-butylamine, n-propylamine or n-
hexylamine, in DMF and dichloromethane, using triethylamine as catalyst and the 
coupling agent BOP, which promotes the activation of the carboxylic acid 1 for further 
nucleophilic acyl substitution, through the mechanism presented in Scheme 2.2.172,173  
 Although amide 3 has already been prepared in 89%174 and in 95%175 using 
thionyl chloride followed by tert-butylamine, in this work we present a one-step 
reaction using milder conditions. 
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Scheme 2.2 - Mechanism for amide synthesis using BOP as activating agent 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 An attempt to prepare amide 6 from 1 (Scheme 2.1) using the above mentioned 
conditions and the amine 2,5-bis-(trifluoromethyl)aniline, afforded compound 7 in 73% 
yield. In this case, the activated intermediate ester 7 was unable to react with the amine 
2,5-bis-(trifluoromethyl)aniline to give 6, probably due to the weak nucleophilicity of 
the deactivated aromatic amine 2,5-bis-(trifluoromethyl)aniline. In order to overcome 
this limitation, amide 6 was obtained by a two-step reaction strategy.141 In the first step, 
the carboxylic acid 1 was activated to the respective acyl chloride by treatment with 
thionyl chloride, in anhydrous tetrahydrofuran and in the presence of anhydrous 
pyridine. This step allowed to transform the initial carboxylic acid into the acyl halide. 
In the second step, the acyl chloride was subjected to reaction with 2,5-bis-
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(trifluoromethyl)aniline in anhydrous tetrahydrofuran and in the presence of anhydrous 
pyridine providing compound 6, in 35% yield. 
 
 
2.1.3. Biochemistry and biology 
 The 5α-reductase inhibitory activity of each steroidal compound was evaluated 
in human prostatic microsomes by a DLLME-GC-MS method previously developed by 
our group, that identifies and quantifies T and DHT, using the internal standards T-d3 
and DHT-13C3.176 The ratio between T/T-d3 and DHT/DHT-13C3 allowed the 
quantification of T and DHT produced after 5α-reductase reaction estimating the anti-
5α-reductase activity of each compound.177  
 The percentage of 5α-reductase inhibition (%) of the synthesized RIs was made 
using the RI finasteride as reference compound (Table 2.2).178 For compounds 3, 4 and 
5, with percentage of 5α-reductase inhibition higher than 60%, the IC50 was also 
determined (Table 2.2).177   
 The effects of the most potent RIs 3, 4, 5 and finasteride were investigated in the 
viability of LNCaP cells, which is a human androgen-responsive prostate cancer cell 
line. It was observed that the tested compounds induced a significant decrease in cell 
viability, being compound 3 the most potent, even more than finasteride.177 
 
 
2.1.4. Structure-activity relationships discussion and conclusions 
 In this study, it was investigated the inhibitory activity of 5α-reductase of a set 
of synthesized steroids. It is known that one of the key structural requirements for 5α-
reductase inhibition is the presence of a 4-en-3-one system in the A-ring and a lipophilic 
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17β-side chain in the D-ring of steroids.145 Furthermore, it has been found that the 
presence at C-17β position of lipophilic amides or esters enhances potency by binding 
to a lipophilic pocket on the enzyme.145 We have investigated these features by 
studying different C-17β chemical modifications (amide, ester or carboxylic acid 
functions) in the potential steroidal RIs. 
 
 
Table 2.2 – Percentage of 5α-reductase inhibition and IC50 values of tested compounds 
in human prostatic microsomes177 
 
 
 
 
 
 
 
 
 
 
 Based on the results obtained (Table 2.2), it is possible to infer that C-17β 
carboxylic acid analogs (1 and 2) (Scheme 2.1) of T are weak RIs, particularly the 3-
deoxo analog 2. In fact, several descriptions referred the importance of a sp2-hybridized 
center at C-3 and C-4 positions of steroids for the 5α-reductase inhibitory activity.145 
Therefore, the lack of that center at C-3 as in 2, results in a decrease in the activity. 
Concerning analog 1, it was already reported as a competitive RI, with 87.7 % 
Compounds 5α-Reductase Inhibition (%) ± SEM IC50 (µM) 
1 29.55 ± 3.09 - 
2 11.04 ± 3.42 - 
3 73.08 ± 3.05 0.37 
4 69.33 ± 1.03 0.46 
5 63.56 ± 1.08 0.61 
6 22.44 ± 2.03 - 
7 49.20 ± 2.51 - 
Finasteride 84.62 ± 1.21 0.096167 
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inhibition for the microsomal 5α-reductase enzyme of human skin.145,179 However, in 
our experimental conditions, using the prostate microsomal enzyme, analog 1 showed 
only 29.55 % of inhibition. 
 Among the amides synthesized and evaluated, the N-tert-butylcarboxamide 3 
(Scheme 2.1) showed the best inhibitory activity. In this case, we combined in the same 
molecule, the A-ring of the substrate T and the C-17β carboxamide group of finasteride 
(Figure 2.4), which resulted in a potent inhibitor. 
 Regarding the N-propylcarboxamide 4 and the N-hexylcarboxamide 5 (Scheme 
2.1) it is possible to infer that these steroids are also strong inhibitors (IC50 of 0.46 and 
0.61 µM, respectively) (Table 2.2). Further, the N-propylcarboxamide 4 is slightly more 
active than the N-hexylcarboxamide 5, however both of them are less active than N-tert-
butylcarboxamide 3, suggesting that a hindered N-alkyl group, as in 3, or a shorter N-
alkyl linear chain, as in 4, in the C-17β carboxamide function favors the 5α-reductase 
inhibitory activity. 
 Concerning compound 6, in spite of having in the C-17β position the same 
group as the potent dutasteride, the N-[2,5-bis(trifluoromethyl)phenyl]carboxamide, 
surprisingly it only exhibits minimal inhibitory activity (22.44 %). This result reveals 
that along with the C-17β carboxamide group, the steroidal A-ring type also determines 
the potency of inhibitors. Regarding the ester derivative 7, our results demonstrate that 
it is a moderate inhibitor (49.20 % inhibition). 
 In this study, it was also evaluated the effect of the most potent RIs, steroids 3, 
4, 5 and finasteride in LNCaP cells viability. This cell line is a human androgen-
responsive prostate cancer cell line, that is a good model to study hormonal therapies for 
this disease.180,181 This cell line responds positively to growth stimulation induced by 
androgens in vitro and in vivo.182,183  
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 The results obtained with T-treated LNCaP cells with RIs 3, 4, 5 and finasteride 
indicate that compounds induced a significant decrease in cell viability, being steroid 3 
the most potent, even more than finasteride. 
 Further, our results suggested that these steroids induced the reduction in cell 
viability in a 5α-reductase-dependent manner, by inhibiting 5α-reductase and the 
conversion of T into DHT. 
   
 In summary, taking into account the studied compounds, it is possible to 
conclude that the C-17β lipophilic carboxamide chemical groups along with the 3-keto-
Δ4 moiety in the A-ring of the steroidal framework, seem to be favourable key features 
for achieving 5α-reductase inhibitory activity, being the steroid with the C-17 N-tert-
butlycarboxamide group (3), the best RI. Furthermore, steroids 3, 4 and 5 as well as 
finasteride induced a decrease in viability of stimulated LNCaP cells in a 5α-reductase 
dependent-manner, being the synthesized steroids 3, 4, and 5 even more effective than 
finasteride. This study will help in the future design of new steroidal RIs contributing to 
the discovery of new drugs with fewer side effects.  
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2.2. EXPERIMENTAL SECTION 
 
 Melting points (mps) and IR spectra were collected as mentioned before (section 
1.6.), except for compound 3 whose IR was recorded using the ATR (attenuated total 
reflectance) device. 1H, 13C NMR, ESI-MS and LC-MS mass spectra were recorded as 
mentioned in section 1.7. 
 Reactions were monitored by thin layer chromatography (TLC) in silica gel 60 
F254 aluminium sheets, as described in section 1.7.  
 4-Androsten-3-one-17β-carboxylic acid (1) was purchased from Fountain 
Limited (Malta). Reagents and solvents were used as obtained from suppliers without 
further purification, with exception to dichloromethane,138 and pyridine,139 which were 
dried through reflux and distillation from CaH2, being stored away from light in a 
brown bottle with type 4Å molecular sieves, under an atmosphere of dry N2. 
 Yields have not been optimized. 
 All compounds possess a purity superior to 98%. The purity was checked by 
HPLC with a C18-reversed phase column and water/acetonitrile 30:70 as solvent. The 
purity of individual compounds was determined from the peak areas in the 
chromatogram of the sample solution. 
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Scheme 2.1 - Synthesis of 5α-reductase inhibitors from 4-androsten-3-one-17β-
carboxylic acid (1) 
 
 4-Androstene-17β-carboxylic acid (2).  
 Sodium borohydride (590.3 mg, 15.6 mmol) was added in small portions to a 
cooled and stirred mixture of trifluoroacetic acid (3.6 mL), glacial acetic acid (3.6 mL) 
and acetonitrile (3.6 mL). After this, a solution of compound 1 (1.0 g, 3.16 mmol) in dry 
dichloromethane (53 mL) was added and the reaction proceeded at room temperature, 
under a stream of dry nitrogen, until all the starting material had been consumed (3 h 20 
min by TLC). The reaction mixture was then neutralized with 10% aqueous NaHCO3, 
extracted with chloroform (4 x 100 mL) and the organic layer washed with water (4 x 
100 mL), dried over anhydrous Na2SO4, filtered and concentrated to dryness. 
Crystallization from ethyl acetate/hexane afforded the pure compound 2 (680.5 mg, 
71%) as white crystals. Mp(ethyl acetate/hexane) 205-208 ºC. IR (NaCl plates, CHCl3) υmax 
cm-1: 3399 (O-H carboxylic acid), 3020 (H-C=), 1701 (C=O carboxylic acid), 1676 
(C=C), 1216 (C-O carboxylic acid). 1H NMR (CDCl3, 600 MHz) δ: 0.75 (3H, s, 18-H3), 
1.02 (3H, s, 19-H3), 2.38 (1H, dd, J17α,16α=9.4, J17α,16β=9.4, 17α-H), 5.30 (1H, bs, 4-H), 
10.46 (1H, bs, COOH). 13C NMR (150 MHz, CDCl3) δ: 13.3 (C-18), 19.2 (C-19), 19.4, 
21.2, 23.4, 24.5, 25.7, 32.5, 33.2, 36.1, 37.1, 37.8, 38.2, 44.3, 54.4, 55.1, 55.9, 119.3 (C-
4), 144.7 (C-5), 179.9 (C20=O). ESI: 303.4 ([M+H]+, 100%). 
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 General method for obtaining N-tert-butyl-3-oxoandrost-4-ene-17β-
carboxamide (3), N-propyl-3-oxoandrost-4-ene-17β-carboxamide (4), N-hexyl-3-
oxoandrost-4-ene-17β-carboxamide (5) and 1H-benzo[d][1,2,3]triazol-1-yl 3-
oxoandrost-4-ene-17β-carboxylate (7). 
 Compound 1 was dissolved in dimethylformamide and triethylamine. The 
solution was cooled in an ice-water bath and the amine was added followed by a 
solution of BOP in dichloromethane. The reaction mixture was stirred at 0 ºC for 30 
min and then at room temperature for 1 h 20 min to 3 h. Dichloromethane was then 
removed under reduced pressure and the resulting solution diluted with water (25 mL) 
and extracted with ethyl acetate (2 x 25 mL). The organic layer was washed 
successively with 1 N aqueous HCl  (3 x 25 mL), water (25 mL), 1 M aqueous NaHCO3  
(3 x 25 mL) and water (2 x 25 mL), dried over anhydrous MgSO4, filtered and 
concentrated to dryness. The residue obtained was purified by silica gel column 
chromatography (petroleum ether 40-60 ºC/ethyl acetate) giving the pure compounds. 
 
 N-tert-Butyl-3-oxoandrost-4-ene-17β-carboxamide (3).  
 Compound 1 (200.0 mg, 0.632 mmol); dimethylformamide (1.3 mL); 
triethylamine (0.1 mL, 0.72 mmol); tert-butylamine (0.1 mL, 0.95 mmol); BOP (279.1 
mg, 0.63 mmol); dichloromethane (1.6 mL); reaction time: 3 h; yield (162.0 mg, 69%) 
as white solid. Mp(petroleum ether 40-60 ºC/ethyl acetate) 219-221 ºC [Lit.174 218-219 ºC from 
acetone]. IR (ATR) υmax cm-1: 3366 (N-H), 1661 (C=O amide and C=O ketone), 1615 
(C=C). 1H NMR (CDCl3, 600 MHz) δ: 0.72 (3H, s, 18-H3), 1.18 (3H, s, 19-H3), 1.35 
(9H, s, 3x -CH3), 5.08 (1H, s, -NH), 5.73 (1H, s, 4-H). 13C NMR (150 MHz, CDCl3) δ: 
13.1 (C-18), 17.4 (C-19), 21.0, 23.2, 24.4, 29.0 (3x CH3), 31.9, 32.8, 34.0, 35.6, 35.7, 
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38.5, 38.6, 43.5, 51.1, 53.8, 55.6, 57.5, 123.9 (C-4), 171.1 (C-5), 171.6 (C20=O), 199.5 
(C3=O). ESI: 372.6 ([M+H]+, 100%). 
 
 N-Propyl-3-oxoandrost-4-ene-17β-carboxamide (4).  
 Compound 1 (200.0 mg, 0.632 mmol); dimethylformamide (1.3 mL); 
triethylamine (0.1 mL, 0.72 mmol); n-propylamine (0.1 mL, 0.95 mmol); BOP (279.1 
mg, 0.63 mmol); dichloromethane (1.6 mL); reaction time: 1 h 20 min; yield (122.6 mg, 
54%). Mp(petroleum ether 40-60 ºC/ethyl acetate) 147-149 ºC. IR (NaCl plates, CHCl3) υmax cm-1: 
3368 (N-H), 1656 (C=O amide and C=O ketone), 1617 (C=C) cm-1. 1H NMR (CDCl3, 
600 MHz) δ: 0.72 (3H, s, 18-H3), 0.92 (3H, t, J=7.4Hz, -CH3), 1.18 (3H, s, 19-H3), 
2.40 (1H, dd, J17α,16α=14.6, J17α,16β=4.9, 17α-H), 3.12-3.33 (2H, m, -CH2-), 5.38 (1H, bs, 
-NH), 5.72 (1H, s, 4-H). 13C NMR (150 MHz, CDCl3) δ: 11.4 (C-18), 13.2 (-CH3), 17.3 
(C-19), 20.9, 23.1, 23.6, 24.4, 31.9, 32.8, 33.9, 35.6, 35.7, 38.6, 41.2, 43.6, 53.8, 55.5, 
57.0, 123.8 (C-4), 171.1 (C-5), 172.4 (C20=O), 199.5 (C3=O). ESI: 358.8 ([M+H]+, 
100%). 
 
 N-Hexyl-3-oxoandrost-4-ene-17β-carboxamide (5).  
 Compound 1 (177.8 mg, 0.562 mmol); dimethylformamide (1.3 mL); 
triethylamine (0.09 mL, 0.64 mmol); n-hexylamine (0.11 mL, 0.84 mmol); BOP (167.2 
mg, 0.38 mmol); dichloromethane (1.6 mL); reaction time 3 h; yield (78.4 mg, 35%). 
Mp(petroleum ether 40-60 ºC/ethyl acetate) 56-61 ºC. IR (NaCl plates, CHCl3) υmax cm-1:  3389 (N-
H), 1656 (C=O amide and C=O ketone), 1621 (C=C). 1H NMR (CDCl3, 600 MHz) δ: 
0.72 (3H, s, 18-H3), 0.87 (3H, t, J=7.0 Hz, -CH3), 1.18 (3H, s, 19-H3), 2.40 (1H, dd, 
J17α,16α=14.5, J17α,16β=5.0, 17α-H), 3.15-3.35 (2H, m, -CH2-), 5.34 (1H, bs, -NH), 5.72 
(1H, s, 4-H). 13C NMR (150 MHz, CDCl3) δ: 13.2 (C-18), 13.9 (-CH3), 17.4 (C-19), 
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20.9, 22.5, 23.6, 24.4, 26.6, 29.8, 31.4, 31.9, 32.8, 33.9, 35.6, 35.7, 38.3, 38.6, 39.5, 
43.6, 53.8, 55.5, 57.0, 123.9 (C-4), 171.1 (C-5), 172.3 (C20=O), 199.4 (C3=O). ESI: 
400.6 ([M+H]+, 100%). 
 
 1H-Benzo[d][1,2,3]triazol-1-yl 3-oxoandrost-4-ene-17β-carboxylate (7).  
 Compound 1 (200.1 mg, 0.632 mmol); dimethylformamide (1.3 mL); 
triethylamine (0.1 mL, 0.72 mmol); 2,5-bis(trifluoromethyl)aniline (0.15 mL, 0.95 
mmol); BOP (279.8 mg, 0.63 mmol); dichloromethane (3 mL); reaction time: 5 h, 
without completion. Crystallization from ethyl acetate gave the pure compound 7 (200.5 
mg, 73%) as white shiny needles. Mp(ethyl acetate) 210-213 ºC. IR (NaCl plates, CDCl3) 
υmax cm-1: 3311 (H-C= aromatic), 3021 (H-C=), 1809 (C=O ester), 1669 (C=C), 1616 
and 1447 (C=C arom), 1070 (C-O ester). 1H NMR (CDCl3, 600 MHz) δ: 0.98 (3H, s, 
18-H3), 1.22 (3H, s, 19-H3), 2.86 (1H, dd, J17α,16α=9.4 Hz, J17α,16β=9.4 Hz, 17α-H), 5.75 
(1H, s, 4-H), 7.41 (1H, m, J=7.4, J=0.9, J=0.9, 3’-H or 6’-H), 7.42 (1H, m, J=7.9, 
J=7.1, J=0.8, 4’-H or 5’-H), 7.54 (1H, m, J=7.9, J=7.1, J=0.8, 4’-H or 5’-H), 8.06 (1H, 
m, J=7.4, J=0.9, J=0.9, 3’-H or 6’-H). 13C NMR (150 MHz, CDCl3) δ: 13.8 (C-18), 
17.4 (C-19), 20.9, 24.0, 24.5, 31.8, 32.7, 33.9, 35.70, 35.74, 37.9, 38.6, 45.2, 52.7, 53.5, 
55.5, 108.2 (C-4), 120.5, 124.0, 124.7, 128.5, 128.6, 143.5, 170.1 (C-5), 170.4 (C20=O), 
199.3 (C3=O). ESI: 434.5 ([M+H]+, 100%). 
 
 17β-N-[2,5-bis(Trifluoromethyl)phenyl]3-oxoandrost-4-ene-17β- carboxamide (6).  
 A solution compound 1 (400.0 mg, 1.26 mmol) in anhydrous tetrahydrofuran 
(15 mL) and anhydrous pyridine (0.1 mL), under a stream of dry nitrogen, was set at 2 
ºC. To this solution, thionyl chloride (0.12 mL, 1,64 mmol) was added and the reaction 
mixture was stirred at 2 ºC for 20 min and then at room temperature for 40 min. The 
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reaction mixture was then filtered and the obtained residue washed with anhydrous 
toluene. The filtered was concentrated under vacuum giving a yellow oil which was 
diluted with anhydrous tetrahydrofuran (20 mL) and anhydrous pyridine (0.1 mL). To 
the resulting solution it was added 2,5-bis-(trifluoromethyl)aniline (0.22 mL, 1.39 
mmol) and the reaction mixture was refluxed for 5 h. After that, it was diluted with 
chloroform (300 mL), and the resulting organic layer was then washed with 1 N 
aqueous HCl  (4 x 100 mL), brine (4 x 100 mL) and water (100 mL), dried over 
anhydrous Na2SO4, filtered and concentrated. The residue obtained was purified by 
silica gel column chromatography (hexane/ethyl acetate) giving the pure compound 6 
(230.9 mg, 35%) as a white solid. Mp(hexane/ ethyl acetate) 204-207 ºC. IR (NaCl plates, 
CHCl3) υmax cm-1: 3315 (H-C= aromatic), 3017 (H-C=), 1706 (C=O ketone), 1664 (C=O 
amide), 1645 (C=C), 1616 and 1473 (C=C aromatic), 1137 (C-F), 1591 (N-H). 1H NMR 
(CDCl3, 600 MHz) δ: 0.82 (3H, s, 18-H3), 1.19 (3H, s, 19-H3), 5.74 (1H, s, 4-H), 7.44 
(1H, d, J4’,3’=8.2, 4’-H), 7.50 (1H, s, 6’-H), 7.72 (1H, d, J3’,4’=8.2, 3’-H), 8.78 (1H, s, -
NH). 13C NMR (150 MHz, CDCl3) δ: 13.2 (C-18), 17.4 (C-19), 20.9, 23.6, 24.3, 31.9, 
32.7, 33.9, 35.6, 35.7, 37.9, 38.6, 44.5, 53.6, 55.7, 58.4, 120.2 (C-4’), 120.4 (C-6’), 
124.0 (C-4), 126.7 (C-3’), 170.7 (C-5), 171.4 (C20=O), 199.4 (C3=O). ESI: 528.5 
([M+H]+, 100%). 
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 INTRODUCTION 
  
 Phytochemicals are powerful food factors, found in fruits, vegetables, and other 
whole foods, that promote profound effects on the human health. It has been found that 
some of these compounds interact with enzymes and nuclear receptors, which leads to 
the modulation of selective physiological mechanisms.184  
 For instance, genistein (Figure 3.1) in soybeans is known to be an agonist of 
ER,184 thus competing with estrogen for binding to the receptor. Chen et al. have also 
shown that isoflavones and flavones (Figure 3.1) are agonists of estrogen-related 
receptors (ERRs)185 and have also isolated and identified procyanidin B dimers (Figure 
3.1) that act as competitive inhibitors of aromatase, supressing the growth of aromatase-
mediated tumors in mice.186  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 - Structures of some phytochemicals 
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 Among phytochemicals, coumarin also called 1,2-benzopyrone (Figure 3.2) and 
its derivatives (coumarins) are widely distributed in nature and many of them exhibit 
useful and diverse biological activities.187-189  
 
 
 
 
 
 
 Coumarin derivatives have been found to have several potential therapeutic 
activities190 including photochemotherapy, anti-tumor and antiviral therapy,191,192 
stimulation of central nervous system, antibacterial,193-195 anti-inflamatory and anti-
coagulant activities.196,197 
 The pattern of substitutions on the coumarin basic chemical structure is believed 
to influence both the pharmacological and biochemical properties of coumarins, 
determining therapeutic applications and toxicity profiles.190,198 For example, coumarin 
and its active metabolite, 7-hydroxycoumarin (umbelliferone) (Figure 3.3), have 
demonstrated growth-inhibitory activity in human breast cancer cell lines such as MCF-
7 and prostate cancer cell lines such as LNCaP.199,200 
 
 
 
 
 
 
O OHO
Figure 3.3 - Structure of 7-hydroxycoumarin 
Figure 3.2 - Structure of coumarin 
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 Among the diverse biological activities of coumarins, the most intriguing one is 
the notable effect of some derivatives against breast cancer.201 By this reason, some 
coumarin derivatives have been evaluated in the last years for breast cancer 
therapy.202,203 Chen et al.184 found 4-benzyl-3-(4’-chlorophenyl)-7-methoxycoumarin 
(Figure 3.4) to be a potent competitive AI (IC50=0.08 µM), suppressing aromatase 
activity and the proliferation of ER-positive MCF-7 breast cancer cells.204  
 The molecular superimposition of the chemical structure of this coumarin 
derivative with the chemical structure of the substrate of aromatase, androstenedione 
(Figure 3.4), allowed establishing the following similarities:184 
- the coumarin rings mimic the A- and B-rings of androstenedione; 
- the 3-(4’-chlorophenyl) group of the coumarin mimics the D-ring and aligns 
near the steroidal C-17 keto oxygen;  
- the 4-benzyl group of the coumarin aligns very closely to the C-19 methyl 
group of the steroidal substrate; 
- the coumarin 7-methoxyl group also aligns very closely with the C-3 keto 
oxygen of the steroidal substrate. 
 
 
 
 
 
 
 
 
 
Figure 3.4 - Alignment of androstenedione with 4-benzyl-3-(4’-chlorophenyl)-7-methoxycoumarin 
(adopted from Chen et al. 184) 
Androstenedione 4-Benzyl-3-(4’-chlorophenyl)-7-
methoxycoumarin 
aromatase. We cannot yet adequately explain these results. On
the opposite end of the molecule, the 3-(4!-chlorophenyl) group
aligns near the C-17 keto oxygen. Both of these groups are
electron-withdrawing groups, suggesting that a compound with
an electron-pulling group in this vicinity will be favored. This
may explain why 4-benzyl-7-methoxy-3-phenylcoumarin
(which is missing an electron-withdrawing group at this posi-
tion) shows weaker activity. These FlexS alignment results,
together with our structure-activity results, strongly suggest
that these three functional groups are crucial for the inhibition
of aromatase by coumarin derivatives.
Interaction of Coumarins with Other Enzymes and Nuclear
Receptors—To assess the potential usage of 4-benzyl-3-(4!-chlo-
rophenyl)-7-methoxycoumarin (the most potent coumarin iden-
tified in this study) as an aromatase inhibitor, we need to rule
out that this compound is cytotoxic. MCF-7aro cells were cul-
tured for 3 days in the presence of up to 40 !M 4-benzyl-3-(4!-
chlorophenyl)-7-methoxycoumarin, letrozole, or anastrozole
but in the absence of the androgen substrate. The coumarin did
not produce any noticeable cytotoxicity (i.e. suppression of cell
proliferation), and this observation was consistent with letro-
zole and anastrozole, which have been Food and Drug Admin-
istration-approved and are currently in use for the treatment of
advanced breast cancer. As expected, aromatase inhibitors sup-
pressed breast tumor growth by inhibiting estrogen biosynthe-
sis and should not act as cytotoxic agents that kill cells in a
non-selective manner.
Furthermore, the selectivity of this coumarin inhibitor was
investigated. We checked the ability of this compound to inhibit
other enzymes and hormone receptors, including steroid 5"-
reductase (which also utilizes androgen as a substrate), andro-
gen receptor, ER", ER#, ERR", ERR#, and ERR$. Both type 1
and 2 steroid 5"-reductase isozymes were inhibited only 11%
with 20 !M of 4-benzyl-3-(4!-chlorophenyl)-7-methoxycouma-
rin.2 Furthermore, through receptor transfection assays, this
coumarin was found not to be an agonist of ER and ERR
isoforms (Fig. 5). It was also found not to interfere with the
interaction of 17#-estradiol (E2) with ERs (data not shown),
indicating that this compound is not an antagonist of ERs.
Although estrogen-related receptors (ERR", ERR#, and ERR$)
share a high amino acid sequence homology with ERs, estro-
gens are not ligands of ERRs. These receptors have been dem-
onstrated to bind as a monomer, with a high affinity binding
site containing the sequence, 5!-TCAAGGTCA-3!, that is also
recognized by another orphan receptor, steroidogenic factor 1.
2 J. Ye and S. Chen, unpublished results.
FIG. 5. Interaction of 4-benzyl-3-(4!-chlorophenyl)-7-methoxy-
coumarin with ER and ERR isoforms. Top panel, co-transfection
experiments with ER binding site containing luciferase reporter
(pGL3(ERE)3_Luc, 0.25 !g) and the expression plasmid for ER" (pSG5-
hER", 100 ng) or the expression plasmid for ER# (pSG5-hER#, 100 ng)
were performed in HeLa cells. After incubation for 24 h in the presence
of 100 nM E2 or 20 !M coumarin, cells were harvested, and the luciferase
activity in the cell lysates was measured. The relative luciferase activ-
ities were calculated by taking that of the vehicle (DMSO) control as “1”
and expressed as the mean " S.D. of three independent transfection
experiments. Bottom panel, co-transfection experiments with the ste-
roidogenic factor 1-binding site containing luciferase reporter ((steroi-
dogenic factor 1)3_SV40_Luc, 0.25 !g) and the expression plasmids for
ERRs (pSG5-ERR", pSG5-ERR#, or pSG5-ERR$, 0.5 !g) were per-
formed in HeLa cells. After 24 h in the presence of 20 !M coumarin, cells
were harvested, and the luciferase activity in the cell lysate was meas-
ured. The relative luciferase activities were calculated by taking that of
the samples without ERR transfection as “1” and expressed as the
mean " S.D. of three independent transfection experiments.
FIG. 4. Alignment of androstenedi-
one with 4-benzyl-3-(4!-chlorophe-
nyl)-7-methoxycoumarin. A, FlexS
alignment of androstenedione with 4-ben-
zyl-3-(4!-chlorophenyl)-7-methoxycouma-
rin. B, chemical structures of the two
compounds.
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 The described alignment strongly suggests that the three functional groups – 3-
(4’-chlorophenyl), 4-benzyl and 7-methoxyl – share the same enzymatic interactions 
with the mentioned groups within androstenedione being superimposable with them. By 
these reasons, the referred functional groups are believed to be responsible for the 
inhibition of aromatase by the mentioned coumarin derivatives. Also, a favourable 
interaction at the 7-position of the coumarin ring is due to the formation of a hydrogen 
bond by the 7-oxygen atom.204  
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 AIM OF THE WORK‡ 
 
  The main goal of this work was to synthesize a set of coumarin compounds in 
order to be further biologically evaluated against aromatase. For this aim, we used the 
4-benzyl-3-(4’-chlorophenyl)-7-methoxycoumarin (Figure 3.4) as a hit compound since 
it has formerly proved to be a potent competitive aromatase inhibitor. Subsequently we 
modified the chemical groups that are believed to be important for the inhibitory 
activity against the enzyme aromatase. With this rationale we intended to explore the 
interactions that aromatase establishes with these groups, in order to understand the 
SAR of this kind of compounds, which will allow the future design and synthesis of 
valuable AIs. It is important to mention that this is a very recent ongoing work and that 
the biological assays are just starting. In this way, here we present our first approaches 
to the design and synthesis of coumarin compounds as potential aromatase inhibitors. 
 
  
  
                                                
‡ This work was developed in the Department of Organic Chemistry of the Faculty of Pharmacy of the 
University of Santiago de Compostela, Spain. 
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3.1 3-THIOPHENE COUMARIN DERIVATIVES 
 
3.1.1. Design and synthesis 
 Although there have been elucidated some features in the coumarin framework 
that enhance the inhibitory activity towards aromatase, as mentioned above, in our work 
we have also been interested in exploring the following modifications: 
i. To substitute the 3-(4’-chlorophenyl) group of the hit coumarin 4-
benzyl-3-(4’-chlorophenyl)-7-methoxycoumarin (Figure 3.4) by a smaller aromatic ring 
with an electronegative hetero atom, as in thiophene ring in order to explore: a) the 
different positioning of the sulphur atom in the thiophene ring, and b) the effect of an 
additional electronegative atom in that ring, such as a bromine atom. 
ii. To remove the 4-benzyl group in order to study how it would affect the 
interaction with the enzyme aromatase. 
iii. To evaluate the influence of different functional groups such as (methyl, 
methoxyl, acetyl and hydroxyl) between C-5 and C-8 positions.  
 
 There are several methods for preparing coumarin derivatives. These include, 
just to mention a few, the classic Pechmann, Claisen, Perkin and Wittig reactions.204-206 
 In the present work, it was followed the Perkin method, which is indeed the 
most versatile process and the one that can use a higher number of starting materials at 
lower cost. The Perkin reaction involves the condensation of a carboxylic acid 
anhydride with an aldehyde in the presence of a weak base to give unsaturated 
carboxylic acids (Scheme 3.1).207,208 The first example of this reaction was described 
by Perkin in 1868 and curiously it involved the synthesis of a coumarin compound by 
heating the sodium salt of salicylaldehyde with acetic anhydride.207,209 The Perkin 
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approach is a very important method for the synthesis of substituted coumarins and the 
reaction presumably proceeds through cinnamic acids as intermediates.207  
 
Scheme 3.1 - General Perkin reaction 
 
 
  
  
 
3.1.2. Chemistry 
 Coumarin derivatives 1-11 were efficiently synthesized according to the 
protocol outlined in Scheme 3.2. This protocol consists in a direct synthetic route 
involving the classical Perkin procedure followed by an intramolecular esterification 
reaction forming the cyclic ester, in this case, the desired coumarin.210-212  
 
Scheme 3.2 - Synthesis of coumarin derivatives using Perkin conditions 
 
 
 
 
 
 
 
 
Reagents and Conditions: (i) DCC, DMSO, 110 ºC. 
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 The reactions were accomplished by condensation of the appropriate substituted 
salicylaldehydes with the adequate substituted α-aryl acetic acids, using N,N’-
dicyclohexylcarbodiimide (DCC), as dehydrating agent. This is a very versatile reaction 
affording different families of substituted coumarins. The mechanism for the formation 
of the desired coumarins is depicted bellow (Scheme 3.3). 
 
 
Scheme 3.3 – Proposed mechanism for the Perkin reaction using DCC 
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 The referred mechanism involves DCC to promote the condensation between 
two molecules of the α-aryl acetic acid (A) in order to form the anhydride (B). This 
anhydride will then react with salicylaldehyde (C) leading afterwards to the cyclic 
intermediate (D), which will then open and react with another molecule of the 
anhydride (B). The reaction proceeds with the formation of derivative (G) through 
species (E) and (F), which will then cyclize affording the desired coumarin (H). 
 
 The acetoxylated coumarin derivatives (12-16, 22-26, 32-36) were synthesized 
by the Perkin-Oglialoro reaction using the convenient α-arylacetic acids and 
salicylaldehyde, in acetic anhydride and potassium acetate (Scheme 3.4).213,214 The 
corresponding hydroxylated derivatives (17-21, 27-31, 37-41) were obtained by 
hydrolysis of the previously obtained esters in the presence of aqueous HCl solution and 
methanol (Scheme 3.4).213,214 
 
 The Perkin-Oglialoro reaction is indeed the most important modification of the 
Perkin reaction, where it occurs the condensation of aromatic aldehydes with α-
arylacetic acids in acetic anhydride and in the presence of a weak base to obtain α-
arylcinnamic acids, being this adaptation an improvement in the classical synthesis of 
coumarins.206,208 
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Scheme 3.4 - Synthesis of coumarin derivatives using Perkin-Oglialoro conditions 
 
 
 
 
 
 
 
 
 
 
 
Reagents and Conditions: (i) CH3COOK, Ac2O, reflux; (ii) HCl 2 N, CH3OH, reflux. 
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3.2. EXPERIMENTAL SECTION 
 
 The 1H and 13C NMR spectra were recorded at 300 and 75.5 MHz, respectively, 
on a Bruker AXM spectrometer. Chemical shifts were recorded in δ values in parts per 
million (ppm) downfield from tetramethylsilane as an internal standard. All J-values are 
given in Hz.  
 Mass spectra were obtained using a Hewlett-Packard 5988A spectrometer.  
 Reactions were monitored by thin layer chromatography (TLC) in silica gel 60 
F254 aluminium sheets. The chromatographic separation of products was made using 
silica gel 60 (230-00 mesh) flash column chromatography. The TLC plates were 
revealed using ultra-violet lamp (254 nm).  
 Yields have not been optimized. 
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Scheme 3.2 - Synthesis of coumarin derivatives using Perkin conditions 
 
 General procedure for the preparation of 3-thiophenylcoumarins (1-11).  
 A solution of 2-hydroxybenzaldehyde/2-hydroxy-5-methylbenzaldehyde/2-
hydroxy-5-methoxybenzaldehyde and the corresponding thiophene acetic acid, 3-
thiophene acetic acid/2-thiophene acetic acid/4-bromo-2-thiophene acetic acid, in 
dimethyl sulfoxide was prepared. DCC was added and the mixture was heated at 110 ºC 
for the adequate period of time, until total transformation of the starting material.  Ice 
and acetic acid were added to the reaction mixture. After keeping it at room temperature 
for 2 hours, the mixture was extracted with diethyl ether (3 x 50 mL). The organic layer 
was extracted with 5% aqueous NaHCO3 (3 x 50 mL) and then water (3 x 50 mL), dried 
over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified 
by flash column chromatography (hexane/ethyl acetate).  
 
 3-(3-Thiophenyl)coumarin (1).  
 2-Hydroxybenzaldehyde (506.6 mg; 4.09 mmol); 3-thiophene acetic acid (728.9 
mg; 5.13 mmol); DCC (1.31 g; 6.35 mmol); DMSO (4 mL). Yield 44 %. 1H NMR (250 
MHz, CDCl3) δ: 7.26-7.39 (m, 3H, H-5’, H-8’), 7.47-7.55 (m, 3H, H-2’, H-4’, H-7’), 
7.92 (s, 1H, H-4), 8.18 (m, 1H, H-5). 13C NMR (75.5 MHz, CDCl3) δ: 116.4, 119.4, 
122.7, 122.9, 124.5, 125.7, 126.0, 126.2, 127.7, 131.1, 134.4, 137.2, 152.6. MS: 228.9 
([M+H]+, 28 %). 
 
 6-Methoxy-3-(3-thiophenyl)coumarin (2).  
 2-Hydroxy-5-methoxybenzaldehyde (500.8 mg; 3.29 mmol); 3-thiophene acetic 
acid (728.9 mg; 4.11 mmol); DCC (1.06 g; 5.14 mmol); DMSO (5 mL). Yield 41 %. 1H 
Chapter III 
Development of Coumarins as Aromatase Inhibitors 
 
 183 
NMR (250 MHz, CDCl3) δ:  3.86 (s, 3H, -OCH3), 6.97 (d, 1H, J5,7=2.9, H-5), 7.09 (dd, 
1H, J7,8=9.0, J7,5=2.9, H-7), 7.29 (d, 1H, J8,7=9.0, H-8), 7.39 (dd, 1H, J4’,5’=5.1, 
J4’,2’=3.0, H-4’), 7.52 (dd, 1H, J5’,4’=5.1, J5’,2’=1.3, H-5’), 7.89 (s, 1H, H-4), 8.20 (dd, 
1H, J2’,5’=3.0, J2’,4’=1.3, H-2’). 13C NMR (75.5 MHz, CDCl3) δ: 55.7, 109.5, 110.5, 
117.3, 118.9, 119.7, 121.5, 125.6, 126.0, 126.1, 134.3, 135.4, 136.9, 156.1. MS: 258.8 
([M+H]+, 33 %). 
 
 6-Bromo-3-(3-thiophenyl)coumarin (3).  
 2-Hydroxy-5-bromobenzaldehyde (500.2 mg; 2.49 mmol); 3-thiophene acetic 
acid (442.7 mg; 3.11 mmol); DCC (801.9 mg; 3.89 mmol); DMSO (4 mL). Yield 58 %. 
1H NMR (250 MHz, CDCl3) δ:  7.24 (d, 1H, J8,7=9.7, H-8), 7.41 (m, 1H, H-4’), 7.50 (d, 
1H, J5’,4’=5.1, H-5’), 7.59 (m, 1H, H-7), 7.68 (bs, 1H, H-2’), 7.84 (s, 1H, H-4), 8.21 (m, 
1H, H-5). 13C NMR (75.5 MHz, CDCl3) δ: 116.3, 118.3, 121.5, 122.6, 126.4, 126.7, 
126.9, 130.4, 133.9, 134.3, 137.0, 151.5, 158.9. MS: 307.8 ([M+H]+, 100 %). 
 
 3-(2-Thiophenyl)coumarin (4).  
 2-Hydroxybenzaldehyde (504.3 mg; 4.13 mmol); 2-thiophene acetic acid (728.3 
mg; 5.12 mmol); DCC (1.33 mg; 6.44 mmol); DMSO (4 mL). Yield 44 %.  1H NMR 
(250 MHz, CDCl3) δ:  7.13 (m, 1H, H-4’), 7.33 (m, 2H, H6, H8), 7.42 (dt, 1H, H-5’), 
7.52 (m, 2H, H-5, H-7), 7.80 (dt, 1H, H-3’), 7.99 (s, 1H, H-4). 13C NMR (75.5 MHz, 
CDCl3) δ: 110.2, 116.3, 119.3, 124.6, 126.9, 127.4, 127.6, 129.3, 131.1, 132.6, 135.4, 
152.6, 163.8. MS: 229.0 ([M+H]+, 26%). 
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 6-Methyl-3-(2-Thiophenyl)coumarin (5).  
 2-Hydroxy-5-methylbenzaldehyde (500.9 mg; 3.67 mmol); 2-thiophene acetic 
acid (651.9 mg; 4.59 mmol); DCC (1.18 g; 5.73 mmol); DMSO (4 mL). Yield 53 %. 1H 
NMR (250 MHz, CDCl3) δ:  2.42 (s, 3H, -CH3), 7.12 (dd, 1H, J4’,5’=5.1, J4’,3’=3.8, H-
4’), 7.29 (m, 3H, H-5, H-7, H-8), 7.42 (dd, 1H, J5’,4’=5.1, J5’,3’=0.9, H-5’), 7.78 (dd, 1H, 
J3’,4’=3.8, J3’,5’=0.9, H-3’), 7.95 (s, 1H, H-4). 13C NMR (75.5 MHz, CDCl3) δ: 20.7, 
116.0, 119.1, 121.7, 124.6, 126.8, 127.4, 132.2, 134.1, 135.5, 150.7, 159.6. MS: 243.0 
([M+H]+, 31 %). 
 
 6-Methoxy-3-(2-thiophenyl)coumarin (6). 
  2-Hydroxy-5-methoxybenzaldehyde (500.6 mg; 3.29 mmol); 2-thiophene acetic 
acid (585.3 mg; 4.12 mmol); DCC (1.06 g; 5.14 mmol); DMSO (5 mL). Yield 47 %. 1H 
NMR (250 MHz, CDCl3) δ:  3.86 (s, 3H, -OCH3), 6.97 (d, 1H, J5,7=2.9, H-5), 7.09 (dd, 
1H, J7,8=9.1, J7,5=2.9, H-7), 7.13 (dd, 1H, J4’,5’=5.2, J4’,3’=3.9, H-4’), 7.28 (d, 1H, 
J8,7=9.0, H-8), 7.43 (dd, 1H, J5’,4’=5.2, J5’,3’=0.7, H-5’), 7.80 (dd, 1H, J3’,4’=3.9, 
J3’,5’=0.9, H-3’), 7.96 (s, 1H, H-4). 13C NMR (75.5 MHz, CDCl3) δ: 55.7, 100.0, 106.5, 
109.1, 111.7, 117.3, 118.3, 119.0, 126.9, 127.4, 127.7, 135.2, 142.8, 156.1. MS: 258.8 
([M+H]+, 27 %). 
 
 6-Bromo-3-(2-thiophenyl)coumarin (7).  
 2-Hydroxy-5-bromobenzaldehyde (502.7 mg; 2.50 mmol); 2-thiophene acetic 
acid (443.8 mg; 3.12 mmol); DCC (801.3 mg; 3.89 mmol); DMSO (4 mL). Yield 51 %. 
1H NMR (250 MHz, CDCl3) δ: 7.20 (m, 1H, H-4’), 7.42 (d, 1H, J8,7=8.8, H-8), 7.71 (m, 
2H, H-7, H-5’), 7.84 (d, 1H, J3’,4’=3.5, H-3’), 8.00 (d, 1H, J5,7=2.2, H-5), 8.49 (s, 1H, H-
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4). 13C NMR (75.5 MHz, CDCl3) δ: 95.5, 116.5, 118.3, 119.2, 121.4, 127.2, 127.6, 
129.5, 130.4, 133.8, 134.8, 147.9, 151.3. MS: 307.8 ([M+H]+, 100 %). 
 
 3-(4-Bromo-2-thiophenyl)coumarin (8). 
  2-Hydroxybenzaldehyde (250.4 mg; 2.05 mmol); 4-bromo-2-thiophene acetic 
acid (568.4 mg; 2.57 mmol); DCC (658.5 mg; 3.19 mmol); DMSO (5 mL). Yield 38 %.  
1H NMR (250 MHz, CDCl3) δ: 7.33 (d, 1H, J5’,3’=1.4, H-5’), 7.38 (dd, 2H, J=8.0, J=1.6, 
H-5, H-8), 7.54 (t, 1H, J=7.6, H-6), 7.55 (t, 1H, J=7.4, H-7), 7.68 (d, 1H, J3’,5’=1.4, H-
3’), 8.01 (s, 1H, H-4). 13C NMR (75.5 MHz, DMSO) δ: 110.7, 115.9, 116.4, 119.2, 
124.5, 126.6, 127.1, 130.8, 138.5, 139.7, 156.9, 157.8, 168.9. MS: 307.8 ([M+H]+, 100 
%). 
 
 6-Methyl-3-(4-bromo-2-thiophenyl)coumarin (9).  
 2-Hydroxy-5-methylbenzaldehyde (252.4 mg; 1.85 mmol); 4-bromo-2-
thiophene acetic acid (508.2 mg; 2.29 mmol); DCC (595.9 mg; 2.89 mmol); DMSO (5 
mL). Yield 34 %. 1H NMR (250 MHz, CDCl3) δ: 2.42 (s, 3H, -CH3), 7.26 (m, 3H, H-5, 
H-7, H-8), 7.31 (m, 1H, H-5’), 7.66 (d, 1H, J=1.4, H-3’), 7.95 (s, 1H, H-4). 13C NMR 
(75.5 MHz, CDCl3) δ: 20.6, 100.0, 108.4, 116.2, 121.8, 124.9, 127.6, 128.9, 132.8, 
134.5, 134.6, 135.9, 153.7, 155.4. MS: 321.7 ([M+H]+, 100 %). 
 
 6-Methoxy-3-(4-bromo-2-thiophenyl)coumarin (10).  
 2-Hydroxy-5-methoxybenzaldehyde (250.5 mg; 1.65 mmol); 4-bromo-2-
thiophene acetic acid (457.1 mg; 2.07 mmol); DCC (532.5 mg; 2.58 mmol); DMSO (5 
mL). Yield 36 %. 1H NMR (250 MHz, CDCl3) δ: 3.89 (s, 3H, -OCH3), 6.98 (d, 1H, 
J5,7=2.9, H-5), 7.12 (dd, 1H, J7,8=9.1 , J7,5=2.9, H-7), 7.27 (d, 1H, J8,7=6.0, H-8), 7.32 
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(d, 1H, J5’,3’=1.5, H-5’), 7.68 (d, 1H, J3’,5’=1.4, H-3’), 7.97 (s, 1H, H-4). MS: 338.0 
([M+H]+, 100 %). 
 
 6-Bromo-3-(4-bromo-2-thiophenyl)coumarin (11).  
 2-Hydroxy-5-bromobenzaldehyde (251.8 mg; 1.25 mmol); 4-bromo-2-thiophene 
acetic acid (344.4 mg; 1.56 mmol); DCC (401.1 mg; 1.94 mmol); DMSO (5 mL). Yield 
59 %. 1H NMR (250 MHz, DMSO) δ: 7.45 (d, 1H, J8,7=8.9, H-8), 7.79 (dd, 1H, 
J7,8=8.7, J7,5=2.3, H-7), 7.84 (bs, 2H, H-3’, H-5’), 7.96 (d, 1H, J5,8=2.4, H-5), 8.63 (s, 
1H, H-4). 13C NMR (75.5 MHz, DMSO) δ: 99.8, 100.8, 102.9, 115.1, 125.9, 134.4, 
141.8, 147.5, 160.5, 164.2, 171.5, 173.4, 175.4. MS: 387.1 ([M+H]+, 23 %). 
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Scheme 3.4 - Synthesis of coumarin derivatives using Perkin-Oglialoro conditions 
 
 General procedure for the preparation of 3-thiophenylcoumarins (12-16, 22-
26 and 32-36).  
 The solution containing CH3COOK, the appropriate thiophene acetic acid, and 
hydroxylated benzaldehyde in Ac2O was refluxed (138 °C) with stirring during different 
periods of time. The reaction mixture was then cooled, neutralized with 10% aqueous 
NaHCO3, and extracted with ethyl acetate.  The organic layers were washed with water, 
dried over anhydrous Na2SO4, filtered, and concentrated to dryness. The products were 
purified by recrystallization in ethyl acetate or ethyl acetate/ethanol. 
 
 6-Acetoxy-3-(3-thiophenyl)coumarin (12).  
 2,5-Dihydroxybenzaldehyde (501.1 mg; 3.63 mmol); 3-thiophene acetic acid 
(515.1 mg; 3.62 mmol); CH3COOK (640.4 mg; 6.52 mmol); Ac2O (4 mL). Yield 54 %. 
1H NMR (250 MHz, CDCl3) δ: 2.34 (s, 3H, -OAc), 7.23 (dd, 1H, J7,8=8.9, J7,5=2.7, H-
7), 7.35 (d, 1H, J8,7=8.9, H-8), 7.30 (d, 1H, J5,7=2.7, H-5), 7.40 (dd, 1H, J5’,4’=5.1, 
J5’,2’=3.2, H-5’), 7.49 (dd, 1H, J4’,5’=5.1, J4’,2’=1.2, H-4’), 7.88 (s, 1H, H-4), 8.20 (m, 
1H, H-2’). 13C NMR (75.5 MHz, CDCl3) δ: 20.9, 117.3, 119.7, 119.8, 124.5, 125.8, 
126.0, 126.1, 126.4, 126.5, 133.9, 136.3, 146.6, 169.2. MS: 287.0 ([M+H]+, 10 %). 
 
 7-Acetoxy-3-(3-thiophenyl)coumarin (13).  
 2,4-Dihydroxybenzaldehyde (502.9 mg; 3.64 mmol); 3-thiophene acetic acid 
(515.8 mg; 3.63 mmol); CH3COOK (639.4 mg; 6.52 mmol); Ac2O (4 mL). Yield 38 %. 
1H NMR (250 MHz, CDCl3) δ: 2.30 (s, 3H, -OAc), 7.04-7.09 (m, 2H, H-6, H-8), 7.35-
7.49 (m, 3H, H-4’, H-5’, H-5), 7.87 (s, 1H, H-2’), 8.14 (s, 1H, H-4). 13C NMR (75.5 
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MHz, CDCl3) δ: 21.0, 99.9, 109.6, 109.7, 118.4, 125.6, 125.9, 126.1, 128.3, 130.7, 
133.9, 136.5, 139.8, 152.3, 168.4. MS: 286.9 ([M+H]+, 5 %). 
 
 8-Acetoxy-3-(3-thiophenyl)coumarin (14).  
 2,3-Dihydroxybenzaldehyde (500.4 mg; 3.62 mmol); 3-thiophene acetic acid 
(515.3 mg; 3.62 mmol); CH3COOK (639.0 mg; 6.51 mmol); Ac2O (4 mL). Yield 45 %. 
1H NMR (250 MHz, CDCl3) δ: 2.42 (s, 3H, -OAc), 7.23-7.26 (m, 2H, H-6, H-7), 7.35-
7.39 (m, 2H, H-5’, H-5), 7.48 (dd, 1H, J4’,2’=1.3, J4’,5’=5.1, H-4’), 7.89 (s, 1H, H-4), 
8.15 (dd, 1H, J=1.3, J=2.9, H-2’). 13C NMR (75.5 MHz, CDCl3) δ: 20.6, 120.4, 120.7, 
124.1, 124.2, 124.4, 125.1, 125.7, 126.1, 126.3, 133.9, 136.6, 137.3, 158.7, 168.6. MS: 
287.0 ([M+H]+, 5 %). 
 
 7,8-Diacetoxy-3-(3-thiophenyl)coumarin (15).  
 2,3,4-Trihydroxybenzaldehyde (500.5 mg; 3.25 mmol); 3-thiophene acetic acid 
(461.1 mg; 3.24 mmol); CH3COOK (573.5 mg; 5.84 mmol); Ac2O (4 mL). Yield 49 %. 
1H NMR (250 MHz, CDCl3) δ: 2.35 (s, 3H, 7-OAc), 2.44 (s, 3H, 8-OAc), 7.13 (d, 1H, 
J=8.6, H-6), 7.39-7.51 (m, 3H, H-4’, H-5’, H-5), 7.90 (s, 1H, H-2’), 8.17 (m, 1H, H-4). 
13C NMR (75.5 MHz, CDCl3) δ: 20.2, 20.6, 118.3, 119.0, 122.3, 124.7, 125.8, 126.0, 
126.3, 129.8, 133.8, 136.3, 144.6, 145.6, 158.6, 167.3, 167.8. MS: 344.9 ([M+H]+, 14 
%). 
 
 5,7-Diacetoxy-3-(3-thiophenyl)coumarin (16).  
 2,4,6-Trihydroxybenzaldehyde (501.7 mg; 3.26 mmol); 3-thiophene acetic acid 
(461.7 mg; 3.25 mmol); CH3COOK (573.0 mg; 5.84 mmol); Ac2O (4 mL). Yield 35 %. 
1H NMR (250 MHz, CDCl3) δ: 2.33 (s, 3H, -OAc), 2.43 (s, 3H, -OAc), 6.99 (d, 1H, 
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J8,6=2.1, H-8), 7.04 (d, 1H, J6,8=2.1, H-6), 7.39 (dd, 1H, J5’,4’=5.1, J5’,2’=3.0, H-5’), 7.48 
(dd, 1H, J4’,5’=5.1, J4’,2’=1.2, H-4’), 7.87 (s, 1H, H-4), 8.13 (dd, 1H, J2’,4’=2.9, J2’,5’=1.2, 
H-2’). 13C NMR (75.5 MHz, CDCl3) δ: 20.9, 21.0, 107.3, 110.9, 112.2, 122.1, 125.8, 
126.2, 126.4, 130.4, 134.0, 146.9, 152.0, 153.4, 168.2, 168.3. MS: 345.0 ([M+H]+, 6 
%). 
 
 6-Acetoxy-3-(2-thiophenyl)coumarin (22). 
 2,5-Dihydroxybenzaldehyde (500.5 mg; 3.62 mmol); 2-thiophene acetic acid 
(515.5 mg; 3.63 mmol); CH3COOK (640.1 mg; 6.53 mmol); Ac2O (4 mL). Yield 53 %. 
1H NMR (250 MHz, CDCl3) δ: 2.34 (s, 3H, -OAc), 7.13 (dd, 1H, J4’,3’=5.1, J4’,5’=3.8, H-
4’), 7.23 (dd, 1H, J7,8=8.9, J7,5=2.5, H-7), 7.31 (d, 1H, J5,7=2.5, H-5), 7.36 (d, 1H, 
J8,7=8.9, H-8), 7.45 (dd, 1H, J5’,4’=5.1, J5’,3’=1.0, H-5’), 7.81 (dd, 1H, J3’,4’=3.8, 
J3’,5’=1.0, H-3’), 7.94 (s, 1H, H-4). 13C NMR (75.5 MHz, CDCl3) δ: 20.8, 117.3, 117.4, 
119.7, 122.2, 124.5, 127.4, 127.5, 128.1, 134.5, 135.5, 146.8, 150.0, 169.1, 169.3. MS: 
287.0 ([M+H]+, 3 %). 
 
 7-Acetoxy-3-(2-thiophenyl)coumarin (23).  
 2,4-Dihydroxybenzaldehyde (501.9 mg; 3.63 mmol); 2-thiophene acetic acid 
(515.7 mg; 3.63 mmol); CH3COOK (639.9 mg; 6.52 mmol); Ac2O (4 mL). Yield 52 %. 
1H NMR (250 MHz, CDCl3) δ: 2.35 (s, 3H, -OAc), 7.11 (m, 3H, H-8, H-6, H-4’), 7.42 
(dd, 1H, J5’,4’=5.1, J5’,3’=1.0, H-5’), 7.54 (d, 1H, J5,6=8.5, H-5), 7.79 (dd, 1H, J3’,4’=3.7, 
J3’,5’=1.0, H-3’), 7.98 (s, 1H, H-4). 13C NMR (75.5 MHz, CDCl3) δ: 21.2, 100.0, 109.9, 
117.1, 118.6, 123.6, 127.1, 127.5, 127.7, 128.3, 132.9, 134.8, 147.8, 152.7, 169.1. MS: 
287.0 ([M+H]+, 4 %). 
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 8-Acetoxy-3-(2-thiophenyl)coumarin (24).  
 2,3-Dihydroxybenzaldehyde (500.8 mg; 3.62 mmol); 2-thiophene acetic acid 
(515.3 mg; 3.62 mmol); CH3COOK (640.8 mg; 6.52 mmol); Ac2O (4 mL). Yield 42 %. 
1H NMR (250 MHz, CDCl3) δ: 2.44 (s, 3H, -OAc), 7.13 (dd, 1H, J4’,5’=5.1, J4’,3’=3.8, H-
4’), 7.28 (m, 2H, H-6, H-7), 7.42 (m, 2H, H-5, H-5’), 7.79 (dd, 1H, J3’,4’=3.8, J3’,5’=1.1, 
H-3’), 7.99 (s, 1H, H-4). 13C NMR (75.5 MHz, CDCl3) δ: 20.6, 120.6, 122.2, 124.4, 
124.5, 125.0, 127.4, 127.6, 127.9, 134.9, 135.6, 137.4, 143.1, 158.2, 168.5. MS: 287.0 
([M+H]+, 7 %). 
 
 7,8-Diacetoxy-3-(2-thiophenyl)coumarin (25).  
 2,3,4-Trihydroxybenzaldehyde (500.3 mg; 3.24 mmol); 2-thiophene acetic acid 
(462.3 mg; 3.24 mmol); CH3COOK (575.6 mg; 5.84 mmol); Ac2O (4 mL). Yield 41 %. 
1H NMR (250 MHz, CDCl3) δ: 2.34 (s, 3H, -OAc), 2.43 (s, 3H, -OAc), 7.13 (m, 2H, H-
6, H-4’), 7.42 (m, 2H, H-5, H-5’), 7.78 (d, 1H, J3’,4’=3.8, H-3’), 7.96 (s, 1H, H-4). 13C 
NMR (75.5 MHz, CDCl3) δ: 20.2, 20.6, 99.9, 117.9, 119.2, 121.7, 123.5, 124.6, 127.4, 
127.6, 127.9, 129.9, 134.6, 144.5, 167.1, 167.7, 168.2. MS: 345.0 ([M+H]+, 3 %).  
 
 5,7-Diacetoxy-3-(2-thiophenyl)coumarin (26).  
 2,4,6-Trihydroxybenzaldehyde (500.4 mg; 3.24 mmol); 2-thiophene acetic acid 
(461.2 mg; 3.24 mmol); CH3COOK (575.8 mg; 5.84 mmol); Ac2O (4 mL). Yield 54 %. 
1H NMR (250 MHz, CDCl3) δ: 2.33 (s, 3H, -OAc), 2.45 (s, 3H, -OAc), 7.01 (d, 1H, 
J8,6=2.1, H-8), 7.07 (d, 1H, J6,8=2.0, H-6), 7.13 (dd, 1H, J4’,5’=5.0, J4’,3’=3.9, H-4’), 7.44 
(bd, 1H, J5’,4’=5.1, H-5’), 7.77 (bd, 1H, J3’,4’=3.7, H-3’), 7.94 (s, 1H, H-4). 13C NMR 
(75.5 MHz, CDCl3) δ: 20.9, 21.0, 97.6, 107.4, 109.9, 112.3, 127.4, 127.5, 128.1, 128.6, 
130.9, 136.7, 146.8, 151.8, 153.1, 168.1, 168.2. MS: 345.0 ([M+H]+, 13 %). 
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 6-Acetoxy-3-(4-bromo-2-thiophenyl)coumarin (32).  
 2,5-Dihydroxybenzaldehyde (300.0 mg; 2.17 mmol); 4-bromo-2-thiophene 
acetic acid (479.9 mg; 2.17 mmol); CH3COOK (387.3 mg; 3.95 mmol); Ac2O (4 mL). 
Yield 52 %. 1H NMR (250 MHz, CDCl3) δ: 2.35 (s, 3H, -OAc), 7.32 (m, 4H, H-5’, H-5, 
H-7, H-8), 7.69 (s, 1H, H-3’), 7.94 (s, 1H, H-4). MS: 365.9 ([M+H]+, 27 %). 
 
 7-Acetoxy-3-(4-bromo-2-thiophenyl)coumarin (33).  
 2,4-Dihydroxybenzaldehyde (312.5 mg; 2.26 mmol); 4-bromo-2-thiophene 
acetic acid (499.5 mg; 2.26 mmol); CH3COOK (402.8 mg; 4.10 mmol); Ac2O (4 mL). 
Yield 55 %. 1H NMR (250 MHz, CDCl3) δ: 2.35 (s, 3H, -OAc), 7.10 (m, 1H, H-5), 7.16 
(bs, 1H, H-8), 7.32 (bd, 1H, J5’,3’=1.2, H-5’), 7.55 (dd, 1H, J7,5=8.4, J7,8=0.7, H-7), 7.67 
(bd, J3’,5’=1.2, H-3’), 7.97 (s, 1H, H-4). 13C NMR (75.5 MHz, CDCl3) δ: 21.1, 109.5, 
110.1, 117.2, 119.5, 126.2, 126.6, 128.2, 129.6, 136.9, 153.1, 158.9, 168.9, 175.5, 
183.7. MS: 365.8 ([M+H]+, 20 %). 
 
 8-Acetoxy-3-(4-bromo-2-thiophenyl)coumarin (34).  
 2,3-Dihydroxybenzaldehyde (299.9 mg; 2.17 mmol); 4-bromo-2-thiophene 
acetic acid (481.4 mg; 2.18 mmol); CH3COOK (384.4 mg; 3.92 mmol); Ac2O (4 mL). 
Yield 64 %. 1H NMR (250 MHz, CDCl3) δ: 2.44 (s, 3H, -OAc), 7.30 (m, 3H, H-5’, H-6, 
H-7), 7.43 (m, 1H, H-5), 7.67 (d, 1H, J3’,5’=1.3, H-3’), 7.98 (s, 1H, H-4). 13C NMR 
(75.5 MHz, CDCl3) δ: 25.5, 114.5, 124.6, 125.4, 130.1, 130.6, 131.2, 131.9, 133.6, 
141.6, 141.9, 142.2, 149.0, 163.0, 173.5. MS: 365.8 ([M+H]+, 25 %). 
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 7,8-Diacetoxy-3-(4-bromo-2-thiophenyl)coumarin (35).  
 2,3,4-Trihydroxybenzaldehyde (348.8 mg; 2.26 mmol); 4-bromo-2-thiophene 
acetic acid (500.6 mg; 2.26 mmol); CH3COOK (401.2 mg; 4.09 mmol); Ac2O (4 mL). 
Yield 58 %. 1H NMR (250 MHz, CDCl3) δ: 2.34 (s, 3H, -OAc), 2.42 (s, 3H, -OAc), 
7.18 (bd, 1H, J6,5=8.6, H-6), 7.33 (bs, 1H, H-5’), 7.42 (bd, 1H, J5,6=8.6, H-5), 7.66 (bs, 
1H, H-3’), 7.96 (s, 1H, H-4). 13C NMR (75.5 MHz, CDCl3) δ: 20.1, 20.5, 101.5, 109.6, 
118.2, 119.1, 120.1, 126.1, 126.9, 128.6, 136.7, 137.0, 144.9, 157.9, 158.0, 167.6, 
168.2. MS: 423.8 ([M+H]+, 7 %). 
 
 5,7-Diacetoxy-3-(4-bromo-2-thiophenyl)coumarin (36).  
 2,4,6-Trihydroxybenzaldehyde (349.6 mg; 2.27 mmol); 4-bromo-2-thiophene 
acetic acid (502.2 mg; 2.27 mmol); CH3COOK (404.0 mg; 4.09 mmol); Ac2O (4 mL). 
Yield 31 %. 1H NMR (250 MHz, CDCl3) δ: 2.34 (s, 3H, -OAc), 2.47 (s, 3H, -OAc), 
7.03 (d, 1H, J8,6=2.1, H-6), 7.35 (d, 1H, J5’,3’=1.2, H-5’), 7.63 (d, 1H, J3’,5’=1.3, H-3’), 
7.94 (s, 1H, H-4). 13C NMR (75.5 MHz, CDCl3) δ: 20.9, 21.0, 98.7, 107.4, 110.4, 112.5, 
125.6, 129.0, 129.2, 136.4, 139.4, 147.1, 151.6, 152.5, 153.3, 168.0, 168.1. MS: 424.0 
([M+H]+, 25 %). 
 
 
 General procedure for the preparation of hydroxylated thiophenylcoumarins 
(17-21, 27-31 and 37-41).  
 Hydroxylated 3-thiophenylcoumarins were obtained by hydrolysis of their 
acetoxylated counterparts. Hence, the appropriate acetoxylated coumarin was mixed 
with 2 N aqueous HCl and MeOH and refluxed (100 °C) with stirring during different 
periods of time. The resulting reaction mixture was cooled in an ice-bath and the 
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reaction products, obtained as solids, were filtered, washed with cold distilled water, 
and dried under vacuum.  
 
 6-Hydroxy-3-(3-thiophenyl)coumarin (17).  
 Compound 12 (251.4 mg; 0.88 mmol); 2 N HCl (20.6 mL); MeOH (8.8 mL). 
Yield 92 %. 1H NMR (250 MHz, DMSO-d6) δ: 7.01 (d, 1H, J5,7=2.8, H-5), 7.06 (dd, 
1H, J7,8=9.0, J7,5=2.8, H-7), 7.27 (d, 1H, J8,7=8.8, H-8), 7.65 (dd, 1H, J5’,4’=5.0, 
J5’,2’=2.9, H-5’), 7.71 (dd, 1H, J4’,5’=5.2, J4’,2’=1.3, H-4’), 8.23 (dd, 1H, J2’,5’=2.9, 
J2’,4’=1.2, H-2’), 8.42 (s, 1H, H-4), 9.78 (s, 1H, -OH). 13C NMR (75.5 MHz, DMSO-d6) 
δ: 112.4, 116.9, 119.8, 120.0, 121.5, 125.7, 126.4, 127.1, 134.9, 137.4, 138.5, 145.9, 
154.0. MS: 245.0 ([M+H]+, 29 %). 
 
 7-Hydroxy-3-(3-thiophenyl)coumarin (18).  
 Compound 13 (227.4 mg; 0.79 mmol); 2 N (20.6 mL); MeOH (8.8 mL). Yield 
91 %. 1H NMR (250 MHz, DMSO-d6) δ: 6.76 (bs, 1H, J=1.6, H-2’), 6.83 (dd, 1H, 
J6,5=8.4,  J6,8=2.1, H-6), 7.58 (d, 1H, J5,6=8.5, H-5), 7.63 (m, 2H, H-4’, H-5’), 8.14 (bs, 
1H, J=2.6, H-8), 8.39 (s, 1H, H-4), 10.62 (s, 1H, -OH). 13C NMR (75.5 MHz, DMSO-
d6) δ: 101.8, 111.9, 113.6, 113.7, 117.0, 124.3, 126.2, 126.8, 129.9, 139.2, 154.5, 161.3. 
MS: 344.9 ([M+H]+, 14 %). 
 
 8-Hydroxy-3-(3-thiophenyl)coumarin (19). 
  Compound 14 (250.7 mg; 0.88 mmol); 2 N HCl (20.6 mL); MeOH (8.8 mL). 
Yield 91 %. 1H NMR (250 MHz, DMSO-d6) δ: 7.09-7.18 (m, 3H, H-5, H-6, H-7), 7.66 
(d, 1H, J=2.8, H-5’), 7.72 (bd, 1H, J=5.1, H-4’), 8.26 (bs, 1H, J=2.8, H-2’), 8.45 (s, 1H, 
H-4), 10.27 (s, 1H, -OH). 13C NMR (75.5 MHz, DMSO-d6) δ: 117.9, 118.0, 118.5, 
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118.6, 124.6, 124.8, 125.7, 126.4, 127.0, 138.9, 142.9, 144.5, 153.1. MS: 245.0 
([M+H]+, 25 %). 
 
 7,8-Dihydroxy-3-(3-thiophenyl)coumarin (20).  
 Compound 15 (250.2 mg; 0.73 mmol); 2 N HCl (20.6 mL); MeOH (8.8 mL). 
Yield 91 %. 1H NMR (250 MHz, DMSO-d6) δ: 6.85 (d, 1H, J6,5=8.4, H-6), 7.09 (d, 1H, 
J5,6=8.4, H-5), 7.63 (dd, 1H, J5’,4’=4.9, J5’,2’=2.0, H-5’), 7.67 (dd, 1H, J4’,5’=4.9, 
J4’,2’=1.1, H-4’), 8.15 (d, 1H, J2’,5’=2.9, H-2’), 8.36 (s, 1H, H-4), 9.44 (s, 1H, -OH), 
10.17 (s, 1H, -OH). 13C NMR (75.5 MHz, DMSO-d6) δ: 112.7, 113.1, 116.9, 119.2, 
124.3, 126.2, 126.9, 131.9, 135.2, 139.8, 149.6, 159.8, 176.4. MS: 261.0 ([M+H]+, 24 
%). 
 
 5,7-Dihydroxy-3-(3-thiophenyl)coumarin (21).  
 Compound 16 (249.8 mg; 0.72 mmol); 2 N HCl (20.6 mL); MeOH (8.8 mL). 
Yield 92 %. 1H NMR (250 MHz, DMSO-d6) δ: 6.23 (d, 1H, J8,6=2.9, H-8), 6.29 (d, 1H, 
J6,8=2.0, H-8), 7.60 (m, 2H, H-4, H-5), 8.09 ( dd, 1H, H-2’), 8.27 (s, 1H, H-4), 10.44 (s, 
1H, -OH), 10.77 (s, 1H, -OH). 13C NMR (75.5 MHz, DMSO-d6) δ: 93.8, 98.5, 102.2, 
105.4, 123.7, 126.2, 126.7, 134.0, 135.4, 140.7, 155.4, 156.3, 162.1. MS: 260.8 
([M+H]+, 20 %). 
 
 6-Hydroxy-3-(2-thiophenyl)coumarin (27).  
 Compound 22 (257.3 mg; 0.90 mmol); 2 N HCl (20.6 mL); MeOH (8.8 mL). 
Yield 91 %. 1H NMR (250 MHz, DMSO-d6) δ: 7.03 (dd, 1H, J7,8=8.9, J7,5=1.9, H-7), 
7.10 (d, 1H, J5,7=2.0, H-5), 7.19 (m, 1H, H-4’), 7.30 (d, 1H, J8,7=8.7, H-8), 7.68 (d, 1H, 
J5’,4’=5.0, H-5’), 7.87 (d, 1H, J3’,4’=3.7, H-3’), 8.52 (s, 1H, H-4), 9.82 (s, 1H, -OH). 13C 
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NMR (75.5 MHz, DMSO-d6) δ: 112.3, 116.9, 119.8, 119.9, 120.0, 126.7, 127.4, 129.0, 
129.0, 135.5, 136.3, 154.2, 154.2. MS: 245.0 ([M+H]+, 11 %). 
 
 7-Hydroxy-3-(2-thiophenyl)coumarin (28).  
 Compound 23 (300.0 mg; 1.05 mmol); 2 N HCl (24.7 mL); MeOH (10.6 mL). 
Yield 86 %. 1H NMR (250 MHz, DMSO-d6) δ: 6.78 (bs, 1H, H-8), 6.85 (m, 1H, H-6), 
7.16 (m, 1H, H-4’), 7.62 (m, 2H, H-5’, H-5), 7.76 (m, 1H, H-3’), 8.45 (s, 1H, H-4), 
10.68 (s, 1H, -OH). 13C NMR (75.5 MHz, DMSO-d6) δ: 101.9, 111.9, 113.9, 116.3, 
125.5, 127.4, 127.7, 136.0, 137.3, 154.3, 159.5, 161.4. MS: 244.8 ([M+H]+, 23 %). 
 
 8-Hydroxy-3-(2-thiophenyl)coumarin (29). 
 Compound 24 (301.2 mg; 1.05 mmol); 2 N HCl (25.0 mL); MeOH (10.6 mL). 
Yield 43 %. 1H NMR (250 MHz, DMSO-d6) δ: 7.10 (dd, 1H, H-4’), 7.19 (m, 3H, H-5, 
H-6, H-7), 7.69 (d, 1H, H-5’), 7.88 (d, 1H, H-3’), 8.54 (s, 1H, H-4), 10.33 (bs, 1H, H-
4). 13C NMR (75.5 MHz, DMSO-d6) δ: 118.0, 118.6, 120.4, 120.5, 124.9, 126.6, 126.7, 
127.5, 128.9, 135.5, 136.8, 144.5, 150.7. MS: 244.9 ([M+H]+, 6 %). 
 
 7,8-Dihydroxy-3-(2-thiophenyl)coumarin (30).  
 Compound 25 (155.6 mg; 0.45 mmol); 2 N HCl (13.0 mL); MeOH (5.5 mL). 
Yield 51 %. 1H NMR (250 MHz, DMSO-d6) δ: 6.86 (d, 1H, J6,5=8.4, H-6), 7.13 (d, 1H, 
J5,6=8.5, H-5), 7.15 (dd, 1H, J4’,5’=5.1, J4’,3’=3.7, H-4’), 7.61 (dd, 1H, J5’,3’=1.0, 
J5’,4’=5.1, H-5’), 7.77 (dd, 1H, J3’,4’=3.7, J3’,5’=1.0, H-3’), 8.45 (s, 1H, H-4), 9.84 (bs, 
2H, -OH, -OH). 13C NMR (75.5 MHz, DMSO-d6) δ: 112.7, 113.3, 119.3, 125.5, 127.4, 
127.7, 129.1, 132.1, 136.2, 137.9, 139.8, 142.6, 149.9. MS: 260.8 ([M+H]+, 16 %). 
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 5,7-Dihydroxy-3-(2-thiophenyl)coumarin (31).  
 Compound 26 (250.0 mg; 0.73 mmol); 2 N HCl (25.0 mL); MeOH (8.8 mL). 
Yield 98 %. 1H NMR (250 MHz, DMSO-d6) δ: 6.25 (d, 1H, J8,6=2.1, H-8), 6.31 (d, 1H, 
J6,8=2.1, H-6), 7.12 (dd, 1H, J4’,3’=5.1, J4’,5’=3.8, H-4’), 7.56 (dd, 1H, J3’,4’=5.1, 
J3’,5’=1.0, H-3’), 7.72 (dd, 1H, J5’,3’=1.0, J5’,4’=3.8, H-5’), 8.33 (s, 1H, H-4), 10.52 (s, 
1H, -OH), 10.88 (s, 1H, -OH).  13C NMR (75.5 MHz, DMSO-d6) δ: 94.0, 102.4, 107.1, 
113.9, 125.2, 127.1, 127.6, 132.3, 136.6, 149.5, 155.2, 156.4, 162.4. MS: 260.9 
([M+H]+, 29 %). 
 
 6-Hydroxy-3-(4-bromo-2-thiophenyl)coumarin (37).   
 Compound 32 (250.0 mg; 0.68 mmol); 2 N HCl (20.6 mL); MeOH (8.8 mL). 
Yield 60 %. 1H NMR (250 MHz, DMSO-d6) δ: 6.42 (d, 1H, J5,7=8.4, H-5), 6.82-7.02 
(m, 3H, H-3’, H-5’, H-4), 7.24 (d, 1H, J7,8=9.5, H-7), 7.97 (d, 1H, J8,7=9.7, H-8), 10.18 
(s, 1H, -OH). 13C NMR (75.5 MHz, DMSO-d6) δ: 112.6, 116.4, 117.3, 118.4, 118.9, 
119.9, 122.4, 124.7, 127.2, 144.3, 150.1, 153.9, 159.8. MS: 323.7 ([M+H]+, 18 %). 
 
 7-Hydroxy-3-(4-bromo-2-thiophenyl)coumarin (38).   
 Compound 33 (100.3 mg; 0.27 mmol); 2 N HCl (8.2 mL); MeOH (8.2 mL). 
Yield 45 %. 1H NMR (250 MHz, DMSO-d6) δ: 6.79 (d, 1H, J8,5=2.1, H-8), 6.87 (dd, 
1H, J6,5=8.5, J6,8=2.1, H-6), 7.59 (d, 1H, J5,6=8.6, H-5), 7.72 (d, 1H, J5’,3’=1.2, H-5’), 
7.77 (d, 1H, J3’,5’=1.2, H-3’), 8.62 (s, 1H, H-4), 10.78 (s, 1H, -OH). 13C NMR (75.5 
MHz, DMSO-d6) δ: 101.9, 109.1, 111.5, 113.9, 114.6, 125.1, 126.7, 130.1, 137.5, 
138.0, 154.3, 157.5, 161.7. MS: 323.9 ([M+H]+, 100 %). 
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 8-Hydroxy-3-(4-bromo-2-thiophenyl)coumarin (39).  
 Compound 34 (100.3 mg; 0.27 mmol); 2 N HCl (8 mL); MeOH (5 mL). Yield 
90 %. 1H NMR (250 MHz, DMSO-d6) δ: 7.18 (m, 3H, H-5, H-6, H-7), 7.79 (s, 1H, H-
5’), 7.88 (s, 1H, H-3’), 8.66 (s, 1H, H-4), 10.37 (bs, 1H, -OH). 13C NMR (75.5 MHz, 
DMSO-d6) δ: 103.3, 118.5, 118.7, 118.9, 120.0, 125.0, 126.4, 127.9, 136.9, 137.7, 
139.1, 140.9, 144.4. MS: 323.8 ([M+H]+, 100 %). 
 
 7,8-Dihydroxy-3-(4-bromo-2-thiophenyl)coumarin (40).  
 Compound 35 (130.0 mg; 0.31 mmol); 2 N HCl (16.2 mL); MeOH (4.6 mL). 
Yield 80 %. 1H NMR (250 MHz, DMSO-d6) δ: 6.88 (d, 1H, J6,5=8.4, H-6), 7.11 (d, 1H, 
J5,6=8.4, H-5), 7.72 (s, 1H, H-5’), 7.78 (s, 1H, H-3’), 8.59 (s, 1H, H-4), 9.54 (s, 1H, -
OH), 10.37 (s, 1H, -OH). 13C NMR (75.5 MHz, DMSO-d6) δ: 109.3, 112.5, 113.5, 
114.5, 119.6, 125.3, 126.9, 132.1, 132.2, 137.8, 138.9, 150.4, 159.4. MS: 339.9 
([M+H]+, 100 %). 
 
 5,7-Dihydroxy-3-(4-bromo-2-thiophenyl)coumarin (41).  
 Compound 36 (50.0 mg; 0.12 mmol); 2 N HCl (8 mL); MeOH (2 mL). Yield 75 
%. 1H NMR (250 MHz, DMSO-d6) δ: 6.26 (d, 1H, J8,6=2.0, H-8), 6.31 (d, 1H, J5,8=2.0, 
H-5), 7.67 (d, 1H, J5’,3’=1.3, H-5’), 7.76 (d, 1H, J3’,5’=1.3, H-3’), 8.44 (s, 1H, H-4), 
10.61 (s, 1H, -OH), 10.94 (s, 1H, -OH). 13C NMR (75.5 MHz, DMSO-d6) δ: 111.1, 
114.4, 124.2, 131.2, 136.3, 143.9, 147.9, 159.8, 165.9, 166.5, 173.5, 174.1, 184.6. MS: 
339.7 ([M+H]+, 100 %). 
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